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Abstract 
 
 
ABSTRACT 
Haemophilia A is the most common bleeding disorder and is caused by deficiency or 
abnormality in coagulation Factor VIII (FVIII). Deletion of the B-domain dramatically 
improves secretion of this protein with no alteration of the pro-coagulant activity of the 
B-domainless FVIII. Previous work has shown that the codon optimisation of FVIII 
increases expression by 10-fold and the novel variant, FVIII-V3, is expressed at higher 
levels than B-domain deleted FVIII (BDD-FVIII) in the context of AAV mediated gene 
transfer in mice. However, the mechanisms underlying these enhancements to 
expression remain undefined. The purpose of this study was to investigate if (1) codon 
optimisation increases FVIII expression by increasing transcription of FVIII mRNA, (2) 
higher level of FVIII expression observed with V3 is due to N-linked glycosylation motifs 
in the B-domain linker and V3.  
In this thesis, I characterised a range of novel FVIII variants to demonstrate that 
functional characteristics were similar to native FVIII.  
Firstly, comparison of FVIII expression levels in lentivirally transduced HEK-293 stable 
cell lines showed codon optimised FVIII variants expressed higher than wild type FVIII 
not only improved mRNA transcription but also FVIII expression. The V3co variant 
expressed FVIII at the highest level in-vitro and by in-vivo AAV gene delivery to mice.  
Secondly, the glycosylation profile of purified FVIII variant proteins was described. We 
show incremental formation of N-glycans within the B-domain linker sequences as 
detected by mass spectrometry analysis. In addition, these novel FVIII variants showed 
thrombin digestion patterns, identical to the commercial rFVIII protein. Furthermore, 
the thrombin generation and vWF/FVIII affinity assay revealed that all variants were 
similar to commercially available B-DD rFVIII. 
Finally, the expression of N-linked glycosylation mutant V5 and through a deletion 
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analysis, short regions from the V3 linker variants using in-vivo AAV gene transfer 
confirming glycosylation of the linker sequence is not an important factor but 
conformation changes may be the key for the improved expresssion profile.  
Overall, these insights will significantly increase the potential for the transition of 
engineered FVIII molecules to clinic. 
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1.1. Bleeding Disorders  
Bleeding disorders are characterised by spontaneous bleeding or excessive bleeding 
after traumatic injuries, often leading to life or limb threatening complications due to local 
pressure effects and/or exsanguination. Defects in blood clotting factors are the cause 
of disease due to the lack of clotting ability of blood (Nathwani et al., 2005). There are 
two major blood clotting diseases, haemophilia, and von Willebrand disease (vWD) in 
order of disease severity. The World Federation of Haemophilia (WFH) estimates that 
more than one in 1000 men and women has a bleeding disorder equating to 6,900,000 
worldwide (Skinner et al., 2012). 
 The term haemophilia is commonly applied to two inherited bleeding disorders, which 
currently affect 17,131 men in the US and 6811 in the UK (WHF, Annual global survey 
2014).  The two conditions are a deficiency of factor VIII (FVIII) known as haemophilia A 
and deficiency of factor IX (FIX) known as haemophilia B, both of which show X-linked 
inheritance. The prevalence of haemophilia B is about a fifth that of haemophilia A. 
Worldwide, there are estimated to be more than half a million people with haemophilia, 
the prevalence varying from 105 to 160 per million of the male population (Bolton-Maggs 
and Pasi, 2003). 
Von Willebrand disease (vWD) is the commonest inherited bleeding disorder, due to 
defects in the quantity and/or quality of the von Willebrand factor (vWF). vWD is present 
in as many as 1% of the general population. In the UK, vWD is the most commonly 
diagnosed bleeding disorder, with currently 10,254 patients registered (WHF, Annual 
global survey 2014). Most of these patients have a mild bleeding tendency, but a few 
have the severe type 3 variant. vWF is a large and complex plasma glycoprotein that is 
essential for normal haemostasis. This disorder is mild, but it is an important cause of 
menorrhagia in affected kindreds. vWD affects both men and women equally, though 
women may experience more problems linked to periods, pregnancy and childbirth. In 
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severe cases, internal bleeding to muscles and joints can occur in a similar way to 
haemophilia (Laffan et al., 2014). 
The mechanism by which coagulation is initiated by injury to the vascular wall is through 
primary haemostasis, the process in which platelets adhere to sub-endothelium (Triplett, 
2000). vWF is essential for platelet adhesion. Following platelet adhesion, thrombin 
generation is initiated by exposure of tissue factor which binds factor VII forming a binary 
activated complex that in turn activates factor X and factor IX. The coagulation factors 
(FVIII, FIX then form a complex on platelet surfaces, which massively accelerates 
thrombin generation. Hence it is evident that vWF, FVIII and FIX are central to this 
coagulation process and consequently any deficiency of these factors leads to failure of 
haemostasis, which manifests as a bleeding disorder.  
 
1.1.1. Haemophilia  
Haemophilia A is the most common severe bleeding disorder and is caused by a 
deficiency or abnormality in coagulation FVIII. 1 in 5000 males is affected by hereditary 
Haemophilia A (Mannucci and Tuddenham, 2001). The F8 gene is located on the X 
chromosome; therefore males are predominantly affected while females are only carriers 
of the genetic defect.  
The genes for F9 and F8 were cloned in 1982 and 1984 respectively. This cloning has 
resulted in important advances in the molecular characterisation of the defects that 
cause the haemophilias and has enabled synthesis of recombinant clotting factor 
concentrates for therapeutic use. In detail, the F8 gene is one of the largest human genes 
measuring 186 kb in length, which maps to band Xq28 at the tip of the long arm of the X 
chromosome (Gitschier et al., 1984; Toole et al., 1984; Vehar et al., 1984; Wood et al., 
1984). 
The F8 gene has two additional genes, FVIII-associated gene A (F8A) and FVIII-
associated gene B (F8B) within intron 22 and two further copies of F8A exist outside 
                                                                                                                          Chapter 1 
 
 23 
(400kb telomeric) the F8 gene (Levinson et al., 1992a; Levinson et al., 1992b). The 
functions of the F8A and F8B genes are unknown, but they are responsible for common 
inversion of FVIII, which is the most common genetic defect in haemophilia A, affecting 
about 45% of individuals with severe disease.  
The large inversion and translocation of exons 1~22 (together with introns) away from 
exons 23~26, is due to homologous recombination between the F8A gene in intron 22 
and one of the F8A copies of upstream of FVIII gene (Fig.1.1) (Lakich et al., 1993). 
Mutations, other than the intron 22 inversions, are predominantly point mutations and 
cause mild haemophilia A (HAMSTeR/HADB, http://www.factorviii-db.org/), which are 
about 85% for mis-sense (a point mutation that codes for change amino acid) mutation, 
and 15% for non-sense (a point mutation resulting in stop codon or truncation) mutation. 
A similar inversion involving intron 1 of the F8 gene has also been described in about 
1~6% of patients with severe haemophilia A in which the two repeated sequences 
(intron1h1/intron1h2) of intron 1 of F8 gene is responsible for recombination between 
sequence internal and external to the factor VIII gene (Graw et al., 2005). 
In haemophilia A, patients with mutations that severely truncate or prevent the production 
of FVIII (Intron 22 inversion, large deletions, non-sense mutations) have a much higher 
frequency (about 40%) of Inhibitors, which are antibodies that neutralise the activity of a 
clotting factor. Inhibitor antibodies to FVIII or FIX may arise as alloantibodies in patients 
with haemophilia A or B who have been transfused with exogenous FVIII or FIX, 
respectively. The development of functionally inhibiting alloantibodies in haemophilia 
represents a serious clinical problem.  
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Figure 1.1. Schematic representation of common inversion of the F8 gene 
The location of F8 gene is illustrated in the region of Xq28 that oriented with the telomere at the 
left to the right of centromere. A) The arrow indicates the direction of two nested genes F8A and 
F8B with two further telomeric copies of sequences homologous to F8A. Three copies of the A 
genes are indicated orientation with black arrow. B) Description of Intra-chromosomal 
recombination by crossing-over between the homologous F8A sequences. C) F8A recombination 
leading to a relocation and inversion of exons 1~22 away from exons 23~26. The diagram was 
adopted from Lakich et al (Lakich et al., 1993). 
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1.1.1.1. Pathology  
The disease phenotype is entirely attributed to the lack of efficiency of functional FVIII 
protein which normally circulates in minute amounts in the plasma (200ng/mL) (High et 
al., 2014). FVIII has a half-life of about 12 hours in adults (shorter in children), circulating 
in plasma in a non-covalent complex with vWF. The vWF protects FVIII from premature 
proteolytic degradation and concentrates it at sites of vascular injury (Bolton-Maggs and 
Pasi, 2003).  
Patients with mild, moderate, and severe forms of the disease have a deficiency in a 
FVIII activity in plasma with levels of 5~40%, 1~5%, and <1%, respectively (White et al., 
2001). Severe haemophilia is characterised by sporadic bleeding into the muscles, joints, 
or internal organs, excessive bleeding after an injury or surgery and spontaneous internal 
haemorrhages (Santagostino, 2014).  
In the early 1960s, the only known effective treatment of haemophilia was with an 
infusion of fresh frozen plasma (FFP). In 1964, Dr Judith Graham Pool developed a 
simple method to separate a cryoprecipitate from plasma containing most of the FVIII in 
a more convenient concentrated form. Subsequently, lyophilised plasma-derived clotting 
factor concentrates were developed and widely used since the 1970s (Skinner, 2012). 
In the early 1990s, bioengineering technology allowed production of recombinant 
proteins to improve biosafety. However, current generations of treatment products have 
a robust safety profile (both plasma-derived and recombinant), but still more than 40% 
of countries report treatment product usage including FFP and cryoprecipitate, showing 
that they are still used for the treatment of haemophilia (Skinner, 2012). The risk of viral 
transmission from FFP and cryoprecipitate remains a significant concern as they are 
often not virus inactivated. 
Recent studies estimated that mean annual cost of haemophilia A treatment per patient 
is $157,180 (USA) (Duncan et al., 2014). A major complication of factor replacement 
therapy is the development of antibody inhibitors against FVIII. Inhibitors arise in a high 
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proportion of patients and result in the requirement of significantly higher doses of FVIII 
to prevent bleeding or complete refractoriness to replacement therapy such that 
alternative and less satisfactory measures have to be taken to control bleeding.  
 
1.1.2. Haemostasis 
Bleeding occurs in haemophilia owing to the failure of secondary haemostasis. 
Haemostasis is a highly localised process in response to blood vessel injury in which 
cessation of bleeding is achieved by a coordinated clotting process involving both 
platelets and coagulation factors, while maintaining the dynamic equilibrium of an 
adequate blood flow but locally stemming the outflow of blood with a platelet-fibrin plug 
at the site of injury. The three essential roles of haemostasis for the survival of any 
organism that has a circulatory system are first, blockade of damaged blood vessels, 
second, keep the blood in a fluid state, and finally remove blood clots after restitution of 
vascular integrity (Versteeg et al., 2013). 
1.1.2.1. Classical coagulation pathway 
In the 1960s, Davie and Ratnoff devised a model for blood coagulation process, which 
described the clotting process as a waterfall. They named this model aptly as coagulation 
waterfall. Independently and simultaneously Macfarlane proposed a cascade 
hypothesis, which was essentially identical to the Davie’s waterfall, but emphasised the 
amplification aspect of the biochemical process invoked to explain blood clotting. The 
original classical waterfall or cascade of reactions involved sequential activation of 
various clotting factors along the intrinsic pathway. Later stimulation by extrinsic tissue 
factor was added and according to this model stimulation of either of these two pathways 
can result in the production of a large amount of thrombin and subsequent formation of 
a fibrin clot (Davie et al., 1964; Macfarlane, 1964). 
The Intrinsic pathway is triggered by auto-activated FXII cleaving pre-kallikrein into 
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kallikrein, which leads to a subsequent activation pathway of FXI, FIX, FX, and FII, which 
components are all present in the blood-along with the two cofactors FVIII and FV 
necessary for full FIX and FX activity respectively. The intrinsic pathway is activated 
when blood comes into contact with hydrophilic negatively charged surfaces in-vitro.  In 
contrast, the extrinsic pathway is activated by exposure of plasma factor VII (FVII) to 
tissue factor (TF, FIII, Thromboplastin, CD142) on the surfaces of cells in the 
extravascular space, which directly induces sequential activation of factor X (FX) and 
prothrombin (FII) (Versteeg et al., 2013). 
The intrinsic and extrinsic pathway divides the initiation of coagulation into two distinct 
parts. The extrinsic pathway is thought to be responsible for the initial generation of 
activated FX (FXa), whereas the intrinsic pathway leads to amplification of FXa 
generation. The intrinsic and extrinsic pathways converge onto FXa, which plays a 
central role in the coagulation cascade (Mackman, 2009; Abdalla and Adam, 2013) 
(Fig.1.2).    
Although this cascade concept supports laboratory evaluation of coagulation disorders 
and demonstrates  the interactions between coagulation factors, it does not adequately 
explain the mechanisms leading to haemostasis  in-vivo (Hoffman, 2003). For instance, 
the cascade model does not explain how the extrinsic pathway appears unable to 
produce sufficient amounts of FX to at least partially compensate for a deficiency of FVIII 
or FIX. In other words, why does activation of FX by the TF/FVIIa complex fail to 
substitute for the FXa that would normally be generated by FIXa/FVIIIa (Hoffman, 2003).  
Those questions have recently been explained by a cell-based concept in which both 
FVIII and FIX are central to the process of blood coagulation and for the adequate 
generation of thrombin.  
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Figure 1.2.The classic cascade model of intrinsic and extrinsic pathways 
The extrinsic pathway starts when an exogenous agent, tissue factor (TF) binds to and activates 
plasma FVII to form an active complex (TF:FVIIa), which directly induces sequential activation of 
FX and prothrombin (green).  The TF:FVIIa complex is the key initiator of the coagulation protease 
cascade and activates both FIX to FIXa and FX to FXa. Components of the intrinsic pathway 
(FXII, FXI, FIX, and FVIII) are all present in the blood (blue). The tenase complex (FVIIIa:FIXa) 
plays a key role in amplifying the clotting cascade by activating FX to FXa. The final step of the 
cascade in which prothrombinase complex (FVa:FXa) converts prothrombin to thrombin is 
referred to as the common pathway. Thrombin, which is the terminal protease of the clotting 
cascade cleaves fibrinogen into soluble fibrin monomers that polymerise. HMWK stands for High-
Molecular-Weight-Kininogen 
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1.1.2.2. Cell-based coagulation model  
The cell-based coagulation model is based on the observation that stabilisation of fibrin, 
is defective if inadequate amounts of thrombin are localised to the evolving clot; the 
model also emphasises that coagulation occurs in a series of three overlapping steps 
that take place on different cell surfaces, rather than as a cascade that produces 
plenteous activated factors and inevitably leads to clot formation (Hoffman, 2003; Smith 
et al., 2009). 
In mammalian blood coagulation, six proteases (FVII, FIX, FX, FXII, protein C, and 
prothrombin) act with five cofactors (TF, thrombomodulin, Protein S, FV and FVIII) to 
control the generation of fibrin (Fig.1.3). The process is initiated and regulated by three 
stages (Initiation, Amplification and Propagation) (Hoffman and Monroe, 2001; Hoffman, 
2003).  
In the initiation stage, classically referred to as the extrinsic pathway of coagulation. TF 
binds to activated FVII (FVIIa) and forms TF/FVIIa complex, which activates small 
amounts of FIX and FX. FXa along with its cofactor, FVa, forms the FXa/FVa 
prothrombinase complex on the surface of cells that express TF. The FV can be activated 
by FXa or non-coagulating proteases, resulting in FVa, which is necessary for the 
prothrombinase complex. This complex transforms small amounts of prothrombin (FII) 
to thrombin (FIIa).  
In the second stage, the amplification phase, the small amounts of thrombin produced 
by cells expressing TF interacts with platelets and the FVIII/vWF complex. This results 
in the activation of cofactors FV, FVIII and activation of zymogen FIX to FIXa, thus begins 
the haemostatic process culminating in the formation of stable fibrin (Versteeg et al., 
2013). 
The propagation stage is characterised by the migration of large numbers of platelets to 
the site of injury and the production of the tenase complex and prothrombinase on the 
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surface of activated platelets. First, FIXa activated during the initiation phase binds FVIIIa 
on the platelet surface forming the FIXa/FVIIIa tenase complex. Once the intrinsic tenase 
complex forms on the activated platelet surface, it rapidly begins to generate FXa on the 
platelet. FXa is also generated during the initiation phase on the TF-bearing cell surface. 
Since FXa is rapidly inhibited as it moves from the TF-bearing cell surface the majority 
of FXa must, therefore, be generated directly on the platelet surface through cleavage 
by the intrinsic tenase complex. Following production, FXa generated on platelets rapidly 
binds to FVa, which cleaves prothrombin (FII) to thrombin (FIIa) and clot forms. 
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Figure 1.3. Cell-based coagulation model of haemostasis 
The cell-based model describes the contribution of various cell surfaces leading to fibrin 
formation. In this model, thrombin generation occurs in three overlapping stages. The three 
phases of coagulation occur on different cell surfaces: Initiation on the tissue factor-bearing cell; 
Amplification on the platelet as it becomes activated; and Propagation on the activated platelet 
surface. TF: Tissue Factor (Factor III), The pathways were adapted from Hoffman et al., 2001. 
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1.2. FVIII Protein Structure  
Human FVIII is a large plasma glycoprotein synthesised as a single-chain polypeptide 
with a predicted molecular mass of 264kDa, corresponding to the mature 2332 amino 
acid sequence, determined from the translation of the cloned gene. After post-
translational modification with N-linked carbohydrate chains, the molecular mass of FVIII 
reaches 330 kDa (Vehar et al., 1984). 
The FVIII protein consists of three A domains (homologous to ceruloplasmin) three a 
domains (acidic amino acid-rich), a B-domain (heavily glycosylated), and two C domains 
(homologous to discoidin), assembled into the primary domain structure: A1-a1-A2-a2-
B-a3-A3-C1-C2 shown in figure 1.4 (Pemberton et al., 1997; Newell and Fay, 2007).  
The three A-domains are flanked by short spacers (a1, a2, and a3) that contain clusters 
of Aspartic acid and Glutamic acid residues as acidic regions. Those short segments of 
negatively charged residues occur at the C-terminal regions of the A1 and A2 domains 
and the N-terminal portion of the A3 domain. These 30~40 negatively charged acidic 
regions are segmented as a1 (337–372), a2 (711–740) and a3 (1649–1689), which are 
thought to function, in part, as binding sites for thrombin and other ligands (Lenting et al., 
1998; Fay, 2004). 
The B-domain is unique and encoded by one of the largest known single exons (Exon14). 
It is composed of 908 amino acids that contain 19 of the potential 25 Asparagine (N)-
linked glycosylation attachment sites on the entire FVIII molecule. The B-domain is the 
most heavily glycosylated region in FVIII, exhibiting no signiﬁcant homology with any 
other known protein such as FV (Pipe, 2009).  
The B-domain is proteolytically released upon activation by thrombin or FXa and is not 
required for pro-coagulant activity in-vitro or in-vivo (Dorner et al., 1987; Eaton et al., 
1986a; Toole et al., 1986).  One function of the B-domain is to modulate the rate of 
thrombin activation. Factor VIII (FVIII) with a truncated B-domain is more rapidly 
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activated by thrombin than full-length FVIII (FL-FVIII), indicating that lower 
concentrations of thrombin are necessary to activate truncated B-domain FVIII, when 
compared to FL-FVIII. If this difference is enough to alter the functional properties of B-
domain in FVIII, it suggests that B-domain deleted FVIII, may be more susceptible to 
proteolytic attack. Further, it is tempting to speculate that the B-domain may function to 
protect the functional domains of FVIII from proteolysis that may occur as the result of 
low amounts of circulating active protease, perhaps thrombin (Eaton et al., 1986b).  
More recently the B-domain has been shown to play a major role in the intracellular 
processing and trafficking of FVIII. Moreover, there is emerging evidence that portions 
of the B-domain may have functional influences throughout the life cycle of FVIII (Pipe, 
2009). 
The C domains are homologous to phospholipid binding proteins which suggesting a role 
in phospholipid interaction (Veeraraghavan et al., 1998; Stoylova et al., 1999). Mutations 
in the C1 domain are commonly identified in haemophilia A patients, yet the role of the 
latter domain in FVIII function or stability is not determined. 
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Figure 1.4. Schematic diagram of human FVIII domains   
Light blue bars indicate small acidic peptides, a1, a2, and a3, which are located in between A and 
B-domain. The acidic peptides a1, a2, a3, and the large B-domain contains function-related 
cleavage sites at one or both of their N- or C-termini, and thus these sites would be predicted to 
be accessible to serine proteases such as thrombin and APC. Thrombin activation sites are 
indicated with a red arrow at 372, 740, 1689, and some of the cleavage sites within the B-domain 
(indicated with an open arrow, 1313), resulting in a mixture of heavy chains of variable size. 
Preparations of plasma-derived human FVIII contain a heterogeneous mixture of dimers because 
of the range of different sizes for heavy chain resulting from additional cleavage sites within the 
B-domain (Pemberton et al., 1997; Graw et al., 2005). 
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1.3. FVIII Secretion 
1.3.1. FVIII Quality control 
Human FVIII is synthesised in vascular-endothelial cells, reticulo-endothelial cells, and 
hepatic sinusoidal endothelial cells ( Stel et al., 1983; Nichols et al., 1998; Nichols and 
Ginsburg, 1999). Moreover, FVIII mRNA was detected in a variety of extra-hepatic 
tissues, including kidney (glomerular microvascular endothelial cells), umbilical vein 
endothelial cells, spleen and lymph node so that may also produce FVIII (Wion et al., 
1985; Levinson et al., 1992a; Levinson et al., 1992b; Fahs et al., 2014; Turner et al., 
2015). Zanolini and colleagues reported that monocytes, macrophages and 
megakaryocytes expressed FVIII (Zanolini et al., 2015). 
The initial stage of FVIII secretion begin with the translocation of mature FVIII polypeptide 
into the lumen of the endoplasmic reticulum (ER), the 19 amino acid signal peptide is 
removed by signal peptidase then N-linked glycosylation occurs (Lenting et al., 1998). 
Within the ER, the early FVIII secretory pathway appears to interact with a number of 
chaperone proteins, including Immunoglobulin binding protein (BiP), calreticulin, and 
calnexin (Dorner et al., 1987; Pipe, 1998). Firstly, the BiP has been known as the 
glucose-regulated protein (GRP78), which is a member of the 70kDa heat shock protein 
(HSP70) family that exhibits a peptide-dependent ATPase activity and for which 
expression is induced by the presence of unfolded protein or unassembled protein 
subunits within the ER. The considerably less efficient secretion of FVIII, relative to that 
of FV, may be explained as follows: BiP binds to FVIII A1 domain hydrophobic 110 amino 
acid region with BiP exhibiting a peptide-dependent adenyl pyrophosphatase (ATPase) 
activity. Therefore FVIII release from BiP and transport out of the ER requires high levels 
of intracellular adenosine triphosphate (ATP). In contrast, FV does not associate with 
BiP and does not require high levels of ATP for secretion (Nichols & Ginsburg 1999; 
Becker et al., 2004). These studies show that the less efficient secretion of FVIII is due 
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to the interaction with these chaperone proteins, causing a signiﬁcant proportion of FVIII 
molecules to be retained within the ER for quality control, thereby limiting the transport 
of FVIII to the Golgi apparatus.  
Secondly, the ER-Golgi proteins (calnexin and calreticulin) are responsible for this 
process and preferentially interact with glycoproteins containing mono-glucosylated N-
linked oligosaccharides. It is also suggested that while moving through the degradative 
and/or secretory pathways (Pipe, 1998), the quality of FVIII is controlled by a glucosyl-
transferase that acts specifically on unfolded glycoproteins. The re-glucosylated protein 
is then once again retained on calnexin or calreticulin; but folded glycoproteins, which 
cannot be reglucosylated, are free to leave the ER and continue to traffic through the 
secretory pathway (Ashkenas and Byers, 1997). Therefore only fully folded FVIII 
escapes the chaperone-mediated retention mechanism and is finally transported to the 
Golgi apparatus and released out of the cell (Fig.1.5) (Nichols and Ginsburg, 1999). The 
necessity for a conformational LMAN1-binding carbohydrate-based structural motif 
provides an additional quality control mechanism for ER exit of properly folded proteins 
(Baines and Zhang, 2007). 
1.3.2. Receptor-mediated FVIII transport  
The FVIII transport mechanisms responsible for exit from the ER to the Golgi apparatus 
have been elevated as key issues for FVIII secretion and quality control. The now well 
established secretory pathway responsible for FVIII is Lectin Mannose-Binding Protein 
1 (LMAN1, also called ERGIC) and Multiple Coagulation Factor Deficiency Protein 2 
(MCFD2) complex (Nichols et al., 1999; Neerman-Arbez et al., 1999; Zhang et al., 2005 
Khoriaty et al., 2012). The LMAN1-MCFD2 complex forms a specific cargo receptor for 
the ER-to-Golgi transport of selected proteins (Zhang et al., 2003).  
LMAN 1 requires Phenylalanine-Phenylalanine (FF) motifs for efficient export from ER 
in the context of larger export signals at the most C-terminal end of its short cytoplasmic 
tail. The efficient export of LMAN1 is dependent upon its oligomerisation, which is based 
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on amino acid residues located in its transmembrane and luminal domains. In contrast, 
the lack of oligomerisation leads to misfolding and protein retention by chaperones 
(Nufer et al., 2003).  
The cytoplasmic tail of LMAN1 contains an FF motif that interacts with the COPII subunit 
(illustrated in Fig.1.6). The majority of LMAN1 is localised to the ERGIC at steady state, 
it cycles the back to the ER via a Lysine-Lysine (KK) ER-retrieval signal that interacts 
with COPI. The luminal part of LMAN1 contains 4-alpha helices that are predicted to form 
a coiled-coil domain and a carbohydrate recognition domain (CRD) that binds mannose. 
The crystal structure of the CRD is similar to leguminous lectins and the calnexin 
(Velloso, 2002). Structural determinants in both the luminal and trans-membrane 
domains lead to oligomerisation of LMAN1, which exists exclusively in two homo-
hexameric forms within the cell. The first form is composed of six disulfide-linked 
monomers and the second form is composed of three disulfide-linked dimers that might 
associate non-covalently through coiled-coil domains (Zhang et al., 2005). 
The cargo proteins of the LMAN1–MCFD2 pathway are required for efficient ER-to-Golgi 
transport of FV, FVIII and two lysosomal glycoproteins cathepsin C(catC), cathepsin 
Z(catZ) (Fig.1.6). Given the evolutionary conservation and the ubiquitous expression 
pattern of LMAN1 and MCFD2, additional cargo proteins also exist. For example, 
Nicastrin, a component of the -secretase complex, and a mutant immunoglobulin heavy 
chain have also been reported to interact with LMAN1 (Baines and Zhang, 2007). 
Interactions between catC or catZ and LMAN1 were also observed. Upon treatment with 
a chemical crosslinker, an estimated 5~20% of FVIII is detected in a tertiary complex 
with LMAN1 and MCFD2, which provides direct evidence for the receptor activity of the 
LMAN1-MCFD2 complex (Baines and Zhang, 2007). The LMAN1-MCFD2 complex and 
FVIII interaction are dependent on the intracellular Ca++ concentration. The MCFD2 
possible to be dispensable for the interaction between LMAN1 and catC or catZ, which 
indicates that MCFD2 is specifically required for recruitment of FV and FVIII to sites of 
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transport vesicle budding within the lumen of the ER (Zhang et al., 2005; Nyfeler et al., 
2006).  
FV and FVIII are homologous proteins that share a common A1-A2-B-A3-C1-C2 domain 
structure. Although the B-domains of FV and FVIII share little sequence identity, both 
are heavily glycosylated. Given the lectin activity of LMAN1, an interaction between 
LMAN1 and the B-domains of FV and FVIII seems a likely possibility. Consistent with 
this, B-DD FVIII is not efficiently cross-linked to the LMAN1-MCFD2 complex. However, 
substantial cross-linking is still detected when glycosylation of FVIII is blocked (Zhang et 
al., 2005). This observation, combined with the MCFD2 in the secretion of FV and FVIII, 
indicates that protein–protein interactions are also important for LMAN1-MCFD2 cargo-
receptor function (.Baines and Zhang, 2007).  
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Figure 1.5. Intracellular processing of FVIII synthesis and secretion in ER and 
Golgi 
The FVIII primary translation product is translocated into the lumen of the ER where N-linked 
glycosylation occurs. The majority of FVIII binds to ER chaperone proteins, which perform quality 
control. A proportion of the molecules attains proper conformation for transport into the Golgi 
where additional complex carbohydrate modification on N-linked glycosylation sites occurs. Also, 
O-linked glycosylation and sulphation of several tyrosine residues in the acidic regions of FVIII 
take place. In the Golgi, the protein is cleaved to its mature heavy and light chain (Kaufman et al., 
1988; Pipe, 2009). 
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1.3.3. LMAN1 and COPI/II interaction 
Alternatively, MCFD2 could be required for the separation of FV and FVIII from LMAN1 
in the ERGIC, which is the site of dissociation of secretary proteins for anterograde 
transport via packaging into COPII coated transport vesicles (Moussalli et al., 1999; 
Zhang et al., 2003). The calcium-dependent LMAN1-MCFD2 complex is an essential 
step in ER-to-Golgi transport for a specific subset of glycoproteins including FV and FVIII 
(Graw et al., 2005; Zhang et al., 2005). The coat proteins (COP1 and COP II) are 
important for FVIII transport between ER to Golgi due to the fact that COPII acts earlier 
in the pathway, apparently driving the initial budding of vesicles from the ER, COPII 
transports cargo from the ER to the Golgi complex (Becker et al., 2004; Baines & Zhang 
2007). Then, COPI becomes associated with new budding vesicles, the COPI complex 
binds to ERGIC membranes and initiates the budding of COPI-coated vesicles. COPI 
clearly plays a critical role in Golgi-to-ER retrograde transport and also possibly 
anterograde  (Nichols and Ginsburg, 1999; Khoriaty et al., 2012)). COP1 and COPII 
coats bind to the ERGIC and drive the lectin-glycoprotein complex into budding vesicles 
(Itin et al., 1996; Lavoie et al., 1999).  
Recruiting cargo proteins to budding vesicles can be catagorised as direct binding to 
components of the COPII coat and specific adaptors (receptors) to link them to COPII 
vesicles. The direct binding is limited to proteins that span the ER membrane due to the 
cytosolic COPII-coat proteins. However, specific adaptors that bind COPII serve as 
cargo receptors for the second class of cargo, which includes both soluble and 
transmembrane proteins. Several classes of ER export motifs include the interactions 
between COPII and transmembrane cargo, which can be recognised by the COPII coat 
proteins (Baines and Zhang, 2007).  
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Figure 1.6. Cargo transport by the LMAN1-MCFD2 complex  
A) FV, FVIII, cathepsin C (CatC), and cathepsin Z (CatZ) bind the LMAN1- MCFD2 complex and 
are packaged into COPII vesicles. B) COPII vesicles bud from the ER membrane and fuse 
together, which leads to form the ER-Golgi intermediate compartment (ERGIC). C) Anterograde 
transport of cargo protein to the Golgi apparatus occurs along microtubules. D) The LMAN1-
MCFD2 complex is recycled back to the ER through COPI vesicles. E) Posttranslational 
modification of the cargo proteins occurs in the Golgi apparatus. F) CatC and CatZ are transported 
to the lysosomes. G) FV and FVIII are secreted outside of the cells. H) In murine megakaryocytes, 
FV is transported and stored in α-granules. Reproduced from Baines and Zhang 2007 (Baines 
and Zhang, 2007; Khoriaty et al., 2012). 
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1.3.4. FVIII Processing in Golgi  
Once in the Golgi compartment, FVIII is among the many proteins to undergo intracellular 
proteolysis. The tertiary structure of FVIII confers on the B-domain region a particular 
susceptibility to proteolysis. The heavy and light chain portions of FVIII form a globular 
domain structure, about 14nm in diameter, while the connecting B-domain region forms 
an extended rod-like structure (Kaufman et al., 1988; Fowler et al., 1990). Moreover, the 
carboxy- terminal region of the B-domain comprises a motif (R-X-X-R) similar to that 
recognised by intracellular proteases of the subtilisin-like family (Barr, 1991; Lenting et 
al., 1998). Consequently, the FVIII polypeptide is cleaved in the B-domain after residues 
1648 to generate the heavy chain of 200kD (A1-a1-A2-a2-B) in a metal ion complex with 
the light chain of 80kD (a3-A3-C1-C2). Within the Golgi apparatus, FVIII undergoes 
modification of the N-linked oligosaccharides to complex-type structures, O-linked 
glycosylation, and sulphation of specific tyrosine residues Y346, Y718, R719, Y723, 
Y1664, and Y1680. 
FVIII protein is also subjected to further partial proteolysis of the B-domain between 
residues 741 and 1648 producing a range of heterodimeric molecules that circulate in 
plasma with varying lengths of B-domain (Fay et al., 1986; Kaufman, 1998). The FVIII 
heavy and light chains remain non-covalently associated through the A1 and A3 domains 
in a metal ion-dependent manner. Considering the structural homology of FVIII to the 
copper-binding protein ceruloplasmin, it is not surprising that copper ions have been 
found in FVIII as well. Moreover, the copper/FVIII ratio, calculated for both proteins, one 
single copper atom present per molecule of FVIII (Bihoreau et al., 1994). Most likely, the 
copper ion binding site is composed of residues His265, Cys310, His315, and Met320 
within the A1 domain and His1954, Cys2000, His2005 and Met2010 for the A3 domain. 
In addition, L649, C692, F697 and M702 in the A2 domain, The copper has three protein 
ligands, 2 Histidine and 1 Cysteine, at this site, because the leucine, isosteric to 
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methionine, cannot be considered as a copper ligand (Messerschmodt and Huber, 
1990). 
Binding of divalent metal ions to this site may allow the A1 domain to adopt an A3 domain 
binding conformation. Alternatively, divalent metal ions may directly bridge the A1 and 
A3 domain by interacting with both domains. In the absence of divalent metal ion, the 
resulting heterodimers were inactive (Wakabayashi et al., 2001). 
Other metal ions are ineffective in promoting reassembly of dissociated heavy and light 
chain, but calcium or manganese ions are efficient in this respect (Nordfang and Ezban, 
1988). However, the speciﬁc activity of FVIII dimers that were re-associated in the 
presence of calcium ions is markedly enhanced by the addition of copper ions. 
Apparently, divalent metal ions serve an auxiliary role to enhance cofactor function of 
FVIII. These observations imply that multiple sites may be involved in the association 
between heavy and light chain. Thus, evidence to date indicates that Cu++ promotes the 
inter-chain association and contributes to the specific activity of FVIII, whereas Ca++ or 
Mn++ is required to promote the active cofactor conformation (Fay, 2004). Therefore, 
the metal ions are important for maintaining the heterodimeric structure of secreted FVIII. 
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1.4. FVIII activation  
Immediately after their release into the blood stream, the inactive FVIII molecules interact 
with large multimeric vWF monomers, to form a tight non-covalent complex. Several 
groups have reported a vWF-binding domain of FVIII. Direct evidence for the binding of 
FVIII light chain to vWF was experimentally demonstrated by Foster and colleagues who 
identified the involvement of amino acid residues 1670-1684 (Lollar et al., 1988; Foster 
et al., 1989). Light chain C2 residues 2303-2332 were implicated in this binding (Saenko 
et al., 1994; Lenting et al., 1999). In addition, Saenko and colleagues demonstrated that 
a3 acidic region and the C2 domain are both directly involved in forming a high-affinity 
binding site for vWF (Saenko et al., 1994; Graw et al., 2005).  The FVIII to vWF binding 
ratio in plasma is 1:50 and this heterodimeric structure of FVIII stabilised by vWF 
interferes with the binding of FVIII to negatively charged phospholipid surfaces and 
inhibited binding of FVIII to FIXa. Thereby the half-life of FVIII circulating in plasma is 
increased (Weiss et al., 1977; Fay, 2004; Fay et al., 2009). The association with the vWF 
protein is the most significant identified determinant of FVIII survival, as it provides 
protection from premature clearance or activation (Lenting et al., 2007). To perform its 
cofactor binding functions, FVIII pro-cofactor is proteolytically cleaved by α-thrombin at 
three arginine residues (R372, R740, and R1689) yielding 50kDa, 43kDa, and 73kDa 
fragments (Fig.1.7). In this process, the variable B-domain fragments and the short a3 
peptides are lost. Finally, FVIII forms an active heterotrimer (FVIIIa) (Pemberton et al., 
1997). Overall, FVIIIa is a heterotrimer comprised of three non-covalently linked 
polypeptide chains: the A3-C1-C2 subunit associated with the A1 subunit which is 
stabilised by divalent metal ion-dependent linkage, whereas the A2 subunit is weakly 
associated with the dimer through electrostatic interactions (Fay et al., 1991). These 
weak interactions contribute to the FVIIIa heterotrimer instability, as the dissociation of 
the A2 domain leads to spontaneous inactivation.  
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Figure 1.7. Activation process of FVIII  
FVIII gene is translated to 2332 amino acid polypeptide, which consists of domain structure A1-
a1-A2-a2-B-a3-A3-C1-C2. Upon secretion, the FVIII is a heterodimer of heavy and light chains 
bound to each other by a divalent metal ion (grey ball) and in complex with the carrier protein von 
Willebrand Factor (vWF). Thrombin, FXa and FIXa mediate activation by proteolytic cleavage at 
specific residues to form a hetero-trimmer. Red arrows indicate thrombin cleavage sites at 
Arginine (R)372, (R)740, and (R)1689. Cleavage at (R)1689 releases the a3 acidic-rich region, 
which dissociates FVIIIa from vWF (Mannucci and Tuddenham, 2001; Pipe, 2009; Saenko et 
al.,1994). Binding of metal ions to this site allows the A1 domain to adopt an A3 domain binding 
conformation. Alternatively, metal ions directly bridge the A1 and A3 domain by interacting with 
both domains simultaneously (Kaufman et al., 1988).  
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1.5. FVIII clearance 
The asialoglycoprotein receptor (ASGPR) is abundantly expressed in the liver. The 
ASGPR is a member of the C-type family of lectins that play a role in calcium-dependent 
binding as an endocytic receptor (Stockert, 1995). It is clear that the ASGPR receptor 
binds oligosaccharides with terminal β-linked N-acetylgalactosamine (GalNAc) or Gal, 
and hence that it can mediate the rapid clearance of glycoproteins bearing these terminal 
sugars from the circulation (Park et al., 2003). Bovenschen et al., concluded by in-vitro 
binding studies that ASGPR is involved in the catabolism of FVIII (Bovenschen et al., 
2005a). 
Free FVIII molecules in plasma are rapidly cleared via low-density lipoprotein (LDL) 
receptor-related protein (LRP1, also known as a α2-macroglobulin receptor or CD91) 
(Saenko et al., 1999; Lenting et al., 2007). LRP is a major endocytic receptor in the liver 
(Moestrup et al., 1992), but it is also expressed in many other cell types and tissues. 
LRP has been established to interact with coagulation FVIII and to mediate its cellular 
uptake into the lysosomal degradation pathway (Lenting et al., 1999; Bovenschen et al., 
2005b). The region of FVIII involved in its binding to LRP was localised within the A2 
domain residues 484~509, based on the ability of the isolated A2 domain and the 
synthetic A2 domain peptide 484~509 to prevent FVIII interaction with LRP (Saenko et 
al., 1999; Bovenschen et al., 2005a). However, Lenting and colleagues reported that 
LRP1 interacts with the light chain of FVIII C2 domain. Interactive sites for FIXa, 
phospholipids and LRP1 binding of FVIII light chain overlap so that vWF interferes with 
the interaction between FVIII light chain and LRP1 (Lenting et al., 1999). 
Removal of free FVIII forces a constant shift from vWF-bound to free FVIII. LRP1 
mediated clearance of unbound FVIII is facilitated by both LDL-receptor (LDLR) and cell 
surface heparan-sulfate proteoglycans (HSPG) (Sarafanov et al., 2001). These 
receptors also have the potential to internalise FVIII by themselves. The vWF prevents 
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binding of FVIII to LRP1 not only in a system using purified proteins but also in cellular 
degradation (Lenting et al., 1999). Degradation of FVIII was completely inhibited by vWF 
because vWF binding to FVIII involves its light chain C2 domain. Moreover, LRP-directed 
antibodies inhibited degradation to a similar extent, suggests that LRP indeed give rise 
to the binding and transport of FVIII to the intracellular degradation pathway (Lenting et 
al., 2007). 
Sarafanov and colleagues reported in-vivo and in-vitro experiments revealing that 
HSPGs are also involved in FVIII catabolism with another LRP-independent pathway. In 
these pathways, HSPGs act as receptors providing the initial binding of FVIII-vWF 
complex to cells (Sarafanov et al., 2001).  
In summary, there are multiple mechanisms for FVIII and vWF complex formation, which 
vWF stabilises hetero-dimeric FVIII structure, and protects FVIII from proteolytic 
degradation by phospholipid binding proteases (activated protein C and activated FX). 
Moreover, vWF interferes with binding of FVIII to phospholipid surface and inhibits 
binding of FVIII to FIXa, thereby prevents the cellular uptake of FVIII (Lenting et al., 
2007). 
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1.6. FVIII therapeutic treatments and risks  
1.6.1. Haemophilia A protein replacement therapy  
The treatment option of FVIII replacement therapy became feasible in the late 1960s to 
early 1970s when it became known that specific FVIII concentrates could be produced 
from pools of donor plasma (Mannucci & Tuddenham 2001). Protein replacement 
therapy has been effective and has resulted in both a dramatic increase in life 
expectancy and a vast improvement in the quality of life. However, while this therapy 
proved effective, one major drawback was the frequent contamination of plasma-derived 
FVIII with several human viruses, such as human immunodeficiency virus and hepatitis 
viruses.  
Approximately 70% of tested persons with haemophilia A (FVIII deficiency) and 35% with 
haemophilia B (FIX deficiency) became seropositive for HIV during the 1980s from 
infectious plasma-derived clotting factor concentrates. (The MMWR [Morbidity and 
Mortality Weekly Report] supplement was prepared as a report to the President and the 
Domestic Policy Council, which was presented to the Council on November 30, 1987).  
Although the coagulation factors have been produced from plasma concentrates for 15 
years, genetically engineered recombinant factors are now available. In spite of 
developing new technology to produce recombinant proteins and improved bio-safety, 
the most fundamental issue in haemophilia treatment is the lack of availability of factor 
concentrates for two-thirds of the world’s patient population. Production of bio-similar 
products and prioritisation of their registration will reduce the cost and make recombinant 
proteins more accessible for those patients coming from developing countries (Peyvandi 
et al., 2013).    
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1.6.2. Inhibitor formation 
Patients with haemophilia A treated with FVIII concentrates are at risk of developing FVIII 
neutralising antibodies (NAbs, Inhibitors).  Inhibitor development is one of the most 
complicated matters in the treatment of haemophilia A as it increases the bleeding 
propensity while it provided treatment with therapeutic FVIII concentrates ineffective 
(Eckhardt et al., 2013). The FVIII mutations that are associated with a high inhibitor 
prevalence are large deletions, nonsense or null mutations, and intron 22 inversions 
(Kempton and White, 2009). 
Oldenburg and colleague are found that 68.8% of patients with large deletions had high-
titer inhibitors compared with only 21.2% with missense mutations; the most common 
intron22 inversion with 38.5% and 30% to 40% with all other mutation types. FVIII 
inhibitor antibodies most frequently bind to the A2 and C2 domains of FVIII, where the 
risk of inhibitor formation is 4-fold greater than in patients with mutations outside this 
region. This finding indicates that the prevalence of inhibitor distribution shows 
dependence on the localisation of mutation (Oldenburg and Pavlova, 2006: Fang et al., 
2007). 
The development of neutralising antibody to FVIII is the most significant complication of 
haemophilia A  treatment, occurring in up to 33% of patients with severe haemophilia A, 
but only in 13% of moderate and mild in haemophilia A (Eckhardt et al., 2013). In the 
presence of an inhibitor, the risks of increased mortality, major bleeding complications 
and the cost of care increase substantially. For this reason, developing methods which 
decrease FVIII inhibitor formation is an important goal (Earnshaw et al., 2015). 
The measurement of FVIII inhibitor potency is standardised to the Bethesda method 
(Kasper et al., 1975), where 50% of FVIII activity, relative to control, after 2 hours of 
incubation is defined as one Unit of inhibitor per mL(Bethesda unit). A patient classified 
as a high responder shows above five units at any point after treatment while a low 
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responder presents a titer below five units despite repeated treatments with FVIII 
concentrate (Schwaab et al., 1995; White et al., 2001). Risk factors for developing 
inhibitors are i) mutation in the F8 gene (large deletions, nonsense mutations or 
inversions), and ii) exposure to FVIII during the first 50 days of FVIII concentrate 
treatment. While the development of inhibitor antibodies after rFVIII replacement therapy 
is a major concern, this therapy is currently the most effective treatment option for 
haemophilia A. New factor replacement therapy methods, which are cost-effective and 
safe, are required. 
1.7. Bioengineering of Factor VIII  
1.7.1. Wild type  
Wild-type FVIII has been consistently reported to be very weakly expressed compared 
with the similar coagulation protein FV (Kaufman et al., 1989; Nichols and Ginsburg, 
1999). The cause of the low expression of FVIII has not been fully explained. Particular 
inhibitory elements were discovered in the coding region of FVIII (nucleotides 1681 to 
2277 and 5002 to 5582nt). The 1.2kb fragment of the FVIII cDNA coding sequences 
decreased mRNA accumulation and FVIII protein production because of the consensus 
destabilising sequences “ATTTA and TATT” nuclear matrix attachment region (MARs) 
(Lynch et al., 1993). A similar discovery by Hoeben and colleague show that 305bp of 
coding sequences is the cause of the low expression of FVIII. Both suggest that the 
repressor sequences act as a transcriptional silencer of expression (Hoeben et al., 1995; 
Fallaux et al., 1996). More detail study has been performed that demonstrates the 305bp 
fragment match with “WTTTAYRTTTW” consensus sequence observed in the 
autonomously replicating sequences (ARS) element is responsible for the effect.  
Overall, the MAR or ARS in the FVIII could explain the repressing effects of the FVIII 
mRNA transcription. 
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1.7.2. Codon optimisation 
The codon is a three-nucleotide RNA sequence that corresponds with a specific 
antisense tRNA, which transports a specific amino acid to the ribosome for protein chain 
elongation during synthesis. The genetic code is redundant in that multiple codons 
specify one amino acid, a finding that has been observed in all species. Codon usage 
plays a major role in determining translational efficiency and rare codons result in 
ribosomal stalling during translation. Recently, algorithms have been developed to 
optimise the translation process for efficient protein production. These codon 
optimisation procedures include the elimination of mRNA secondary structures, which 
leads to an efficient translational performance from mRNA (Johnston et al., 2012). 
Cannarozzi and colleagues showed that subsequent occurrences of the same amino 
acid do not use codons randomly in coding sequences, but favour codons are used for 
the same tRNA. The effect is discovered in rapidly induced genes, which involves both 
frequent and rare codons and diminishes only slowly as a function of the distance 
between subsequent synonymous codons. Therefore the translation speed can be 
controlled by tRNA consumption at the ribosome complex (Cannarozzi et al., 2010). Thus 
appropriate usage of tRNA pools in host cells for mRNA translation might be developed 
through evolution to improve the protein yield to survive in extreme environments, which 
require high success rate for the selection process (Tuller et al., 2010). 
Boël et al. suggested that codon content influences protein expression more strongly 
than mRNA-folding parameters. The less efficiently translated protein sequences 
exhibited greatly reduced mRNA levels in-vivo. Moreover, the codon content modulates 
a kinetic competition between protein elongation and mRNA degradation that is a central 
feature of the physiology of translation in E. coli (Boël et al., 2016). 
In addition, by quantifying translational efficiency in healthy and cancerous tissues in 
human and mouse, they showed that many different sets of mRNAs could be equally 
well translated irrespective of their cell-type specificity. This stability of translational 
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efficiency is best explained by differences in GC (Guanine-Cytosine) content between 
genes. The GC variation across the mammalian genome is most likely a result of the 
interplay between genome repair and gene duplication mechanisms, rather than 
selective pressures caused by codon-driven translational rates. Consequently, codon 
usage differences in mammalian transcriptomes are most easily explained by well-
understood mutational biases acting on the underlying genome. Therefore, the 
hypothesis of codon usage biases postulated to exist within mammalian transcriptomes 
might be explained by differences in GC content across the genome.  More evidence 
discovered from mammalian genomes suggests that mutational bias is a sufficient 
explanation for variations in codon usage between sets of genes. For example, when 
compared to prokaryotes, the mammalian genome is better optimised for complex 
transcriptional and post-transcriptional regulation than for codon adaptation.  
Overall, protein translation efficiency and stability can be modified according to the 
mammalian codon usage which can be applied for biosynthesis of stable proteins 
(Rudolph et al., 2016). 
 
1.7.3. Codon optimisation for FVIII 
Human FVIII expression levels are significantly lower than similarly sized proteins.  The 
main reason for this is the inefficient transport of the primary translation product from the 
ER to the Golgi and low mRNA expression (Dorner et al., 1987; Kaufman et al., 1988). 
There are many hurdles to overcome to improve the weak FVIII expression because 
transcribed mRNA levels are very low due to the wild-type FVIII genomic sequence 
containing multiple transcriptional silencers such as ARS/MARs (Lynch et al., 1993; 
Hoeben et al., 1995; Koeberl et al., 1995; Fallaux et al., 1996).  
To improve FVIII expression level, deletion of the entire B-domain leads to a 17-fold 
increase in mRNA and primary translation product, but the amount of secreted protein 
improved only 30%. Which suggests that the rate of ER-Golgi transport is important in 
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reducing protein secretion (Pittman et al., 1994; Miao et al., 2004). Over the last decade 
FVIII bioengineering has been intensively carried out to improve secretion efficiency, 
plasma half-life, functional activity and reduce antigenicity/immunogenicity. As this 
activity has largely occurred in the commercial sector some details of production are 
obscure. However, in at least one academic study, FVIII expression in-vitro and in-vivo 
has been improved by codon optimisation (Ward et al., 2011). In particular direct 
comparison between non-codon-optimised and codon-optimised FVIII showed that 
codon optimised FVIII cDNA sequence improved protein expression by 7- to 30- fold as 
opposed to the wild-type FVIII (Ward et al., 2011).  A similar result reported from Radcliffe 
and colleagues that lentiviral vectors which contained codon engineered FL-FVIII led to 
a siginificant increase in titre of approximately 10-fold but also achieved high secretion 
levels of FVIII. Non-codon optimised FVIII expression was below the limits of detection 
of the assay. In contrast, the codon-optimised FVIII was calculated to contain in excess 
of 100-fold more FVIII than the lowest standard. Therefore, codon optimisation had 
improved full length FVIII expression dramatically. In contrast, for B-domain deleted FVIII 
comparison of a non-codon optimised with a codon-engineered sequence yielded only 
modest improvements in titer and expression (Radcliffe et al., 2007). 
Moreover, Johnston and colleagues reported the controversial result that they used a 
codon optimised hybrid FVIII transgenes, which did not enhance Human/Porcine (HP) 
FVIII expression (Johnston et al., 2012). They concluded that the ineffectiveness of the 
expression of HP-FVIII may be due to the innate high expressing characteristics of HP-
FVIII.  Therefore, the possible mechanism for the enhanced levels of FVIII from a codon 
optimised FVIII transgene could be due to either enhanced codon usage for translation 
or the removal of cryptic sequence, which contains transcriptional silencers and inhibitory 
sequences found within the human FVIII cDNA (Johnston et al., 2012). 
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1.7.4. B-domain deleted FVIII 
Current research shows that the B-domain is not required for FVIII activity and that 
deletion of this domain dramatically improves secretion and stability of this protein. It is 
reported that the removal of B-domain has no effect on the pro-coagulant activity of FVIII. 
Moreover, reduction in the size of the glycoprotein improves its mRNA expression and 
secretion (Toole et al., 1986; Pittman et al., 1993; Pipe, 2009). B-domain deleted 
recombinant FVIII (rFVIII-BDD) products are the newest subset of FVIII protein, and the 
B-domain is replaced with short amino acid sequences that link the 90kDa and 80kDa 
domains of active FVIII (heavy and light chains).  
A, B-domain-deleted (BDD)-rFVIII, rFVIII SQ, was originally characterised by Pharmacia 
& Upjohn (Stockholm, Sweden) and clinical studies began in 1993 and rFVIII SQ was 
eventually developed commercially through an agreement with Genetics Institute (USA), 
then a subsidiary of American Home Products (and eventually Wyeth), in 1997 and was 
finally approved as ReFacto® in March 2000 (Pipe, 2008). 
Commercial recombinant BDD-FVIII (ReFacto®) was first introduced for clinical use 
more than a decade ago. ReFacto® contains a neo-antigenic site (the “SQ” link) which 
generated by joining of Ser743 in the N-terminus with Gln1638 in the C-terminus of the 
B-domain. However extensive clinical use of ReFacto® has shown no increase in the 
frequency of neutralising hFVIII antibodies in patients treated with this product (Lind et 
al., 1995; Sandberg et al., 2001; Lusher et al., 2003; Gringeri et al., 2004; Pollmann et 
al., 2007).  
While ReFacto® was the first modified rhFVIII, on the market new products, have 
recently emerged. By 2014, Novo Nordisk introduced a 21 amino acids linker containing 
truncated B-domain rFVIII Turoctocog alfa (NovoEight®), which is a new rFVIII molecule 
with a truncated B-domain. The molecule consists of a heavy chain containing the A1-
A2 domains, a truncated B-domain coding for 21 amino acids of the naturally occurring 
B-domain (amino acid 741-750 fused with 1638–1648) and the light chain (A3-C1-C2 
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domains). The modified B-domain was selected to achieve a well-defined product, which 
produced in CHO cells in serum-free conditions and formulated without animal- or 
human- derived materials thereby providing a solid basis for establishing a robust 
purification process (Ezban et al., 2014). 
Recently, the firm Octapharma introduced “Nuwiq®” for the production of which producer 
cell lines of human origin (human-cl) have been used for the first time to produce rhFVIII. 
The human-cl rhFVIII consists of a 170kDa protein comprising the functional A and C 
domains of human FVIII with a linker sequence of 16 amino acids inserted between the 
A2 and A3 domains. The first eight amino acids in the N-terminal part of the linker derive 
from the native protein B-domain while the remainder sequence was chosen to provide 
a recognition site for furin or furin-like proteases. This short sequence “QAYRYRRG” 
showed similarity with the sequence “QAYR-RRG” present in a protein of 800 amino 
acids expressed by the KIAA1462 gene in human neural cells in the mainly cerebral 
cortex (Sandberg et al., 2012). The reason for using a human cell line is due to generate 
an authentic human pattern of PTMs which leads to precisely folded and fully active 
FVIII. This is of particular importance as PTMs have been demonstrated to impact on 
rhFVIII activity. The new human cell line-derived recombinant human FVIII (Human-cl 
rhFVIII) protein is the first native and unmodified human rFVIII product produced in a 
human cell line (Sandberg er al., 2012; Kannicht et al., 2013). Human-cl rhFVIII is 
manufactured without additive animal, or human derived materials during production and 
purification (Valentino et al., 2014). 
Biogen Idec /SOBI introduced a 15 amino acids linker BDD-FVIII Fc which has a longer 
half-life. rFVIII-Fc is a B-domain deleted FVIII molecule, which consists of the dimeric 
constant region (Fc) of IgG1 and the terminal half-life of rFVIIIFc (19 hours) was 
extended 1.5-fold compared rFVIII (Dumont et al., 2012). 
Bayer (Bayer Healthcare) has created a PEGylated rFVIII (BAY 94-9027) using site-
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directed mutagenesis. They modified a B-domain deleted rFVIII through the introduction 
of a single cysteine at amino acid 1804 specifically conjugated to a 60kDa PEG molecule. 
In clinical studies, BAY 94-9027 demonstrated equivalent recovery and an improved PK 
profile compared with rFVIII-FS (Kogenate®, FL-FVIII), with a ~19 hours half- life (~13 
hours for rFVIII-FS) (Mei et al., 2010; Coyle et al. 2014). 
 CSL Behring developed a B-domain deleted rFVIII with a covalent bond between the 
heavy and the light chain of FVIII (Lonoctocog alfa), circulating as a single-chain FVIII 
molecule (Schulte, 2013). rVIII-Single chain has a single-chain design in which a 
truncated B-domain covalently links the heavy and light chains improved intrinsic 
stability. In addition, it has been shown that the affinity of rVIII-Single chain for vWF is 
markedly higher, and its pharmacokinetic properties are improved, compared with full-
length rFVIII (Schmidbauer et al., 2015).  
In 2004, Pipe and colleagues created and tested FVIII expression plasmids containing 
human B-domain fragment with varying numbers of glycosylation sites ranging from N1-
N8. They found that including a 226 amino acids linker containing six N-linked 
oligosaccharides, in the domain increased mRNA stability and production (Miao et al., 
2004). 226aa/N6 has six N-linked oligosaccharides within a truncated B-domain spacer 
inserted into otherwise wild-type BDD-FVIII (Fig.1.5). This variant had the most 
increased mRNA and primary translation product levels and improved secretion 
efficiency. In contrast, Kolind and colleagues have reported novel B-domain deleted 
mutants with varying linker lengths and numbers of N-linked glycosylation sites. Their 
results showed that short linker B-domain FVIII constructs were better expressed than 
longer B-domain linker and that presence of N-linked glycosylation sites showed no 
improvement to FVIII yield in serum-free condition. From this work, no unifying 
explanation or conclusions were derived (Kolind et al., 2010).   
In 2013, McIntosh and colleagues developed a novel B-domain deleted FVIII named V3, 
the V3 peptide was flanked by 14 amino acids SQ residues from the N- and C-terminal 
                                                                                                                          Chapter 1 
 
 57 
ends of the B domain. This variant was developed for AAV gene therapy for haemophilia 
A.  It was found that rAAV-HLP-codop-hFVIII-V3 mediated higher hFVIII antigen 
expression in two different murine models compared with codon optimised FVIII SQ 
containing 14 amino acids linker identical to SQ and a FVIII with a 226aa truncated B-
domain each in the same AAV cassette. Significantly, the manner in which the N-
glycosylation triplets from the B-domains are brought together appeared to be important, 
because minor changes to the 17 amino acids peptide (V3) markedly affected expression 
levels in-vivo and in-vitro (McIntosh et al., 2013). 
Notwithstanding theoretical objections, the practical advantages render BDD-FVIII more 
attractive, because, as has been suggested it is safe, efficacious, and immunologically 
similar to wild-type FVIII. The particular advantages of B-domain deleted FVIII for 
therapeutic use includes its greater level of expression and significantly reduced 
heterogeneity. Thus, the cost of production should be significantly less than wild-type 
FVIII for producing recombinant FVIII.  In addition, the limited size of the cDNA construct 
allows its insertion in most viral vectors (including Adeno associated virus) with the aim 
of therapeutic gene transfer (Pittman et al., 1993; Chao et al., 2000; Chao and Walsh, 
2001). 
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Figure 1.8. Schematic diagram of FVIII variants  
FVIII variant domain structures were illustrated as full length FVIII (FL-hFVIII), B-domain deleted 
FVIII (BDD-hFVIII), and 226 amino acid lengths truncated B-domain of N6-hFVIII. 
Full-length hFVIII (FL-hFVIII) represent 25 N-linked glycosylation sites and full-length B-domain 
with 908 amino acids. BDD-hFVIII, Ser743 was fused to Gln1638, creating a 14 amino acid “SQ” 
linker between the C-terminus of the 90kDa chain and N-terminus of the 80kDa chain. N6 hFVIII, 
226 amino acid reserved from N-terminus of B-domain and fused to Gln1650 in a3 region, creating 
a 226 amino acid /N6 linker. Potential N-linked glycosylation sites are indicated by lollipops. Blue 
lollipops (N7-N19) inside of full-length B-domain were excluded in this study. 
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1.7.5. Commercial recombinant FVIII 
1.7.5.1. History of recombinant proteins and current developing products 
The F8 gene was cloned in 1984, which allowed recombinant human FVIII (rFVIII) to be 
produced and purified from mammalian cell culture. Thereafter, the first generation of 
recombinant full-length FVIII (rFL-FVIII) was introduced in the early 1990s, which is CHO 
cell-derived full-length FVIII (Recombinate®, Baxter), and the following year the BHK cell 
derived rFL-FVIII (Kogenate®, Bayer). Ten years later, in 2000 Wyeth developed the 
second generation of B-domain deleted rFVIII (ReFacto®). Another so-called second-
generation modification was the removal of human albumin from formulation stabilising 
the final product of rFL-FVIII (Kogenate®, Bayer). The third generation production 
method of Kogenate (also marketed as Helixate), Advate, and ReFacto® does not 
contain any animal or human proteins in the culture medium. However, these products 
were generated in non-human cell lines, which produce recombinant glycoproteins with 
a rodent glycosylation pattern. By this consideration, recently Biogen Idec/SOBI and 
Octapharma companies developed products which are produced in HEK-293 cells 
(Casademunt et al., 2012). Their products have been tested in clinical trials and are 
approved by health authorities. Currently, several companies supply rFVIII, in which FL-
FVIII or B-domain deleted product are present (Table 1.1). The Baxter (now 
Baxalta/Shire) production system includes co-expression of vWF, but this is removed 
from the final product. 
An approach to improve coagulation factors is to extend their half-life. Obtaining half-life 
extension has been challenging for therapeutic proteins but is now being applied to FVIII.  
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Company Product Generation Gene Cell line 
Baxter 
 
Recombinate® 1 FVIII/VWF CHO 
Advate 3 FVIII/VWF CHO 
Bayer 
 
Kogenate® 1 FVIII CHO 
Kogenate FS 2 FVIII BHK 
CSL Behring Helixate 2 FVIII BHK 
Pfizer 
 
ReFacto® 2 BDD-FVIII CHO 
ReFacto AF 3 BDD-FVIII CHO 
Green Cross 
 
GreenGene 2 BDD-FVIII CHO 
GreenGene F 3 BDD-FVIII CHO 
Biogen Idec/SOBI Eloctate® 3 BDD-FVIII Fc HEK 
Novo Nordisk NovoEight® 3 tBDD-FVIII CHO 
Octapharma Nuwiq® 3 tBDD-FVIII HEK 
 
Table 1.1. Recombinant human FVIII concentrates 
Recombinant human FVIII is produced from three different cell lines by genes carrying FVIII/vWF, 
FVIII, BDD-FVIII and truncated BDD-FVIII. Biogen Idec and Octapharma produced rFVIII from 
human cell lines.  The B-domain engineered rFVIII protein products enlarged in the 3rd generation 
of recombinant FVIII. Abbreviation: CHO, Chinese hamster ovary; BHK, Baby hamster kidney; 
HEK, Human embryonic kidney. 
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1.7.5.2. Current strategies to improve FVIII half-life  
Human FVIII is large, complex protein, and its half-life is relatively short, which 
necessitates frequent dosing to maintain therapeutic levels. Modifications that extend 
the product’s half-life could theoretically allow for extended dosing intervals (Schulte, 
2013). Recombinant factors with longer residual time in circulation would cumulate the 
benefits of reducing the frequency of infusions thus improving the compliance with 
improved prophylaxis regimens for haemophilia A patients by reducing the frequent 
injection of rFVIII requiredby by its short half-life (Pan et al., 2009).  
In this context, several strategies are being exploited to optimise the pharmacokinetics 
of therapeutic FVIII, which include coupling of the effector protein to polyethylene glycol 
(PEG), dimeric Fc fragments of human immunoglobulin G, or human serum albumin (Ing 
et al., 2016). 
PEGylation used for many therapeutic proteins, which have been approved for variety of 
chronic diseases. However, PEGylation of FVIII is difficult due to large moledular weight 
which lead to different characteristics and activity levels. Therefore the chemicaly 
modified PEGylation of FVIII has been developed that the selective PEGylation was 
achieved by  a mutation in the light chain of FVIII. Other approaches to increase the 
functional half-life of drugs include the production of recombinant fusion proteins where 
the FVIII actvities are modified through the fusion to a Fc-domain or albumin of an 
antibody (Stennicke et al., 2013). 
Modification with PEGylation is a method to improve the pharmacokinetic profile and 
extend half-life about 2.5-fold. The circulation of therapeutic proteins by increasing size 
leads to reduction of renal clearance. The clearance of FVIII take place primarily in the 
liver where interaction occur with low-density lipoprotein receptor-related protein (LRP). 
The FVIII modification by PEG polymers might achieve a longer-acting FVIII due to 
reducing binding of the PEG-conjugated FVIII to LRP (Pan et al., 2009; Turecek et al., 
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2012). PEGylation of FVIII was shown to confer prolonged efficacy in haemophilic mice, 
as compared to unmodified FVIII (Mei et al., 2010).  
rFVIII-Fc is a fusion protein, which composed of a single B-domain-deleted FVIII 
molecule to the dimeric Fc fragments of human immunoglobulin G. rFVIII-Fc exhibits 
approximately 2-fold extension in half-life in haemophilia A mice and dogs (Dumont et 
al., 2012).  
The CSL Berhring rVIII-Single chain was designed with a covalent bond between the 
heavy and light chains of FVIII. The heavy and light chains of native FVIII, are held 
together by a metal-ion bridge, which makes the FVIII molecule relatively unstable. The 
recombinant single-chain FVIII (rVIII-Single chain) further strengthens the interaction 
between these two FVIII chains and results in a significantly increased binding to vWF.  
The half-life of vWF bound FVIII is about 12 hours in contrast free FVIII shows only an 
hour. Consequently, the increased proportion of vWF bound FVIII leads to an extension 
of the FVIII half-life (Oldenburg and Albert, 2014; Schmidbauer et al., 2015). 
Reduced interaction with clearance receptor (Baxter, Bayer and Novo Nordisk), 
interaction with the neonatal Fc receptor and immunoglobulin molecules protecting the 
protein from intracellular degradation finally increased FVIII half-life by 2-fold (Biogen 
Idec/SOBI) (Powell et al., 2012).   
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1.8. Post-translational modifications (PTMs) 
Post-translational modifications (PTMs) are important in regulating the folding of protein, 
activity, and stability by covalent linkage to new functional groups, such as acetate, 
phosphate, and methyl groups. For many PTMs, including acetylation, glycosylation, 
methylation, phosphorylation, SUMOylation, succinylation and ubiquitination tens of 
thousands of sites can now be confidently identified and localised in the sequence of the 
protein (Olsen et al., 2013; Liu et al., 2016).  
PTMs dynamically alter the compartmentalisation, trafficking, and physical interaction of 
key molecules that regulate immunological processes (Liu et al., 2016). Some PTMs, 
including glycosylation, lipidation and disulfide bridge formation are stable and are 
important for maturation and proper folding of newly synthesised proteins. Others, such 
as phosphorylation, are more transient and have essential roles in intracellular signalling. 
A protein can be modified by more than one type of PTMs or multiply modified by the 
same PTMs at different residues (Deribe et al., 2010). Importantly, >95% of these data 
are derived from mass spectrometry (MS) based proteomic which has considerably 
extended our knowledge about the occurrence and dynamics of protein post-
translational modifications. So far, quantitative proteomics has been mainly used to study 
PTM regulation in cell culture models and focus on quantifying, sometimes slight relative 
changes of modified peptides between different sample states. Cell culture conditions 
may be manipulated to influence productivity and PTMs for example, temperature, 
growth rate and media composition (Butler, 2005). 
It is suggested that analysis of aberrant PTM patterns in human disease would provide 
new insights that might have a direct impact in the clinic (Olsen et al., 2013; Pagel et al., 
2015).  
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1.8.1. Glycosylation 
Glycosylation is a post-translational protein modification that expands the diversity of the 
proteome. Eukaryotic glycoproteins have been implicated in cellular processes including 
the intracellular targeting, immune response, intercellular recognition, protein folding and 
stability (Varki, 1993). A variety of glycan-protein linkages have been identified in 
glycoproteins from bacterial organisms to a eukaryote (Weerapana and Imperiali, 2006). 
The intensive research of glycosylation systems in eukaryotic organisms has been 
carried out since the 1930s; it raised assumptions that bacteria and archaea were 
deprived of this important protein modification (Messner, 2004). 
Glycosylation can introduce heterogeneity through the generation of different 
oligosaccharides, and variable addition of outer arm sugars as the glycoprotein transits 
in the Golgi. The presence and nature of the oligosaccharide (glycoform) may impact 
glycoprotein folding, stability, trafficking and immunogenicity as well as its primary 
functional activity (Walsh and Jefferis, 2006). 
In an individual glycoprotein, more than one carbohydrate unit is often present, attached 
at different positions by either an N-linkage, 0-linkage or both. Moreover, each 
attachment site frequently accommodates different glycans; a phenomenon referred to 
as site heterogeneity. This results in micro-heterogeneity of the whole molecule and 
creates discrete subsets, or glycoforms, of a glycoprotein that have different physical 
and biochemical properties. This may lead to functionally diversified glycosylation of any 
protein, which is dependent on the cell or tissue in which it is produced. Thus the 
polypeptide encodes information that directs its own pattern of glycosylation (Lis and 
Sharon, 1993). 
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The structural changes of glycan play critical roles on many glycoproteins in modulating 
functional activity and immunogenicity. Moreover, the diversification in carbohydrate 
structures has been associated in the pathogenesis of many human diseases, such as 
cancers which are related with alterations in protein glycosylation ( Preston et al., 2013; 
Holst et al., 2016).  
Genetic engineering makes it possible to produce glycoproteins in heterologous systems 
on a large scale, both for research purposes and for therapeutic use. For instance, 
oligonucleotide-directed mutagenesis allows for specific changes in the primary structure 
of glycoproteins and facilitates the examination of factors governing site-specific 
glycosylation and oligosaccharide processing. In glycoproteins with more than one 
glycan, mutagenesis provides insights into the contribution of each glycan to the overall 
properties of the molecule (Lis and Sharon, 1993). Several factors may influence glycan 
biosynthesis, namely, the under or overexpression of glycosyltransferases, the 
impairment of glycosyltransferase chaperone function, altered glycosidase activity, 
changes in the tertiary conformation of a given peptide or growing glycan, and the 
availability of sugar nucleotide donors, cofactors and acceptor substrates (Ferreira et al., 
2016).   
N-linked glycans on glycoproteins are attached to the side chain of asparagine (Asn), 
and the N-linked glycosylation begins in the endoplasmic reticulum (ER). The attachment 
of N-linked carbohydrates to proteins is thought to occur during or shortly after 
translocation of the nascent chain into the lumen of the endoplasmic reticulum. The 
oligosaccharide chain is transferred by the enzyme oligosaccharryl transferase to the 
asparagine in the consensus tripeptide Asn-X-Thr/Ser, where X is any amino acid except 
proline (Mononen and Karjalainen, 1984). The initial 14 sugar core of N-linked glycan is 
mannose-rich (Glc3Man9GlcNAc2) structure, which  attached during protein synthesis 
in the ER. Subsequently, the core glycan is modified by a series of glycosyl-transferases 
and glycosidases through the ER and the Golgi apparatus. The ER chaperone proteins 
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calnexin and calreticulin engaged with newly synthesised glycopeptides. Calnexin is a 
lectin that binds to N-linked oligosaccharides and assists glycoproteins during initial 
folding or oligomeric assembly to prevent aggregation, leaving the ER prematurely and 
to ensure quality control (Hammond et al., 1994; Hebert et al., 1995).  
N-linked glycans are further modified in Golgi where the properly folded glycoproteins 
are transported from the ER. Due to the fact that more than a hundred 
glycosyltransferases are found in the human genome, the complexity and heterogenecity 
of the final N-linked carbohydrate structure exist in nature. Overall, N-linked glycans can 
be classiﬁed into 1 of 3 subgroups: high-mannose, hybrid, or bi- tri- tetra complex (Fig. 
1.6).  
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Figure 1.9. Biosynthesis of N-glycan in Eukaryotes 
N-linked glycosylation starts in the ER and antennary structures are further processed in the Golgi 
apparatus. N-linked glycans can be classiﬁed into 1 of 3 subgroups: high-mannose, hybrid, or bi- 
tri- tetra complex depending on antennary structures (Preston et al., 2013). 
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1.8.2. Human FVIII N-linked glycosylation 
Recent studies have focused on the post-translational modifications, and specifically 
glycosylation of the FVIII protein, suggesting their pivotal role in FVIII biosyntheses, 
stability, quality control, secretion, activation and clearance. Glycoproteins that are 
incorrectly glycosylated fail to fold properly and/or fail to exit the ER, and are 
consequently degraded (Varki, 1993). 
FVIII has a heavily glycosylated B-domain region containing 19 N-linked glycosylation 
sites. A large proportion of FVIII is not secreted, which was detected in a stable complex 
with BiP. However, the deletion of the heavily glycosylated region showed efficent FVII 
secretion due to reduced binding  with BiP (Dorner et al., 1987). The deletion of most of 
the highly glycosylated internal domain of FVIII produces a protein which retains pro-
coagulant activity and displays higher levels of secretion compared with FL-FVIII (Toole 
et al., 1986).   
The utilisation of N-linked glycosylation sites on a protein may influence the extent and 
stability of an association with BiP, and this can be correlated with the efficiency of 
secretion. In the absence of normal N-linked glycosylation efficient secretion is impaired. 
The un-glycosylated protein displays increased association with BiP and this complex is 
stable and not secreted. N-linked glycosylation sites on FVIII play a role in its efficient 
secretion and the extent and stability of its association with BiP. In the case of FVIII, 
deletion of the heavily glycosylated region by removal of protein sequence resulted in a 
reduced association with BiP (Dorner et al., 1987).  
Consequently, the 19 N-linked sites clustered in the FL-FVIII (B-domain: 19, Total: 25) 
may be presented in an appropriate conformation for too short a period of time (4~6 
hours) for efficient glycosylation. Some molecules may, therefore, exhibit incomplete N-
linked glycosylation. Further, it was observed that inhibition of N-linked glycosylation 
enhances association with BiP; incomplete glycosylation of FVIII may result in stable 
association with BiP and retention in the cell (Dorner et al., 1987).  
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Interestingly, de-glycosylation of a human recombinant FVIII variant resulted in a 
substantial impairment of its clotting activity, suggesting the significant role of glycans in 
FVIII functions. Moreover, heavily glycosylated B-domain deleted FVIII, which has 
reduced polysaccharide moieties induces inhibitors, suggesting that glycosylation 
changes directly or indirectly through alteration of structure conformation, modifies the 
immunogenicity of the protein (Lee et al., 1998). The small conformational changes in A 
and C domains led to the N-linked glycosylation to this epitope, which may play a critical 
role in the loss of FVIII activity (Kosloski et al., 2009).  
1.8.3. Recombinant protein production in mammalian cells 
For large-scale production, recombinant proteins are expressed in immortalised 
mammalian cells. Chinese hamster ovary (CHO) cells, Baby hamster kidney (BHK), 
Human embryo kidney (HEK-293), Mouse myeloma (NS0), SP2-0 (hybridoma), HKB11 
and human retinal cells (PER-C6) have each gained regulatory approval for recombinant 
protein production (Wurm, 2004; Swiech et al., 2012). Mammalian cell systems are 
attractive to produce- recombinant proteins, because of capacity for proper protein 
folding, assembly and post-translational modifications. Significant progress in 
developing and engineering new cell lines, introducing novel genetic mechanisms in 
expression, gene silencing, and gene targeting has been achieved. Understanding 
glycosylation has become one of the foci of research and development. Transient gene 
expression technology platforms play more important role in biopharmaceutical 
manufacturing (Zhu, 2012). The development of a manufacturing process for a 
recombinant protein in mammalian cells is well established and constantly being 
improved with current technology. 
HEK-293 cells were first established by Dr Frank Graham in 1977.  These HEK-293 cells 
have been widely employed as an expression host in scientific research over the last 
half-century.  Adherent HEK-293 cell lines were adapted to suspension cell culture in 
2003 by Invitrogen. Since then human cell lines have been evolved that are easily grown 
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in animal origin free raw materials under serum-free conditions while eliminating 
concerns associated with the use of animal-derived serum. A suspension cell does not 
require enzymatic or mechanical dissociation and typically achieves cell densities of 
3x106cells/mL in shaker or spinner culture and 4x106cells/mL in bioreactor culture. 
Consequently, it is now easy to scale up a cost effective culture method (Gibco, 2003). 
Nowadays, human origin cells are used for bulk protein production, batch harvesting and 
many research applications. The human cell line contains the translational machinery 
and all the subcellular compartments, which is required to generate correctly folded and 
fully active FVIII, with a genuine human pattern of PTMs and human protein-like 
molecular structure assembly (Zhu, 2012).   Despite the safety and efficacy of 
recombinant protein expression in hamster or mouse cells, the glycosylation pattern is 
of profound importance when considering their potential as expression systems for 
biosynthesis of human recombinant glycoproteins. Non-human cells simply do not 
glycosylate according to the human-type. These differences in glycosylation pattern may 
be highly immunogenic in humans, and/or may cause rapid clearance of the recombinant 
protein from circulation (Brooks et al., 2004). 
 The anticipated benefit of using human cells in the production of rFVIII is avoidance of 
development of inhibitors due to non-human glycosylation pattern (Goudemand et al., 
2006). Immunogenicity not only remains a serious cause of morbidity in patients but also 
4-fold increases the annual cost for treatment (Gringeri, 2003). Due to the PTMs 
expected to be produced in recombinant proteins, human cell line PTMs are more similar 
to their natural proteins and reduce the potential immunogenic reactions against 
nonhuman epitopes, therefore human cell lines are an attractive alternative for protein 
production for human therapeutic proteins (Swiech et al., 2012; Zhu, 2012). 
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1.8.4. Cell type specific Post-translational modifications  
Various host cell lines are available to express recombinant proteins. However PTMs 
differ between species and are organ specific, hence producing recombinant 
glycoprotein by a human cell line is important for prevention of potential novel 
immunogenicity by non-human PTMs (Böhm et al., 2015;  Kannicht et al., 2013). 
According to literature, production of FVIII in human cells produces similar post-
translational modifications to those observed in the human plasma FVIII product 
(Sandberg et al., 2012). Additionally, rFVIII expression in a human cell line avoids the 
expression of the antigenic carbohydrate epitopes Gala1-3Gaβ1-GlcNAc-R (α-Gal) and 
N-glycolylneuraminic acid (Neu5Gc), which are present on hamster glycoproteins, and 
so in CHO and BHK cell line produced proteins (Valentino et al., 2014). The anti-α-Gal 
is the most abundant natural antibody in all humans (~1% of circulating immunoglobulins 
in humans), and it mediates the rejection of pig xenograft organs in humans. The α-Gal 
epitope has clinical potential in the production of vaccines expressing α-Gal epitopes 
that can be targeted to antigen-presenting cells, thereby increasing the immunogenicity.  
There are different types of PTMs in FVIII glycoprotein; this glycoprotein has 25 N-linked 
glycosylation sites, seven O-linked glycosylation sites and six sulphation in full-length 
FVIII (Kannicht et al., 2013; Preston et al., 2013). Glycosylation alters the functional and  
structural properties of a protein and is responsible for physiological properties, 
immunological properties, receptor binding and intracellular sorting. FVIII contains six 
tyrosine residues that are modified by posttranslational sulphation for full FVIII pro-
coagulation activity and stability. These sulphation sites have a critical role in FVIII/vWF 
binding affinity because thrombin cleavage sites are located in the tyrosine sulphation 
border. Moreover, sulphation of FVIII Tyrosine1680 is vital for the interaction with vWF 
and influences the half-life of FVIII in the circulation. In addition, the current study uses 
human cell lines for the production of the FVIII protein to ensure that it is efficiently 
glycosylated in the hope of reducing the immunological response to the FVIII protein that 
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is observed in 30% of the patients treated with the current protein concentrates which 
are manufactured in CHO or BHK cell lines.   
 
1.8.5. Comparison of the most common epitopes between plasma-derived 
FVIII and rFVIIIs 
Although non-human originated cell line produced most abundant Gal-α1,3-Gal and 
Neu5Gc, however, there are many epitopes represented depend on basic sources of 
purification or production. The most common epitopes are represented in Figure 1.10. 
Although HEK-293 cell lines human origin cell line but introduced by the kidney, so 
fucosylated LacdiNac epitope represented with human plasma-derived protein. In blood 
group antigens, Lewis x/a existed plasma-derived FVIII, rodent cell line and Human cell 
lines derived rFVIII. Other blood A.B.O group’s epitopes present human plasma protein 
glycans and plasma-derived FVIII. 
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Figure 1.10. Most common features of glycans of plasma glycoproteins, compared 
with those found in human FVIII therapeutic replacement proteins  
Abbreviation: pdFVIII, Plasma-derived FVIII; rhFVIII, Recombinant human FVIII derived; CHO, 
Chines Hamster Ovary cell derived rFVIII; BHK, Baby hamster kidney cell derived rFVIII; HEK-
293F, Human embryo kidney cell line 293F derived rFVIII. The structures were modified from 
Kannicht et al. (Kannicht et al., 2013).   
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1.9. Gene delivery technology 
In order to study the functional role of genes, it is necessary to manipulate the expression 
of specific genes in target cell populations. Gene manipulation has been achieved using 
transgenic animals or non-viral gene transfections including naked DNA (Kofler, 1998), 
electroporation (Li et al., 1997)  and liposomes (Nicolau et al., 1987). However, non-viral 
transfer systems are relatively inefficient in post-mitotic neuronal cells. In addition, 
transgenic methods are expensive and time-consuming. In contrast, recombinant viral 
vectors are able to achieve efficient long-term transduction in a variety of cell types.  A 
number of viral vector systems are now further developed with the aim of producing an 
optimised vector that can transduce with high efficiency, provide a robust and long-term 
expression, and elicit no host immune response. 
 
1.9.1. Non-viral vectors 
Non-viral vectors have the advantage of avoiding some of the problems associated with 
viral vectors such as oncogenic effects and unexpected immune response. Further, non-
viral vectors have advantages regarding simplicity of use and ease of large-scale 
production. These techniques are categorised into two general groups: first, naked DNA 
delivery by physical methods, such as electroporation, second, delivery mediated by a 
chemical carrier such as cationic polymer and lipid. 
 
1.9.1.1. Naked DNA delivery 
Transfection of naked DNA into cells is highly inefficient because cellular uptake of DNA 
relies on non-specific endocytosis and these naked DNAs are degraded by the 
lysozyme. Therefore, naked DNA import into the nucleus is more difficult (Wiethoff and 
Middaugh, 2003). However, these cellular DNA uptakes can be improved by the use of 
electroporation which increases cell permeabilization through controlled electric fields 
(Coster and Chilcott, 2002). The injection of naked DNA followed by the application of 
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pulsed electric fields has been used for gene transfer to the liver (Liu and Huang, 2002), 
skin (Zhang et al., 2002), and subcutaneous tumours (Lucas et al., 2002). 
 
1.9.1.2. Chemical Carrier 
A common physical method of introducing DNA into cells relies on the use of cationic 
carrier (Pedroso de Lima et al., 2001; Taranejoo et al., 2015). The addition of cationic 
lipids (in the form of liposome) to plasmid DNA decrease the negative charge of the 
nucleic acid and facilitates its interaction with the cell membrane (Wiethoff and 
Middaugh, 2003). Liposomes are lipid bilayers entangle a fraction of aqueous fluid. DNA 
will spontaneously associate to the external surface of cationic liposomes, and these 
liposomes will interact with the cell membrane. Using this method in-vitro 90% 
transfection efficiency can be achieved. To enhance the transfection efficiency obtained 
with liposomes in hard to transfect cells, molecular conjugates consisting of a protein 
such as an asialoglycoprotein and transferrin or synthetic ligand have been used. 
Despite these improvements in non-viral gene delivery, transfection of certain cell types 
remains inefficient in comparison to viral vectors (Washbourne and McAllister, 2002). 
Non-viral gene transfer systems are also comparatively toxic to certain cell types.  The 
toxicity is mainly due to its cationic nature and a non-cleavable molecular structure that 
restricts its biomedical applications (Taranejoo et al., 2015). 
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1.9.2. Viral vectors 
Viruses are obligate intracellular parasites that have evolved to efficiently replicate their 
genetic material while avoiding detection by the host immune system. Hence, by 
replacing non-essential viral genes with foreign genes of interest a harmless highly 
efficient recombinant viral vector gene delivery system can be made. Viral gene delivery 
allows the expression of a gene in almost any mammalian cell type. However, selecting 
the best viral gene delivery system for a particular experimental aim can be challenging. 
Viral based vector systems that are under development include Adenovirus, Adeno-
associated virus and lentivirus. Table 1.2 shows most common viral vectors used in gene 
transfer. 
 
 
Table 1.2. Viral vectors for in-vivo gene transfer  
Viruses have advantages and limitations for gene delivery. Although adenovirus is able to 
package up to 35kb large genome, adenovirus is highly immunogenic. In contrast, AAV is less 
immunogenic and has only 4.7kb packaging capacity. The lentivirus is capable of long-term gene 
expression due to the viral genome integration into a host cell. However it might thereby cause 
insertional mutagenesis.  
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1.9.2.1. Pseudo typed Lentiviral vectors 
The lentiviruses are a subgroup of the retroviruses, the family Lentiviridae, which are 
able to infect both proliferating and non-proliferating cells (Kim et al., 1998). They are 
more complicated than simple retroviruses and containing six proteins tat, rev, vif, vpr, 
nef and vpu, Vpr, Vif and Nef found in the viral particle, are involved with integration, 
maturation and budding during the viral life cycle. Vpu indirectly assists in the assembly 
of the virion by promoting the release of newly synthesised env glycoproteins from CD4 
molecules. This enables env to be transported to the cell surface, providing proteins for 
the outer membrane coat. 
Tat and rev provide essential gene regulatory functions and are therefore present in all 
lenti viruses. They enhance the rate of transcription and mediate nuclear export of un-
spliced viral RNA, respectively (Blesch, 2004). The lentivirus-encoded gag matrix 
protein, integrase enzyme and vpr protein interact with the nuclear import machinery and 
facilitate the import of the viral genome. 
The most commonly used lentiviral vectors have been developed from the Human 
Immunodeficiency Virus-1 (HIV-1). An Early version of recombinant HIV vectors was of 
limited use due to their strict host cell tropism and the conserved potential risk of 
generating wild-type virus (Poznansky et al., 1991). In order to overcome the host cell 
tropism, lentiviral vectors were pseudo typed with the vesicular stomatitis virus G (VSVG) 
envelope protein. This increased the host cell tropism of lentiviral vectors and 
substantially reduced the potential to form wild-type HIV (Naldini et al., 1996). The use 
of a separate plasmid containing  a heterologous envelope makes it extremely unlikely 
to generate replication-competent virus, as two independent homologous recombinant 
events would have to occur. VSVG pseudo-typed vectors transfect both dividing and 
non-dividing cells in vitro (Reiser et al., 1996). 
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1.9.2.2. Improve Biosafety using pseudo-typed lentivirus 
The possibility of insertional activation of an oncogene following transfection of lentiviral 
vectors has been addressed by the development of self-inactivation (Sin) lentiviral 
vectors. The HIV-1 provirus is separated into the cis-acting sequence, and trans-acting 
sequence, this split-genome, the conditional packaging system is based on existing viral 
sequences and acts as a built-in device safeguarding against the generation of 
productive recombinants to improve biosafety (Dull et al., 1998).  HIV contains two 
regulatory genes, tat and rev, essential for viral replication and four accessory genes, 
vif, vpr, vpu, and nef that are not crucial for viral growth in-vitro but are critical for in-vivo 
replication and pathogenesis. Consequently, the cis–acting sequences (LTR, RRE, 
splice donor, acceptor, Ψ, PBS, PPT and cPPT) are instead linked to the transfer vector 
constructor. The transacting genes (gag, pol, env) are located on two separate plasmids. 
The transfer vector consists of modified LTRs, a transgene driven by a suitable promoter 
and packaging signal (Figure.1.8). The 3’ sequence of the U3 element has been modified 
remaining only 18bp, thus eliminating promoter activity and ensuring that proviruses 
resulting from this vector can not transcribe their full genome and therefore self-
inactivating (Sin)(Zufferey et al., 1998). 
Further features of these vectors include an extended packaging signal the cPPT/CTS 
(central termination sequences) element, which enhances transduction in non-dividing 
cells. The 3rd generation packaging system matches the performance of its predecessors 
regarding both yield and transducing efficiency. However, it increases significantly the 
predicted biosafety of the vector (Dull et al., 1998; Zuffery et al., 1998).  
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Figure 1.11. Schematic representation of the HIV provirus and the 3rd generation 
packaging constructs 
A) The original HIV-1 provirus, B) 3rd generation self-inactivate shuttle plasmid, C) Packaging 
plasmids. Separate trans- and cis-acting element improve biosafety from self-inactivation pseudo-
typed HIV. The self-inactivating (Sin) lentiviral shuttle vector; strong trans-activator tat and rev 
exons have been deleted, and the viral sequences upstream of the gag gene have been replaced, 
the 3’ LTR has an almost complete deletion of the U3 region, which is replaced by the TAT-
independent Rous Sarcoma Virus (RSV) promoter. The vector contains a central polypurine tract 
(cPPT) to enhance vector potency and transgene expression. The 3rd 
generation packaging constructs: pMD.G, encodes an envelope to pseudotype the vector, here 
shown coding for vesicular stomatitis virus glycoprotein (VSVG) gene derived from the CMV 
promoter. pMDLg/pRRE expresses the gag and pol genes under the CMV promoter. RSV-Rev 
expresses the rev cDNA. Ψ-packaging signal, CMV is the hCMV promoter, PA-polyadenylation 
signal. The plasmid structures were modified Dull et al. (Dull et al., 1998). 
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1.9.2.3 Adeno associated virus 
AAV vectors are developed from a parvovirus, which is naturally occurring adeno-
associated virus.  It was first isolated in 1966 in studies of pathogens in the respiratory 
tract.  AAV is not autonomously replicating in animal hosts or cell cultures but it is rather 
dependent on a helper virus, adenovirus or herpes simplex for replication (Buller et al., 
1981; Mingozzi and High, 2013). 
AAV belongs to the Parvoviridae family of viruses. Viruses in this family are small (20 to 
26 nm) non-enveloped viruses containing a single-stranded DNA viral genome 
approximately 4.7kb size with palindromic 145 bases Inverted terminal repeat (ITRs) at 
each terminal. The genome of AAV encodes two open reading frames (ORFs), one 
encoding the genes responsible for replication (Rep gene) and the other encoding the 
viral structural capsid genes (Srivastava et al., 1989; Berns, 1990). 
Four regulatory proteins (Rep78, 68, 52 and 40) with overlapping amino acid sequences 
are translated from both spliced and un-spliced forms of the two mRNAs transcribed from 
the left side open reading frame. The right side opens reading frame contains the Cap 
gene, which produces three viral capsid proteins (VP1, VP2, and VP3). The unspliced 
transcript produces VP1 (87kDa), the biggest of the capsid proteins. The spliced 
transcript produces VP2 (72kDa) and VP3 (62kDa). The VP3 represents 80% of the total 
virion protein mass. 
The AAV life cycle has a lytic and lysogenic stage for successful infection. In the 
presence of helper virus (adenovirus or herpes virus), the lytic stage occurs. During this 
stage, AAV undergoes productive infection characterised by genome replication, viral 
gene expression, and virion production (Daya and Berns, 2008). 
AAV genome is the only example of an exogenous DNA that integrates at a specific site 
(ql3.3-qter) in the human genome chromosome 19 and integrated AAVS1 site (Linden 
and Winocour, 1996). This site was first identified in cell culture (Kotin et al., 1992), and 
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has also been identified in human tissues infected with wild-type AAV.  However, in 
human tissues AAV was predominately found non-integrating in episomal forms, 
mirroring what is observed with recombinant vectors (Schnepp et al., 2005). In addition, 
In-vitro experiments suggest that the AAVS1 locus is a safe integration site. It  remains 
to be evaluated that AAV integration into this site is suitable for human gene therapy 
applications (Daya and Berns, 2008). 
 Current understanding of this process implicates cis-active signals, both in the viral 
genome and at the site of integration, as well as Rep 68/78 (AAV vector virions from 
which the rep gene has been deleted do not integrate in a site-specific manner) (Kyöstiö 
et al., 1994;  Linden and Winocour, 1996). 
 
1.9.2.4. Recombinant Adeno associated virus (rAAV) 
The viral genome comprises with genes and cis-acting regulatory sequences, and it is 
used for the design of recombinant viral vectors (Kay et al., 2001). Recombinant AAV 
vectors have 96% of the viral genome removed from the vector, only the two 145-base 
pair (bp) ITRs which is sufficient for packaging and integration (Samulski et al., 1983). 
The original recombinant AAV (rAAV) was produced by the transfection of a plasmid 
encoding the transgene cassette flanked by ITRs with a plasmid encoding rep and cap 
genes flanked by ITRs, which involved in intermolecular recombination (Yan et al., 2005). 
The transfected cells were then infected with a helper virus, such as Herpes or 
Adenovirus (Buller et al., 1981; Samulski et al., 1983). 
Figure 1.12 shows that rAAV packaging plasmids, the Rep/Cap genes contained plasmid 
decisive viral serotype and transgene expression cassette, which included tissue specific 
promoter and transgene followed by a polyadenylation signal (pA), Adenoviral helper 
plasmid which contains the minimal relevant function of Viral RNA (VA) and E2A and 
E4A genes.  
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Due to the difficulty to achieve high titre of viral production, and possible contamination 
of adenovirus or wild type wtAAV, the rAAV vector production systems have been 
optimised in a number of ways (Peel and Klein, 2000). Safety and vector yield have been 
improved in a number of ways. The first, packaging plasmid optimised and second, only 
the relevant helper functions in adenoviral helper plasmid design (Li et al., 1997b; Xiao 
et al., 1998).  
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Figure 1.12. Schematic represents of rAAV viral packaging plasmids  
A) Rep (Rep 78/68/52/40) and Capsid (VP 1/2/3) genes contained plasmid, B) Transgene 
expression cassette, which included promoter, transgene and followed by polyadenylation signal 
(pA), C) Adenoviral helper plasmid (Type-2 or 5 adenovirus), which is minimized to contain only 
relevant functions of Viral RNA (VA) and E2A and E4A genes minimized. E; denotes the early 
mRNAs that expressed before the initiation of viral DNA replication. The E2 for encodes DNA 
polymerase that binds to the ITRs, so transcription and replicates the viral genome. The E4 viral 
gene is involved in early transcription and disruption of the cytoskeleton. pA; Polyadenylation 
signal. 
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1.9.2.5. Serotypes 
Recombinant AAV production requires shuttle AAV2 vector that has inverted terminal 
repeats (ITR), helper, and capsid plasmids (Hastie and Samulski, 2015).  The capsid can 
be chosen for a specific tissue or cell type.  
Numerous AAV serotypes have been identified with variable tropism; however, all of 
them share the same properties including genome size and organisation and, with small 
differences, the inverted terminal repeats share structure and function. At least 13 human 
and more than 100 nonhuman primate AAV serotypes have been identified so far, and 
rational design and evolution-based strategies have further engineered AAV capsides 
(Daya and Berns, 2008; Hastie and Samulski, 2015). The virus particles are purified by 
either column chromatography or gradient centrifugation. Caesium chloride (CsCl2) or 
iodixanol is the most used for the gradient centrifugation, which can provide flexibility 
because a single method can be used to purify different AAV serotypes (Ayuso et al., 
2009). 
One of the obstacles to AAV gene therapy is the presence of neutralising antibodies 
(NAbs) in human populations consequent on naturally occurring infection by wild type 
AAV. Current AAV-based vectors of common serotypes have significant rates of 
seropositivity ranging from 30% of the population with Nabs to AAV8 and about 60% of 
the population with pre-existing anti AAV2 immunity. It has been shown that pre-existing 
NAbs to the viral vector limits effective gene transfer in a way that is influenced by the 
route of administration and organ targeted. Whether AAV capsid modifications or the use 
of novel AAV serotypes will circumvent this obstacle remains to be seen (Calcedo et al., 
2011). 
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1.9.2.6. Tissue-specific promoter 
The expression cassette consists of promoter, transgene and polyadenylation signal in 
addition to the viral ITRs. Vector properties that could reduce some of the risks including 
infectivity of special cell or tissue (Kay et al., 2001). Therefore, choosing the correct 
promoter, especially a tissue-specific promoter, is a major step toward achieving 
successful transgene expression (Shevtsovva et al., 2005; Zheng et al., 2008).  
1.9.2.7. AAV engineering for large transgenes 
The main limitation of using AAV is the limited genome capacity for self-complementary 
(sc) and single-stranded (ss) DNA - maximum 2.3kb and 4.7kb respectively; however, 
the transgenes required for diseases such as Cystic fibrosis, Haemophilia A,  and Leber's 
Congenital Amaurosis (LCA, RPE65) are larger than 5kb. In order to deliver such large 
therapeutic genes, investigators have attempted different strategies. 
AAV vectors for delivery of larger genomes have been produced; however, these vectors 
are inefficient, and multiple investigators have characterised their limitations (Allocca et 
al., 2008; Lu et al., 2008; Wu et al., 2010). The large transgenes using AAV vectors 
include splitting large genomes for co-delivery using two AAV vectors, or exploiting head-
to-tail concatemer formation. Despite solving the current packaging limitations of AAV 
with this approach, cells have to be infected with numerous virus particles to increase 
the efficiency of transduction, and the system is dependent on the homologous 
recombination (Halbert et al., 2002). Using deleted transgenes that retain therapeutic 
potential and optimising expression cassettes with minimal transcriptional regulatory 
elements, when possible, have emerged as alternative solutions. 
Partially packaged vectors could be able to re-enter the virus replication after infection.  
It would require either two packaged ITRs or ITR correction of the truncated end of the 
genome. The large-gene reassembly mechanism of the partial packed vectors are 
different since the partially packaged genomes are missing an ITR and because the ITRs 
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are thought to stimulate intermolecular recombination and non-homologous end joining 
(Inagaki et al., 2007; Lai et al., 2010). 
There are many ways to approach fitting a bigger gene into a smaller virus, for example,  
truncating the gene and use the short  transcriptional regulatory elements (Ghosh et al., 
2008; Ostedgaard et al., 2005). Moreover, there are dual AAV trans-splicing or hybrid 
vectors for large transgenes. The trans-splicing system transgene cassette is split 
between two rAAV vectors containing appropriately placed splice donor and acceptor 
sites. Transcription from rAAV molecules is followed by correct splicing of the mRNA 
transcript, resulting in a functional gene product. This application enables AAV to deliver 
therapeutic genes up to 9kb in size; however, it is less efficient than rAAV.  
The major problem in the current dual-vector approaches is that they all depend on the 
molecular property of the target gene itself. Essentially, an optimal gene-splitting site 
must be present in order to efficiently express a gene with the trans-splicing and 
overlapping AAV vectors (Ghosh et al., 2008). The hybrid vectors significantly improved 
transduction of the trans-splicing vectors. Trapani and colleagues generated efficiently 
transduced dual hybrid AAV vectors, which reconstitute a large gene by either trans-
splicing, homologous recombination, or a combination of the two (hybrid) (Trapani et al., 
2014). These strategies for large transgene expressing via AAV vectors have potential 
to be effective depending on the transgene and provide evidence of the efficacy of over-
sized transgene delivery. 
1.9.3. Current status of gene therapy for Haemophilia 
Haemophilia has been an attractive target for investigation of gene therapy approaches 
because biologically active clotting factors can be delivered by various viral delivery 
methods, which could lead to a modest increase in clotting factor levels that can rescue 
haemophilia (High and Anguela, 2015). Particularly, here are several reasons why 
haemophilia A is suitable candidate for gene therapy: i) FVIII production is not regulated 
in response to bleeding; ii) The broad therapeutic index of FVIII minimises the risk of 
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overdoses; iii) Delivery of FVIII into the bloodstream does not require expression of the 
gene by a specific organ and iv) even low levels of the protein can be beneficial (Kaufman 
et al., 1999; Roth et al., 2001). In the last two decades, gene therapy approaches have 
been applied to haemophilia via non-viral or viral gene deliveries summarised in table1.3 
(Roth et al., 2001;  Powell et al., 2003; Manno et al., 2003; Manno et al., 2006). AAV-
based gene transfer for haemophilia B has been one of the highlights of successful 
clinical viral gene therapy advances in the past five years (Nathwani et al., 2011; 
Nathwani et al., 2014). In contrast, clinical trials for haemophilia-A using viral vectors 
(Adenovirus, Retrovirus and AAV) showed unsuccessful results that failed to achieve 
persistent phenotypic correction, which utilised ex-vivo fibroblast transduction, a 
retrovirus vector, or AAV for FVIII gene delivery (Monahan et al., 2010) (Table 1.3). 
The big obstacle for AAV gene transfer for haemophilia A is that at 7kb the cDNA of full 
length FVIII far exceeds the 4.7kb limit of AAV packaging capacity. Because the large B-
domain is not necessary for pro-coagulant activity, a B-domain deletion version of FVIII 
could be created and named FVIII-SQ, which has only a 14 amino acid linker between 
a2 and a3. Therefore, current gene therapy applications for haemophilia A have focused 
on B-domain deleted FVIII due to its advantages of reduced overall cDNA size for 
packaging into viral vectors and increased mRNA levels (Pipe, 2009). 
The B-domain deleted hFVIII trial has been carried out recently, in which the AAV vector 
contains single stranded rAAV2/5 FVIII SQ, sponsored by BioMarin therapeutics, (clinical 
trials identifier  #: NCT02576795) (High and Anguela, 2015).  The preliminary data has 
been released from an ongoing Phase I/II clinical trial in which nine severe haemophilia 
A patients have received a single dose of the therapy and seven of those have been 
treated at the high dose, 6x1013vg/kg. For the seven patients treated with the high dose, 
as of each patient’s most recent reading (12~28 weeks, post- administration), six of 
seven patients had FVIII levels above 50%, and the seventh was above 
10%.  Moreover, there are no serious clinical complications observed 
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(https://www.hemophilia.org/Newsroom/Industry-News/ Preliminary-Clinical-Trial-Data-
Shows-Progress-for-BioMarin-s-Factor-VIII-Gene-Therapy-National haemophilia 
foundation).  
Another novel 31 amino acid linker peptide between the a2 and a3 was generated by the 
Nathwani group and is currently in the process of being developed as a clinical grade 
single stranded HLP (liver specific) promoter-driven FVIII V3co packaged in AAV8 and 
produced in HEK-293T cells for human trial (Prof Amit Nathwani, personal 
communication). 
Overall, viral gene therapy promises to deliver a significant advance over current 
treatment for haemophilia.  
  
                                                                                                                          Chapter 1 
 
 89 
 
 
Table 1.3. Summary of completed and ongoing Phase I/II clinical trials for 
haemophilia gene therapy  
Gene therapy clinical trials for haemophilia have used three types of viral vector, adenovirus, 
retrovirus and AAV. One patient received an adenoviral-mediated treatment for haemophilia A, 
and there has been one trial of retroviral gene transfer of FVIII, and the remaining treatment has 
been used AAV. The table adopted and modified from Swystun et al. (Swystun and Lillicrap, 
2016).  
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1.10. Research Aim  
The aim of this project was to investigate functional roles of modified B-domain linkers 
of FVIII. We aimed to determine if the length of B-domain and N-linked glycosylation of 
FVIII influences FVIII expression.  
 
1.10.1. Brief outline of strategy:  
 
B-domain deleted (BDD) FVIII retains full procoagulant function, while partial BDD FVIII, 
where 226 amino acids of the N-terminal remain (referred to as N6), increases in-vitro 
secretion of FVIII 10-fold compared with BDD-FVIII (Miao et al., 2004). Since N6-FVIII 
retains the six N-linked glycosylation consensus sequences (N-X-T/S) dispersed across 
the proximal 226 amino acids, it was hypothesised that the N-linked glycosylation motifs 
of N6-FVIII are key for improvement of FVIII expression. This led to the development of 
a 31 amino acid B-domain linker, FVIII-V3, consisting of six N-linked glycosylation triplets 
juxtaposed  (McIntosh et al., 2013). To further improve FVIII expressions, the natural 
FVIII coding sequences were modified to optimal mammalian coding sequences (codon 
optimisation), resulting in a 20-fold increment of FVIII mRNA expression as opposed to 
native FVIII mRNA (Ward et al., 2010).  
Currently, the most effective version of engineered FVIII is FVIII-V3, which has shown 
efficient and sustained transgene expression in-vivo using AAV. However, the 
mechanisms behind the improved expression of FVIII-V3 has not been established.  
To address this, I investigated the length effects of the N-linked glycosylation motifs and 
FVIII expression. In this study, I undertook a head to head comparison of in-vitro FVIII 
expression levels of codon optimised FVIII constructs and performed biochemical 
analysis for novel FVIII variants. Furthermore, I developed additional mutants to 
understand minimum linker length and optimal composition, which were validated in-
vivo.  
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Strategy:  
 
1. Wild type SQ, N6 FVIII variants and Codon optimised FVIII variants (V1, V3, V5, N6, 
and SQ) were cloned into the pRRL-PGK-WPRE-SV40 pA vector for lentivirus 
production.  
2. Stable cell lines expressing FVIII variants were derived and evaluate mRNA 
transcription levels and FVIII expression. 
 
3. Optimised purification method for FVIII proteins was developed to enable analysis of 
the biochemical features of FVIII variants. 
 
4. The N-linked glycosylation pattern of FVIII variants was investigated using mass 
spectrometric analysis. 
 
5. FVIII variants were cloned into the pAV-HLP-pA vector for AAV production, then the 
efficacy of AAVs was assessed in-vivo using the C57BI/6 mouse model. 
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2.1. Basic Bacterial Manipulation  
2.1.1. Transformation of E-coli with Plasmid DNA  
Plasmid DNA (0.1-0.01 ng/5μL) was incubated with 50μL of competent cells (DH5α, New 
England Biolabs[NEB], Hitchin, UK) in a 2mL tube (supplied with competent cells) for 30 
minutes on ice. The cells were then heat shocked for 40 seconds in a 42°C water bath 
and immediately returned on ice for a further 2 minutes. Subsequently, 450μL of sterile 
SOC medium (supplied with competent cells) were added, and the cell suspension was 
incubated at 37°C and shaken at 200 rpm for an hour. Following incubation, 50uL of cell 
suspension was spread using a sterile plastic rod onto a 90mm Petri-dish (VWR , 
Lutterworth, UK) containing solid Luria-Bartani (LB, MP Biomedicals, Cambridge, UK) 
agar medium (10g bacto-trypton, 5g yeast extract, 10g NaCl and 15g Agar) containing 
the appropriate antibiotics. The Petri dishes were then incubated overnight at 37°C in an 
inverted position to allow for bacterial colony growth. 
 
2.2. Molecular cloning 
2. 2.1. DNA Restriction Digest 
DNA was cut with restriction enzymes to excise the required DNA fragments from 
plasmids. Restriction digests were carried out using the following conditions. 5µg DNA 
was added to 5µL of the appropriate reaction buffer (10X, NEB), 0.5µL 100X BSA 
(Bovine serum albumin), 1unit of the required enzyme (NEB) and molecular biology 
water added up to 50µL. Reactions were carried out at 37°C for 1.5 hours. All digested 
vector backbone and FVIII insert DNA samples were analysed on a 1% agarose gel at 
120V.  
 
 
 
 
                                                                                                                          Chapter 2 
 
 94 
2.2.2. Isolation of Plasmid DNA fragments by Agarose Gel Electrophoresis         
Electrophoresis grade agarose (Bioline, London, UK) was dissolved at the desired final 
concentration (usually 1% [w/v] depending on DNA size) in 1x TBE (Tris-Borate-EDTA) 
buffer. To dissolve the agarose, the solution was boiled in a microwave oven. The gel 
mix was then allowed to cool to 60°C, following which SYBR® Safe (Fisher Scientific, 
Loughborough, UK) was added to the mix at the final concentration 0.5μg/mL. The gel 
mix was immediately poured into a gel former containing a suitably sized comb and 
allowed to set. Subsequently, it was submerged in a horizontal gel electrophoresis tank 
containing a 1XTBE buffer. Sample loading dye was added to each DNA sample, a 
ladder was added to one well of the gel for size determination (Hyperladder 1Kb, Bioline) 
Required bands were excised and purified using the Gel Purification kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. The agarose gel was viewed 
under blue light illuminator, and a gel fragment (containing the DNA fragment of interest) 
was excised from the rest of gel with a clean scalpel and placed in a 1.5mL 
microcentrifuge tube (Eppendorf, Stevenage, UK).  Three volumes of binding buffer QG 
(supplied by the manufacturer) was added to one volume of gel, followed by incubation 
at 55°C for 10 minutes to assist dissolution of the gel slice into the buffer. When agarose 
gel had dissolved, one gel volume of Propanol-2 (VWR) was added, and then the sample 
was transferred to QIAquick® spin column (supplied by the manufacturer) and centrifuged 
down at one minute, 12,000xg. The flow-through was discarded and 750μL wash buffer 
PE was applied to the column, which was spun down and the eluent discarded. Finally, 
30μL of ddH2O (double distilled water) was added to the column, and allowed to stand 
for one-minute incubation. Then finally centrifugation of the column for one minute at 
12,000xg enabled collection of the eluate containing isolated DNA.  
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2.2.3. Dephosphorylation of Backbone DNA 
To remove 5’ phosphate groups from vector backbone DNA (to prevent self-ligation) 
remaining DNA was incubated at 37ᵒC for an hour with 1X NEB buffer 3 (NEB) and 
0.5units/µg DNA Calf Intestinal Phosphatase (CIP, NEB). DNA was purified by using the 
gel extraction kit (Qiagen) as per the manufacturer’s instructions. 
 
2.2.4. Klenow filing 
Sticky ended DNA was blunt ended by 3' overhang removal and 3' recessed end fill-in. 
For this DNA was dissolved in 1X NEB buffer 4 (NEB) at a final concentration of 33μM 
deoxyribonucleotide triphosphats (dNTP, Life technology). Then 1 unit DNA Polymerase 
I, Large Fragment (Klenow, NEB) per microgram DNA was added and the mixture 
incubated for 15 minutes at 25°C.  0.5M ethylene-diamine-tetra-acetic acid (EDTA) was 
added to a final concentration of 10mM and heated at 75°C for 20 minutes to stop the 
reaction. DNA was cleaned by PCR purification (Qiagen) to remove enzyme. 
 
2.2.5. DNA ligation 
All ligations for the cloning of FVIII elements into the pRRL PGK WPRE backbone and 
FVIII elements into the pAV2 HLP pA backbones were carried out using Quick DNA 
ligase (NEB) according to manufacture’s recommendations. Briefly, an insert to vector 
molar ratio of 1:1 to 5:1 was used. To the DNA 10µL of 2X Quick DNA ligase buffer 
(supplied by the manufacturer), 1µL of Quick DNA ligase (400U/µL, supplied by the 
manufacturer) and up to 10µL molecular biology water was added. As negative control 
vector backbone DNA alone or insert DNA were used under the same reaction 
conditions. Control reactions were later used to determine relative background levels of 
self-ligated backbone DNA. All reactions were incubated for 10 minutes at room 
temperature; the ligated product was then transformed into One shot® Stable3 
competent E.coli (Invitrogen Life Technologies, Paisley, UK). 
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2.2.6. Transformation of One Shot® Stbl3TM Bacterial Cells  
For transformation of plasmid DNA, 50uL of individual One shot® Stable3 competent 
cells were thawed briefly on ice. 5µL of each ligation mixture including negative control 
was then added to one individual aliquot of competent cells and left for 10 minutes on 
ice. For positive control 1µL of 50pg/µL, PUC19 plasmid DNA (Life Technology) was also 
added to 50µL of One shot® Stable3 cells and incubated on ice for 30 minutes. Next, to 
allow for the uptake of DNA, all samples and controls were heat shocked at 42°C for 40 
seconds and immediately placed on ice for a further two minutes. 250µL of SOC medium 
(Life Technology, supplied by the manufacturer) was then added to each sample 
followed by one hour incubation at 37°C 220rpm with shaking. As all constructs 
contained an ampicillin resistance gene, total reactions were spread onto agar plates 
containing 100µg/mL carbenicillin (Melford, Suffolk, UK) under aseptic technique. Plates 
were incubated at 37°C overnight for the colony formation then selection of colonies was 
performed the following day.  
 
2.2.7. Screening colonies 
To determine whether ligations had been successful plates were first checked to ensure 
that higher numbers of colonies were present for each construct in comparison to 
negative control. The positive control plate was used to verify that transformation had 
occurred. Following these checks colonies were picked using pipette tips and placed in 
5mL of LB medium (MP Biomedicals) containing carbenicillin 100μg/mL. Samples were 
left in a 37°C shaking incubator overnight.  
The following day, DNA was extracted from 1mL of the cultures using the NucleoSpin® 
Plasmid Kit (Fisher Scientific) as per the manufacturer’s instructions. 4mL of each culture 
was reserved and stored at 4°C. To ascertain whether the correct clones had been 
generated the extracted DNA was used in a diagnostic restriction digest whereby the 
enzymes selected would generate fragments of sizes that enabled correct constructs to 
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be differentiated from the incorrect only. All diagnostic digests were carried out at 37°C 
for 2 hours with the following components per sample: 5µL DNA, 1µL 10X Buffer 
(supplied by the manufacturer), 0.1µL 100X (BSA), 0.25µL enzyme and 3.65µL 
molecular biology water. Samples were run on a 1% agarose gel at 120V for an hour.  
Where positive digests were identified the corresponding 4mL of reserved bacterial 
culture was used to inoculate a further a 500mL of LB medium containing ampicillin. 
These cultures were incubated at 37°C overnight with 225rpm shaking. The next day 
DNA was extracted from the cultures using the endonuclease free MAXI Prep kit 
(Qiagen) as per the manufacturer’s instructions.  
 
2.2.8. Site-Directed Mutagenesis  
The linker peptide variants were generated using the Q5® Site-Directed Mutagenesis kit 
and primer designated NEB program (NEB). The pair of primers for FVIII variants were 
designed using NEBase Changer.  pAV HLP FVIII-V3 pA was used as the PCR template.  
Table 2.1 shows each primer pair for PCR.  
To prepare PCR mixture: Q5 Hot Start High-Fidelity 2X Master Mix 12.5μL, 10μM each 
forward and reverse primer, 10ng of template DNA and top up Nuclease-free water until 
25μL. Mix reagents completely and then transfer to a thermocycler. Perform the following 
cycling conditions: Initial denaturation, 98°C 30 seconds, then followed by 25cycles 98°C 
10 seconds, 50~72°C 10~30 seconds, 72°C 20~30 seconds/kb. The final extension is 
72°C 2 minutes. After PCR, there is one more step: Kinase, Ligase & DpnI (KLD) 
treatment assemble the following reagents: 1μL of PCR product, 5μL of 2X KLD Reaction 
Buffer, 1μL of 10X KLD Enzyme Mix and 3μL of Nuclease-free Water, mix well and 
incubate at room temperature for 5 minutes. After PCR and DNA transformed as 
recommended E.coli strain (DH5α).  
Colonies pick up then performed mini-prep for DNA extraction. All mutations were 
confirmed by DNA sequencing (Beckman, UK). 
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Table 2.1. Primer sets for mutagenesis  
FVIII variants N0 to N5 generated based on pAV2 HLP V3 plasmid. Primer pairs were 
designed for NEB Q5 site direct mutagenesis using NEBase Changer. 
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2.3. Genomic copy number correction  
2.3.1. Quantitative Real-Time PCR (qPCR) for the determination of proviral 
copy number for human cell lines 
To determine FVIII genome copy number per cell, genomic DNA was extracted from 
stable cell lines using the DNeasy® Blood and Tissue kit (Qiagen) as per the 
manufacturer’s instructions. For each sample DNA was diluted to an approximate 
concentration of 7.5ng/µL and loaded in 5µL per well in duplicate to a 96 well Q-PCR 
plate. 20µL of Q-PCR master mix (12.5µL 2X SYBR Green master mix, 1µL forward PGK 
primer- 5’ TCTCGCACATTCTTCAC GTC-3’, 1µL reverse PGK primer- 5’ 
GTCCGTCTGCGAGGGTACTA-3’ each 2.5µM, 5.5µL molecular biology water per well) 
was then added to each well and cycling conditions were carried out. Thermal cycling 
was started with denaturation at 95ᵒC for 10 minutes, followed by 35 cycles of 95ᵒC for 5 
minutes, 95ᵒC 10 seconds and 60ᵒC for 30 seconds. The amplication was followed by 
melting curve analysis. Copy number was determined by a pRRL PGK WPRE plasmid 
DNA standard (PGK primers above), and DNA concentration for each sample was 
determined from levels of housekeeping gene expression (derived from a human 
genomic DNA standard using GAPDH primers in a separate reaction). To calculate 
copies per cell of PGK copy number results were divided by the amount of DNA in each 
sample (ng); these Figures were then multiplied by 37.5 (the theoretical amount of DNA 
loaded in each well) and divided by 5,681 (the approximate number of cells from which 
37.5ng of DNA is derived from human diploid copy per cell). To normalise FVIII levels for 
viral genome copy number (FVIII/copy/cell) values of % normal FVIII was divided by copy 
number from the corresponding cell line’s DNA sample. 
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2.3.2. Quantitative RealTime PCR (qPCR) for the Determination of Proviral 
Copy Number for Mouse liver tissue 
To determine viral genome copy number per cell, genomic DNA was extracted from 
mouse liver sample using the DNeasy® Blood and Tissue kit (Qiagen) as per the 
manufacturer’s instructions. For each sample DNA was diluted to an approximate 
concentration of 7.5ng/µL and loaded in 5µL aliquots in duplicate to a 96 well Q-PCR 
plates. 20µL of Q-PCR master mix (12.5µL 2X SYBR Green master mix, 1µL forward 
FVIII HC primer 5’ -AAGGACTTCCCCATCCTGCCT-3’, 1µL reverse FVIII HC primer 5’-
GGGTTGGCAGGAACCTCTGG-3’ each 2.5µM, 5.5µL molecular biology water per well) 
was then added to each well and cycling conditions were carried out as described 
previously. Copy number was determined by a FVIII V3 plasmid DNA standard (using 
FVIII HC primers), and DNA concentration for each sample was determined from levels 
of housekeeping gene expression (derived from a mouse genomic DNA standard using 
mouse GAPDH primers in a separate reaction). To calculate copies per cell FVIII HC 
copy number results were divided by the amount of DNA in each sample (ng); these 
Figures were then multiplied by 37.5 (the theoretical amount of DNA loaded in each well) 
and divided by 6528.5 (the approximate number of mouse diploid cells from which 37.5ng 
of DNA is derived). To normalise FVIII levels for viral genome copy number 
(FVIII/copy/cell) values of % normal FVIII was divided by copy number from the 
corresponding liver DNA sample. 
 
2.4. Total RNA extraction 
To determine RNA levels per viral genome copy per cell, stable cell lines were 
homogenised using 1mL syringe and RNA was then extracted using the RNeasy Plus® 
kit (Qiagen) as per the manufacturer’s instructions. 
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2.4.1. Measurement of FVIII RNA copy number analysis 
500ng of RNA was converted to cDNA by using the Superscript III RT cDNA synthesis 
kit (Life technology). 2µL of cDNA samples, cDNA standards and negative controls (-RT 
and water) were then loaded onto 96-well Q-PCR plates in duplicate. 18µL of master mix 
(10µL 2X SYBR Green master mix, 1µL forward WPRE primer-5’ 
TTCTGGGACTTTCGCTTTCC-3’, 1µL reverse WPRE primer- 5’ CCGACAACA CCAC 
GGAATTA-3’, each 2.5µM and 6µL molecular biology water per well) was then added to 
each well, and Q-PCR cycling conditions were carried out as previously described. To 
normalise the data for the amount of cDNA loaded for each sample, a separate Q-PCR 
to quantify levels of housekeeping gene cDNA was performed using human GAPDH 
primers (5’-GGAGTCAACGGATTTGGTCGT-3’, 5’-GGCAACAATATCCACTTT ACC-3’) 
suitable for cDNA samples (Qiagen). To calculate RNA/copy/cell values of WPRE copies 
were divided by results for cDNA concentration (ng). Results were then divided by viral 
genome copy number per cell to give an approximation of transcription levels per copy. 
 
2.4.2. Relative quantification measurements 
The mRNA copy numbers of each cell types were calculated as follows: mRNA copy 
numbers = 2–CT, where CT is the average threshold cycle number of the gene of 
interest. The normalised gene mRNA copy number is the copy number of the gene of 
interest divided by the copy number for GAPDH. The change in threshold cycle for each 
gene = ΔCT:  The change in threshold cycle number relative to FVIII variants= ΔΔCT:  
The fold-changes of FVIII variants are calculated by raising 2 to the negative power of 
the ΔΔCT value for each gene. For each FVIII gene ΔΔCT = 0, and 20 = 1. 
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2.5. Cell Culture Methods 
2.5.1. Propagation of adherent cell lines 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Paisley, UK) was purchased from 
Life technology.  HEK-293T adherent cells (St Jude Children’s Hospital, Memphis, USA) 
were grown in DMEM containing 4.5g glucose, 1mM L-glutamine and 10% (v/v) heat 
inactivated Foetal Bovine Serum (FBS, Gibco). Cells were grown at 37°C in a humidified 
5% CO2 incubator (Eppendorf) until cell populations were 80% confluent. Prior to sub-
culturing to new flasks cells were washed in PBS (Phosphate Buffered Saline). Cells 
were detached by incubating in Trypsin-EDTA (TE, Invitrogen) for 5 minutes at 37°C. 
Trypsin was inactivated by dilution in 10 times complete cell culture medium, cells were 
then centrifuged at 400xg (Beckman Coulter, High Wycombe, UK) for 5 minutes. The 
supernatant was then discarded and the pellet re-suspended in DMEM containing 10%.  
 
 
2.5.2. Propagation of suspension cell lines  
Suspension HEK-293F cells (Invitrogen Life Technologies, Paisley, UK) were grown at 
37°C in a humidified incubator with 8% CO2 on 130rpm shaking incubator until cell 
populations reached 2.5x106cells/mL. Prior to subculturing to new flasks, cells were 
centrifuged at 100xg (Beckman) for 5 minutes. The supernatant was then discarded and 
the pellet re-suspended in Glutamax containing Freestyle293 SFM (Life Technology) 
media. Cells were inspected daily for viability and were maintained in 125mL Erlenmeyer 
flasks (Corning, Appleton Wood, Birmingham, UK). 
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2.5.3. Long Term Storage of Cell Lines  
2.5.3.1. Cryopreservation for adherent cell lines 
Adherent HEK-293T Cells were centrifuged at 400xg for 5 minutes and re-suspended at 
a final density of 1x107cells /mL of cryopreservation medium (9 volumes of FBS, 1 
volume of Dimethyl sulfoxide [DMSO, Sigma]). The suspension was quickly transferred 
into 1mL labelled cryovials (Nunc, VWR) and the vials were then frozen at -80oC in a Mr 
Frosty containing isopropanol for 24 hours to ensure a -1°C /minute freeze rate. Finally, 
the vials were transferred to liquid nitrogen for long-term storage.  
 
2.5.3.2. Cryopreservation for suspension cell lines 
Suspension HEK-293F cells were centrifuged at 100xg for 5 minutes (Beckman bench 
top) and then re-suspended in a minimal volume of medium, vortexed for 45 seconds, 
and viability examined with trypan blue (Sigma) and counted. Cells were diluted 
1x107cells per ml in a 1:1 (v/v) mixture of conditioned medium and fresh Freestyle 293 
SFM with 7.5% DMSO. The vials were frozen in the same manner as the adherent HEK-
293Tcells. 
 
2.6. Production of Viral vectors 
2.6.1. The 3rd generation Pseudo-typed Lentivectors  
2.6.1.1. Co-transfection of HEK-293T cells 
Early passage (≤P30) of HEK-293T cells were cultured in 150cm2 round tissue culture 
plates (Greiner, Stonehouse, UK) until they reached 80% confluence. Cells were 
cultured at 37ᵒC, 5% CO2 in DMEM (Gibco, Paisley, UK) with 10% FBS (Gibco) and 
enzymatically passaged every 2~3 days. For each virus construct 2×150cm2 plates of 
HEK-293T cells were used at 2x107cells on the day of transfection. For the transfection 
mixture 60μL of 1mg/mL Polyethyleneimine (PEI Max, Polysciences Inc, Northampton, 
UK) was added to 3mL serum free DMEM. In a separate tube 5ug of VSVG plasmid 
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(containing enveloping genes), 4.6μg of KGP3R plasmid (containing gag/pol genes), 
2.4μg of RTR2 plasmid (containing RRE gene), 48μg of a transgene containing plasmid, 
were added to serum-free DMEM to a final volume of 3mL. The mixture containing DNA 
was then filtered into the PEI-containing mixture through a 0.45µm syringe filter. The 
solution was mixed and incubated at room temperature for 15 minutes in the hood (light 
off). The 3mL of transfection solution was then added dropwise to each 150cm2 dish.  
 
 
 
 
 
Figure 2.1. Schematic diagram of third generation lentiviral vector plasmids 
The 3rd generation lentiviral vectors were improved bio-safety, because the original HIV-I provirus 
was separated to four plasmids. Shuttle vector comprised the transgene, the gag/pol packaging 
construct, Rev protein construct, and Envelop construct (Commonly use VSVG). 3rd generation 
lentivirus particles were produced by transient transfection to HEK-293Tcells.  
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2.6.1.2. Viral supernatant harvest and concentration 
After 24 hours of incubation, mediums were changed with 15mL of fresh 10% FBS-
containing DMEM medium. The first harvest was taken after 24 hours, and another 15mL 
of fresh medium was added; after a further 24 hours, the second harvest was carried 
out. The combined first and second harvest of virus-containing cell culture mediums were 
centrifuged at 400xg for 5 minutes. Virus-containing mediums were then spun at 400xg 
for 5 minutes at 4ᵒC, passed through a 0.45µm filter and spun at 46,600xg for 120 
minutes at 4ᵒC Beckman SW32 rotor. The supernatant was discarded, and the viral pellet 
was dissolved in 200uL of DMEM or 150-fold concentrated. Finally, each virus was 
aliquoted in a 10μL vial and stored at -80ᵒC.  
 
2.6.1.3. Titration of Lentiviral Vectors by Quantitative Real-Time PCR (q-
PCR) 
The viral titer was determined using the Q-PCR Lentivirus Titration Kit (Applied Biological 
Materials, ABM, London, UK), per the manufacturer’s instructions. In brief, 2μL of the 
diluted purified viral preparation was added to 18μL of Virus Lysis Buffer and incubated 
at room temperature for 3 minutes. This solution is now referred to as the viral lysate. 
2.5µL of viral lysate, 10μL reagent mixer, and 12.5µL of master mix were then loaded 
onto 96-well Q-PCR plates in duplicate. Two positive controls (STD1 and STD2) and 
negative controls were then added to each well. The Q-PCR primers supplied in this kit 
which is designed for all HIV-1 based vectors were added. Detection and cycling 
conditions were carried out as described in the manufacturer’s instructions. The Ct value 
of the viral lysate is used to determine the titer of the unknown viral sample. The titer of 
viral samples can be calculated from Ct values by using company supplied on-line 
lentiviral titre calculator at https://www. Abm good. com/ viralexp/ LentiTitre. php. 
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2.6.2. Production of Adeno Associate Virus 
2.6.2.1. Co-transfection of HEK-293T cells 
For each virus 10×150cm2 plates of low passage (≤P30), HEK-293T cells were used at 
approximately 80% confluence on the day of transfection. Cells were cultured at 37°C, 
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) with 10% heat-inactivated 
FBS and enzymatically passaged every three days. For the transfection mixture 750μL 
of 1mg/mL PEI was added to 15mL serum free DMEM. In a separate tube 225μg of 
Adeno helper plasmid (containing essential genes from the adenoviral genome that 
support rescue and replication of AAV genomes), 75μg of Rep2/Cap8 plasmid and 75μg 
of single stranded transgene containing plasmid was added to serum free DMEM to a 
final volume of 30mL. The mixture containing DNA was then filtered into the PEI-
containing mixture through a 0.45µm of polyethersulfone (PES, Sartorius, Epsom, UK) 
syringe filter. The solution was mixed and incubated at room temperature for 15minutes. 
3mL of transfection solution was then drop wised to each 150cm2 dish.  
 
2.6.2.2. Cells and supernatant harvest 
After 24 hours of incubation, the medium was replaced with serum-free DMEM, and 
further 48 hours later cells were harvested using cell scrapers. Cells and supernatants 
were centrifuged at 800xg for 10 minutes. Supernatants were kept at 4°C for further 
PEGylation step, and cell pellets were re-suspended in TD buffer, pH7.5 (140mM NaCl, 
25mM Tris, 3.5mM MgCl2, 5mM KCl, and 0.7mM K2HPO4 in one litre of distilled water)  
 
2.6.2.3. Lysis of cell pellet 
Cell pellets were re-suspended in TD buffer. To lyse the cells and release viral particles 
freeze-thaw cycles of 5 minutes at liquid nitrogen (LN) followed by 5~10 minutes at 37°C 
were repeated at least five times.  
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2.6.2.4. PEGylation 
2.6.2.4.1 Preparation for 40% PEG (2.5M NaCl) 
Prior to preparing solution of 40% polyethylene glycol (PEG, Sigma), the 2.5M NaCl 
has prepared.  First, add 146.1 g of NaCl (Sigma) to 800mLs distilled water, and 
dissolved properly then add 200g of polyethylene glycol (PEG).  Allow PEG to dissolve 
by stirring and heating at 37oC.  Then add a further 200g of PEG.  Once fully dissolved 
adjust the volume to 1L and store at 4°C. 
 
2.6.2.4.2. PEGylation of viral supernatant  
 Prior to purification, the supernatant was PEGylated by the addition of 40% PEG solution 
to a final concentration of 8% PEG. The supernatant and PEG solution was incubated 
on ice for 2 hours followed by centrifugation at 4000xg 30 minutes at 4°C.   After 
centrifugation viral particles are sedimented with the PEG, the supernatant was 
discarded, and the pellet was dissolved in 1% Sarkosyl final concentration (Sigma).  
Finally, viral supernatant pellet and cell pellet were mixed (maximum volume: 12mL) and 
incubated at 37°C for 30 minutes with 50units/mL Benzonase (Sigma).  Lysates were 
then spun at 4000×g for 20 minutes at 18°C, passed through a 0.45µm PES filter to 
remove cellular debris. 
 
2.6.2.5. AAV Purification  
 
2.6.2.5.1. Iodixanol purification 
First, place 12mL of crude AAV prep in 89mm sorvall tubes using a long metal needle. 
This was then underlay with 9mL of 15% iodixanol using a syringe and long needle or 
kwill tube.  Additional layers of 7mL 25% iodixanol, 5mL 40% iodixanol, and finally 5mL 
60% iodixanol were also underlayed. Tubes were heat sealed and placed in a 70Ti rotor 
(Beckman Dickson), and centrifuged at 270,217xg, 75 minutes, 18°C and deceleration 
brake 1. After the centrifugation, the virus is contained in the 40% iodixanol layer.   
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To remove the virus, the tube was pierced with a 19-gauge needle, then swapped to a 
19-gauge needle with a syringe attached. To allow the virus to be drawn out the top of 
the tube was pierced with a needle. The 40% layer was removed, taking the interphase 
between 40% and 60%, but avoiding the interphase between 40% and 25% as empty 
AAV particles collect in this interphase. The iodixanol-containing virus was placed into 
Amicon 100K filter device (Amicon, Millipore), which is pre-washed with PBS, the 
iodixanol is centrifuged for 20 minutes at 3000xg.  After centrifugation, the virus is 
retained in the top of the device, and the iodixanol is in the flow through.  The 
virus/iodixanol was topped up with PBS and mixed, then centrifuged 400xg again for 5 
to 10 minutes.  This was repeated until the iodixanol had been removed and final volume 
was 1mL.  Purified AAV was filter sterilised through 0.22μm PES syringe filter (Sartorius) 
and stored at 4°C for further use. 
 
 
Figure 2.2. Separation of AAV particles from Iodixanol gradients and Amicon 
filtration 
Three layers of iodixanol gradients separate AAV in the ultracentrifuge step. AAV can be collected 
from 40% iodixanol layer by using syringe needle. Virus contained 40% iodixanol layer was dilute 
with PBS, then iodixanol was removed by amicon 100k filter system. 
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2.6.2.6. AAV titrering 
2.6.2.6.1. Titration of AAV by Q-PCR 
To determine viral titre for single-stranded AAV HLP FVIII pA viruses, primers against 
the FVIII HC (Heavy chain) were used, and the titer of all AAV2/8 viruses was determined 
from a standard generated from a linearized FVIII HC containing plasmid DNA. Each 
virus was quantified in three different dilutions (1:100, 1:1000 and 1:10000). 10µL of virus 
samples, negative control samples (Water) and standards were added to 96-well plates 
in triplicate. To each well the following master mix was added: 12.5µL 2X QuantiFast 
SYBR Green PCR master mix (Qiagen), 1µL forward primer, 1µL reverse primer (each 
2.5µM), 0.5µL molecular biology water (15µL master mix/well). Plates were then sealed, 
briefly spun by centrifugation and placed in a thermal cycler (Realplex, Eppendorf). After 
an initial heating period of 5 minutes at 95°C, the following steps were carried out for 40 
cycles: 95°C 10 seconds and 60°C 30 seconds. The copy number of viral genomes was 
calculated from the standard curve using Realplex software (Eppendorf). To calculate 
viral genome copies per mL, copy number recorded per 10µL reaction was multiplied by 
the dilution factor and 100.  
 
2.6.2.6.2. Titration of AAV by Alkaline gel   
AAV was titred under denaturing conditions. The alkaline agarose gel was prepared by 
melting 0.8g agarose in 98mL water; once the gel had cooled to 50°C, 2mL alkaline 
electrophoresis buffer (50X; 2.5M NaOH, 50mM EDTA), was added, the gel was poured 
and allowed to set. 
To 25μL of AAV, 8.5μL of alkaline sample loading buffer (4X; 20% Glycerol, 4X alkaline 
running buffer, 1.2% SDS, the tip of Xylene cyanol) was added and mixed; samples were 
cooled on ice before loading on the gel. When setting the gel was transferred to the 
electrophoresis chamber in the cold room after ensuring that the apparatus and the 
alkaline electrophoresis buffer were at 4°C. Samples and 5μL Hyperladder I (Bioline) to 
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wells on either side of the samples were loaded onto the gel. The gel was run overnight, 
16~18hrs at 20V in the cold room. 
To stain the gel, the gel was gently rocked in three gel volumes of 0.1M Tris, pH 8.0 for 
an hour to neutralise the gel. The gel was then transferred to a one gel volume solution 
of 4XGelred (GelRed Nucleic Acid Gel Stain, 10,000X, Biotium, Cambridge Bioscience, 
Cambridge, UK) in 0.1M NaCl and rocked gently for 2 hours. The gel was rinsed twice 
in water. Gel image was captured using a UV transilluminator (Genesys), bands were 
quantitated using Gene Tools, and virus concentration were calculated by DNA 
concentration of the band and the genome size of the virus.  
In the sense of limited packaging capacity of single stranded AAV (approximately 4.7kb), 
linker modified FVIII viral particles were tested for DNA packaging condition using 
alkaline gel analysis, which exhibits total genome of AAV. Fully packaged self-
complementary AAV viral DNA, which is containing a 2.3kb transgene of human FIX 
(hFIX) exhibit clear one band on the alkaline gel (Fig.2.3.A), while the FVIII carrying AAV 
genomic DNA bands showed multiple bands across the gel suggesting fragmented FVIII 
DNAs were packaged into the virus. These results suggested that not all the vector 
sequences were completely packaged into AAV capsids. The wide range of smears 
confirmed that a heterogeneous mixture of genomes with different lengths was packaged 
into AAV capsids (Lu et al., 2008). The size of top the band was approximately between 
4.87kb to 5.13kb, which was followed by fragmented DNAs (Fig. 2.3.B).  
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Figure 2.3. Encapsidation of AAV vector with extra-large genome  
Alkaline gel analysis of packaged AAV genomes. Viral DNA visualized by Gel-red staining in 0.8% 
alkaline gel electrophoresis. 
A) A typical alkaline gel with a DNA standard and full packaged 2.3kb human FIX small transgene, 
which packaged by self-complementary shuttle vector, presented double size of 4.6kDa single 
DNA band B) Alkaline gel analysis of viral genomes extracted from single stranded rAAV8 HLP 
hFVIII variants, 5.13kDa 31aa V3, 5.12kDa of N5, 4.9kDa of N4, 4.9kDa N3, 4.9kDa of N2, 4.9kDa 
of N1 and 13aa 4.87kDa of N0, viral particles. Each viral DNA shows the size and those over-
sized AAV heterologous bands spreading from 5.2kb down to 1kDa. Full packaging size we 
expect to be 4.87kb to 5.13kb. 
 
 
 
 
2.7. Viral transduction and Single clone selection 
2.7.1. Cell preparation and transduction 
Early passage (≤p30) adherent HEK-293T cells were seeded at a density of 
1x105cells/well into 12-well plates. The following day media was removed and replaced 
with 300uL of media containing lentivirus at a multiplicity of infection (MOI) of 10. After 4 
hours the media volume was restored by the addition of 700μL of 10% FBS containing 
DMEM.  
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2.7.2. Single clone selection 
After lentiviral transduction, a heterogeneous population of cells with viral inserts will be 
achieved, in order to achieve a homogenous selection a single cell was isolated and 
expanded. We diluted a cell suspension and plated into 96-well plates so that on 
average, each third well will contain a single cell. We harvested polyclonal cells and 
counted cells using a chamber slide. After carefully visually inspecting cells in the 
counting chamber slide by microscopy, two separate chambers were counted four times 
and cells were then re-suspended in 1x106cells/mL. Cells were then diluted to 5 cells/Ml, 
200µL of the solution was transferred into each well of a 96-well plates using a 
multichannel pipette. 
 
2.8. Sample preparation for Coagulation assay 
Cells were seeded at 1x106cells/well in 6-well plates. 24 hours later the media was 
discarded and cells washed with PBS, 1mL of serum-free DMEM was added to each 
well, and 24 hours later media was used in an Enzyme-Linked Immunosorbent Assay 
(ELISA) to screen clones for FVIII expression. 
 
2.8.1. Transient transfection of Huh 7 and HEK-293T cell lines 
To test hFVIII expression from plasmid DNA, transient transfection was carried out on 
Huh 7 and HEK-293T cells for subsequent FVIII ELISA on supernatants. The day before 
transfection 5×105 cells was plated per well in 6-well plates. On the day of transfection 
2µg of the plasmids were added to 100µL of serum-free X-VIVO (Lonza, Nottingham, 
UK). In a separate tube 1µL of PEI (1mg/mL) was added to 100µL X-VIVO. The two 
solutions were then mixed, incubated at room temperature for 20 minutes and added to 
the cells. After 4~6 hours, the medium was replaced with 10% FBS containing DMEM.  
After 48 hours transient transfection, the medium was changed with 1mL of serum-free 
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X-VIVO, then further incubated at 37°C and finally, supernatants were harvested and 
stored at -80°C.  
 
2.8.2. Coagulation Assays  
2.8.2.1. Measurement of human FVIII antigen level from cell lines 
To determine FVIII antigen levels, two different ELISA methods have been used. The 
Affinity Biologicals FVIII antigen kit (Affinity Biologicals, Quadratech, Epsom, UK) is 
polyclonal, and the other one is monoclonal anti-(FVIII light chain)-IgG detection antigen 
kit (Diagnostica Stago, Reading, UK). We used Affinity Biologicals FVIII antigen kit for 
our earlier screening test, which we used for single clone selection for each variant. 
However, it later transpired that this kit was not detecting accurately the FVIII levels in 
the B-domain deleted and truncated B-domain linker constructors. However, it is valid 
for internal comparison for each variant. Six well plates were coated with 1X Geltrex (Life 
Technology) at room temperature for 60 minutes then 1x106cells per well added.  24 
hours later FBS containing medium was discarded, and the cells were washed with 2mL 
of PBS. Finally 2mL of the fresh serum-free medium was added. The media was 
harvested after a further 24 hours, by centrifugation at 400xg for 5 minutes, the FVIII 
levels in the supernatant were then determined by ELISA.   
 
2.8.2.2. Factor VIII Antigen ELISA  
2.8.2.2.1. Affinity biological FVIII antigen assay (Polyclonal antibody) 
An immunocapture assay was used to determine hFVIII: Ag levels in cell culture samples 
from HEK-293T cells. In brief, 96-well plates were coated overnight at 4°C (Maxisorp, 
Nunc, Fisher Scientific) with an Affinity-purified antibody to FVIII (Affinity Biologicals, 
Polyclonal Antibody). After blocking at room temperature for one hour (PBS/6% 
BSA/0.05% Tween 20), an hFVIII ELISA kit was used for subsequent steps (F8C-EIA, 
Quadratech Diagnostic). Standards and samples were diluted 1:10 ELISA kit diluent in 
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the diluent buffer and were loaded in duplicates (50µL/well). Standards were made by 
serial dilutions of murine plasma spiked with recombinant human FVIII, starting 
concentration 4 IU/mL (11th FVIII British Standard: 95/608, 6.9 IU/mL, National Institute 
for Biological Standards and Control, South Mimms, UK). We set up a FVIII antigen 
assay using recombinant human FVIII standard (IU/mL) as described above and 
assumed parity between 1 IU/mL and 100% FVIII antigen value. It should be noted, 
however, that this is not correct, and that the units used are not appropriate for a standard 
used to measure % FVIII antigen.  
 After washing the plate to remove unbound material, a total of 100µL/well of the 
polyclonal horseradish peroxidase–labelled detecting antibody was used as a secondary 
antibody.  A peroxidase conjugated the second antibody to FVIII was added to the plate 
to bind to the captured FVIII. After washing the plate to remove unbound conjugated 
antibody, the peroxidase activity was detected by incubation with O-phenylenediamine 
(OPD, Sigma). After 15 minutes incubation time the reaction was quenched with the 
addition of 50μL of 3M Hydrochloric acid (HCl, Sigma) and the colour produced was 
quantified using microplate reader at a wavelength of 490nm.   
 
2.8.2.2.2. Monoclonal FVIII antigen by Asserachrom Stago Kit (Monoclonal 
antibody) 
To determine FVIII antigen levels per stable cell lines the ASSERACHROM FVIII: Ag kit 
(Diagnostica Stago) was used. This kit is an antigenic assay for the quantitative 
determination of FVIII by ELISA. FVIII to be measured is captured by monoclonal anti- 
FVIII light chain IgG antibody coated on the internal walls of plastic microplate wells. 
Calibrator (lyophilised human plasma calibrator, assay value provided in the kit) for 
analysis were prepared as kit instruction. Samples were diluted with supplied kit buffer 
and assayed as per the manufacturer’s instructions. Results were then divided by viral 
genome copy number per cell to calculate FVIII Ag /copy/cell  
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2.8.2.2.3. Mouse plasma FVIII antigen assay 
Mouse blood was collected in 0.136 Molar, trisodium citrate anticoagulant (1:9 v/v to 
blood, Sigma) with the gentle mix. Blood was centrifuged 2500×g for 15 minutes at 4°C.  
Plasma samples were quickly snap frozen in dry ice then stored at -80°C. Plasma 
concentration of mouse FVIII antigen was determined by the ASSERACHROM FVIII: Ag 
kit (Diagnostica Stago) as per the manufacturer’s instructions. 
 
2.8.2.3. Factor VIII Activity Assay  
2.8.2.3.1. Measurement of FVIII Activity level from culture medium and 
mouse plasma  
 
FactorVIII: C is a chromogenic assay for testing the cofactor activity of FVIII:C (BIOPHEN 
FVIII:C, Quadratech). In the presence of FIXa, phospholipids and calcium, thrombin-
activated FVIII:C forms an enzymatic complex, which activates FX to FXa. This activity 
is directly related to the amount of FVIII: C, which is the limiting factor in the presence of 
a constant and excess amount of FIXa. Generated FXa is then exactly measured by its 
activity on specific FXa chromogenic substrate. FXa cleaves the substrate and releases 
p-nitroaniline (pNA). The amounts of pNA generated are directly proportional to the FXa 
activity. Finally, there is a direct relationship between the amount of FVIII:C in the 
assayed sample and FXa activity generated, measured by the amount of pNA released. 
Samples were diluted 1:10 and 1:20 in sample diluent provided (R4) and run in duplicate 
on plates. A standard curve plotting FVIII cofactor activity against pNA released was 
constructed by diluting Biophen normal control plasma (Quadratech Diagnostics). The 
Kit contained two controls, which were also used as a further quality control for the assay. 
The assay was performed as per the manufacturer’s instructions. Results were then 
divided by viral genome copy number per cell to calculate FVIII:C / copy /cell values. 
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2.8.2.3.2. One-stage clotting assay (Activated Partial Thromboplastin Time) 
FVIII levels were measured using a one-stage clotting assay (Activated Partial 
Thromboplastin Time; APTT) on an ACL TOP 700 (Instrumentation Laboratory, MA, 
USA).    HemosIL SynthASil APTT reagent and FVIII deficient plasma (contains vWF 
levels at ~90 IU/dL) were used against frozen plasma calibrator (CRYOcheck reference 
plasma, Precision BioLogic Inc, Dartmouth, Canada).   
Purified FVIII variants were diluted into FVIII deficient plasma (HemosIL). An eight point 
calibration curve was constructed by the ACL TOP (range 0~150%) from the plasma 
calibrator in triplicates. The diluted FVIII variant samples were then analysed by parallism 
dilutions (1:10, 1:20 and 1:40).  Values for variants were calculated in IU/dL by the ACL 
TOP coagulometer.  The Coefficient variation (CV) value of the Intra and inter assay are 
represented in table 2.2. 
 
 
Table 2.2.  Percentage of CVs for Factor VIII assays: One-stage clotting assay on 
an ACL TOP 700 
Intra and inter level of normal and abnormal exhibited similar CV value. 
CV: Coefficient variation, kindly provided by Anne Riddell at Haemophilia and Thrombosis Centre 
in the Royal free hospital. 
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2.9. Thrombin activation assay 
2.9.1. Thrombin generation assay 
Thrombin generation was measured with the Calibrated Automated Thrombogram 
System (CAT, Diagnostica Stago) based on Fluoroskan Ascent Analyzer (390nm 
excitation 460nm emission wavelength: Thrombinoscope, Diagnostica Stago). Before 
starting the assay, all reagents [PPPlow (1pM tissue factor and 4μM phospholipid 
reagent, thrombinoscope, Diagnostica, Stago), Thrombin Calibrator (Thrombinoscope, 
Diagnostica Stago) to which had been added 1mL double distilled H2O and vortexed] 
were put on ice; meanwhile warming up the FluCa buffer in the 37˚C water bath for 15 
minutes. The CAT machine has a calibrator step. In the 96-well round bottom plates set 
up for the experiment, all samples were assayed in triplets and the calibrator used two 
wells, and quality control (QC) samples were assayed for internal control. Protein sample 
and the calibrator were vortexed and 20μL from each added to the round-bottom 96-well 
plates. Then 80μL samples were added into 20μL of the trigger (PPPlow).   Next, the 
plate was put in the machine for 5 minutes at 37˚C. The pre-warmed buffer with Fluca 
substrate was diluted 1:40 and vortexed immediately the mixture and adds 20μL 
FluCa/well with a repeater. After adding the FluCa to each well and then start the 
programme. For the negative control, FVIII deficient plasma was used (HemosIL, 
Werfen). This assay has been performed at Katharine Dormandy Haemophilia and 
Thrombosis Centre in the Royal free hospital (London, UK). Table 2.3 represents the 
precision values of CV for CAT Fluoroskan Ascent Analyzer. 
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Table 2.3. Percentage of CV values for thrombin generation assays (CAT 
Fluoroskan Ascent Analyzer) 
The CV values of inter assay were higher than intra assay. LT: Lag time, PH: Peak height, ETP: 
Endogenous Thrombin Potential. The values of CVs were provided by Anne Riddell in the Royal 
free hospital London.  
 
 
2.9.2. Thrombin digestion 
Cleavage reactions containing 50nM rFVIII and 1nM thrombin (Sigma-Aldrich) was 
performed by incubating at 37°C for an hour followed by SDS-poly acrylamide gel was 
performed. 
 
2.10. SDS-PAGE and Western Blot 
2.10.1. Preparation of samples for SDS–Poly Acrylamide Gel 
Total volumes of 13μL sample and 2.5μL of 4x loading dye with 1μL of reducing agent 
were added. 
Samples mixed then heat-treated at 98°C for 5 minutes. After briefly cooling down they 
were spun down without delay. Samples were loaded onto the gel and add anti-oxidant 
added into the running buffer. The samples were then run on a 4~12% NuPage Bis-Tris 
gradient protein gel with MOPS buffer at 200V, 120mA, 90 minutes with reducing agent.  
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2.10.2. Membrane transfer  
Proteins separated by SDS-PAGE gels were electrophoretically transferred onto 
polyvinylidene-difluoride (PVDF, GE Healthcare) membranes by using mini-gel transfer 
kit (Invitrogen).  
One hour before starting membrane transfer, 200mL of transfer Buffers were prepared 
and cooled down at 4°C.  Six pieces of Whatman 3MM paper (5mm) to be a little larger 
than the gel.  Cut one piece of PVDF membrane to be the same size as the gel. Take a 
small container and pour in a small amount of transfer buffer. Soak three pieces of 3MM 
papers in the buffer then place in the apparatus.  Then soak the PVDF membrane and 
place on top of the 3MM papers.  Separate the gel from the metal plate and carefully 
place on top, then add three more pie ces of 3MM papers soaked in transfer buffer. Roll 
over a pipette to remove any air bubbles. Set apparatus to run at 0.8mA/cm2 for an hour. 
 
2.10.3. Antibody and ECL 
 At the end of the transfer remove the gel from the membrane, cut or mark one corner to 
indicate the correct orientation. Place in blocking buffer (Roche Diagnostics, Burgess 
Hill, UK) for an hour at room temperature on shaker or overnight in the 4°C. Dilute the 
primary antibody 1:1000 with 50% blocking buffer and 50% TBS-T (0.05% Tween 20). 
Place on a shaker for two hours at room temperature or overnight in the fridge. Washing 
with TBS-T three times at 10 minutes each. Dilute secondary antibody anti-mouse HRP 
1:10000, place on a shaker for one hour at room temperature. Washing with TBS-T three 
times again. The bound HRP was subsequently detected using an Enhanced 
Chemiluminescence system (ECL TM, Fisher Scientific). The membrane was then 
exposed to X-ray film (GE Healthcare) to detect the resulting light emissions. Exposure 
times were then increased or decreased according to the strength of the signal.  
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2.11. Protein staining 
2.11.1. Silver staining 
Silver staining is a sensitive procedure to detect trace amounts of proteins in gels. 
Purified recombinant FVIII protein quantities are present at a very low concentration; we 
used silver staining for detection of individual protein bands under reducing conditions. 
The samples were treated PNGase F (Invitrogen) endoglycosidase for an hour before 
analysis to demonstrate proteolytic activation and the presence of N-linked glycan 
modifications. 
A purified protein or PNGase F treated glycoproteins were mixed with protein loading 
dye and NuPAGE sample reducing reagent (Invitrogen), the mixture was heated at 95°C 
for 5 minutes. The denatured samples were then separated on 4~12% Bis-Tris gel 
(Invitrogen) with MOPS running buffer. After electrophoresis, the SDS-poly acrylamide 
gel was stained by SilverXpress silver staining kit (Invitrogen) according to the 
manufacturer’s instruction. 
 
2.11.2. Sypro Ruby staining 
Sypro Ruby staining is a very simple staining with sensitivity comparable to silver 
staining. Pre-staining preparation steps are the same as silver staining, after SDS-
PAGE, the BIS-TRIS gel was fixed with methanol and staining solution (Thermo 
Scientific) for overnight staining at room temperature. The stained gels were washed with 
ultra-pure water for 30 minutes.  The staining was visualised by placing on a UV 
transilluminator document system. 
 
2.11.3. Coomassie staining 
Coomassie blue is commonly used to stain proteins in SDS-PAGE gels. The gels are 
soaked in dye, and the excess stain is then eluted with a solvent destaining step. This 
treatment allows the visualisation of proteins as blue bands on a clear background. Pre-
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staining preparation steps same as Silver and Sypro Ruby staining, after SDS-PAGE, 
staining solution (50% Methanol, 40% Water, 10% Acetic acid and 0.25% Coomassie R-
250 [Sigma]) was added cover the gel. Staining was carried out for 2~3hours with gentle 
rocking, followed by destaining solution (25% Methanol, 68% Water, 7% Acetic acid) 
overnight.  
 
2.12. PNGAse F digestion 
2.12.1. PNGase F treatment 
Peptide -N-Glycosidase F, also known as PNGase F (NEB), is an amidase that cleaves 
between the innermost GlcNAc and asparagine residues of high mannose, hybrid, and 
complex oligosaccharides from N-linked glycoproteins. For the analysis, 200~500ng of 
purified recombinant FVIII glycoprotein was combined with 2µL of 10X Glycoprotein 
Denaturing Buffer and H2O (if necessary) to make a 20µL reaction volume. The 
glycoprotein was denatured by heating at 95°C for 5 minutes followed by chilling on ice. 
Make a total reaction volume of 40µL by adding 4µL 10X G7 Reaction Buffer, 4µL 10% 
NP40 and 6µL H2O. The reaction was divided into two and a half treated with 1µL 
PNGase F, mix gently and incubate reaction at 37°C for one hour, a sample without 
PNGase F was kept on ice.  
 
2.12.2. FVIII polyclonal antibody 
The blots were probed either with a 1:5000 dilution of polyclonal sheep anti-hFVIII 
horseradish peroxidase antibody (SAF8C-HRP, Affinity Biologicals, Quadratech 
Diagnostic). 
 
2.12.3. FVIII Monoclonal antibody 
The heavy chain was identified by monoclonal ab78876 (Abcam, Cambridge, UK) which 
has an A2 domain for epitope recognition site. Light chain was identified by Ab41188 
                                                                                                                          Chapter 2 
 
 122 
(Abcam), which has an a3 binding epitope; both primary antibodies were used at 1:1000 
dilution. Monoclonal heavy and light chain antibodies were then detected with anti-
mouse HRP (Horseradish Peroxidase) conjugated IgG secondary antibody. 
 
2.13. In-Vivo Procedures  
2.13.1. Preparing Adeno Associated Virus for mouse injection  
All mice used in the study were male C57BL/6 aged between four and eight weeks 
(Charles River, Margate, UK). Single-stranded AAV2/8 FVIII viruses were prepared in 
up to 200μL in X-VIVO 10 media, and 5x1010vg/mouse was administered via tail vein 
injection with 3~4 mice per group. Intravenous tail vein injections of FVIII expressing 
AAV into C57BL/6 mice were performed by Dr Cecilia Rosals (University College 
London), according to approved UK Home Office and Institute guidelines at University 
College London via the tail vein using no anaesthetics.  
 
2.13.2. Tail Vein Injection  
Blood samples in mice were collected in 0.136 Molar trisodium citrate anticoagulant (1:9 
v/v to blood) tubes 4 weeks after the injection date by terminal blood collection after 
sacrifice. Liver tissues were also collected and snap frozen on dry ice for genomic DNA 
extraction.  
 
2.14. Recombinant FVIII purification 
The purification process for rhFVIII produced in the adherent HEK-293T cells is 
illustrated below.  A total of two purification steps is employed to remove host cells, 
medium components, and a chemical reagent during culture and purification. 
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Figure 2.4. Recombinant human FVIII purification steps 
FVIII containing media were collected twice from stable cells, and membrane-bound FVIII was 
harvested by using 0.5M NaCl. Purification was performed by affinity column (FVIIISelect, 
Healthcare, Stevenage, UK) then total eluants were applied to a weak anion exchange column 
(DEAE FF, Healthcare, Stevenage, UK). 
 
 
 
2.14.1. Sample preparation for Äkta Explorer 
Purification of recombinant FVIII proteins was carried out using a two-step purification 
method. The first step is an affinity column chromatography procedure and the second 
column is weak anion exchange column for the polishing step. Stable expressing 
adherent cells were grown up in a large T-1000, five-layer flask (Fisher Scientific). Day1, 
3 x108cells were split into T-1000 flask with 200mL of DMEM containing 10% FBS. 24 
hours later FBS contained medium was discarded, and cells washed twice with PBS, 
then 200mL of DMEM serum free media was added. A further 24 hours later media was 
harvested and replaced with fresh 200mL of serum free DMEM. To the harvested media 
1mM benzamidine (Sigma) was added to prevent trypsin, trypsin-like enzymes, and 
serine protease from inactivating rFVIII. Media was centrifuged at 400xg for 5 minutes 
and filtered through a 0.22μm vacuum filter (Corning) and keep at 4ᵒC for purification. 24 
hours later a 2nd harvest was done, cells were washed, and 100mL of additional 0.5M 
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NaCl containing serum free DMEM was then incubated at 37ᵒC for 5 minutes to harvest 
membrane bound recombinant FVIII. The second harvest and membrane-bound FVIII 
were diluted with 100mL of serum free DMEM. In total 200mL of membrane-bound FVIII 
supernatants were treated in the same way as the first harvest. The chromatographic 
operations were performed at 4oC on Äkta Explorer (GE Healthcare) Fast protein liquid 
chromatography (FPLC) systems controlled by Unicorn Version 5.2 Software. All 
purification steps followed according to Tang et al  (Tang et al., 2013).  
 
2.14.2. FVIII affinity column 
FVIII purification is based on highly cross-linked agarose base matrix, which enables 
rapid processing of large sample volumes. The ligand is a 13kDa recombinant protein, 
the structure of which is based upon a Saccharomyces cerevisiae derived single domain 
antibody fragment. The ligand is attached to the porous base matrix via a hydrophilic 
spacer arm making it easily available for binding to recombinant B-domain deleted FVIII 
(McCue et al., 2009). Briefly, following line washing with the appropriate buffers, the 
affinity medium was equilibrated in 20mM Immidazole/ 10mM CaCl2/ 400mM NaCl/ 
100ppm Tween 80, pH 7.0 at a flow rate of 1mL/minutes. The cultivated media obtained 
from T-1000 flask preparations was then loaded onto the 1mL FVIIIselect (GE 
Healthcare) packed column at 1mL/minutes (traceable as an increase in absorbance at 
260nm and 280nm as unbound protein and DNA exits the column). Residual unbound 
protein and cellular debris were washed off. After washing with buffer A and then with a 
mixture of 30% Buffer A (Table 2.2) and 70% of Buffer B. The protein was eluted with 
50% ethylene glycol containing Buffer B (pH 6.5), which was collected in 1mL fractions 
into tubes. The FVIII containing fractions were identified by a peak in absorbance at 
260nm and 280nm. All fractions were pooled, and normally a pool volume of around 
10mL was obtained. The fractions were stored at -80ᵒC until sufficient material was ready 
for the polishing DEAE FF column. 
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2.14.3. Diethylaminoethyl (DEAE) Sepharose Fast Flow Column 
FVIII containing fractions were diluted (9-fold) in Buffer C (20mM MOPS/ 10mM 
CaCl2/100ppm Tween80, pH 7.0). The sample proteins were loaded onto the column at 
1mL/minute (traceable as an increase in absorbance at 260nm and 280nm as unbound 
protein exits the column). After washing the column with a mixture of 80% Buffer C and 
20% of Buffer D, the bound FVIII was eluted with a mixture 60% Buffer C and 40% of 
Buffer D, Residual unbound protein and cellular debris was washed off. The pure 
recombinant FVIII protein was eluted in 1mL fractions into tubes. The FVIII containing 
fractions were identified by absorbance at 280nm. All fractions were pooled and 1% 
sucrose (Sigma) w/v was added as a stabiliser, and aliquots stored at -80°C. 
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Equilibration buffer 20mM Immidazole 
  
 10mM CaCl2 
 400mM NaCl 
 200ppm Tween 80 
 pH 7.0 
Buffer A 20mM Immidazole 
 20mM CaCl2 
 1mM NaCl 
 200ppm Tween 80 
 pH 6.5 
Buffer B 20mM Immidazole 
 20mM CaCl2 
 1.5M NaCl 
 200ppm Tween 80 
 50% W/W Ethylene glycol 
 pH 6.5 
Buffer C 20mM MOPS 
 10mM CaCl2 
 100ppm Tween 80 
 pH 7.0 
Buffer D 20mM MOPS 
 10mM CaCl2 
 1M NaCl 
 100ppm Tween 80 
 pH 7.0 
 
Table 2.5. FVIII purification buffers  
All buffers filtered with 0.45um filter system and kept at 4ᵒC. 
Abbreviation: ppm; parts per million. 
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2.15. Immunocytochemistry 
2.15.1. Split cells on coverslips 
13mm cover glass (VWR) was sterilised in 100% ethanol for two hours, and replaced 
into the wells of 24-well plates. The lid was left open to allow the ethanol to evaporate in 
a class II cabinet. The coverslips were the coated with 200μL of 1x Geltrex (Life 
Technology) diluted with DMEM and incubated at room temperature for an hour. After 
incubation, the coating media was discarded coating media, and 5x104cells were added 
per well in a volume of 500μL.  
 
2.15.2. Staining 
Stable cells grown on coverslips were washed in 1X PBS and fixed in 4% PFA (Para 
formaldehyde) for 10 minutes at room temperature. Following fixation, cells were blocked 
and rehydrated for 10 minutes in 1XPBS supplemented with 1% BSA and 0.1% Triton 
X-100 (Sigma). Cells were transferred into primary antibodies (appropriately diluted in 
1X PBS, 1% BSA, 0.1% Triton X-100, Table 2.3) and incubated with constant shaking 
for either 1hour at room temperature or overnight at 4ᵒC. Following incubation with 
primary antibodies, cells were washed in 1XPBS, 0.1% Triton X-100 and then incubated 
for 30 minutes with secondary antibodies. Cells were then washed three times with PBS 
before count-staining with 0.5mg/mL DAPI (4',6-diamidino-2-phenylindole, Sigma). 
Coverslips were mounted onto gelatin-coated slides with Vectashield non-quenching 
mounting medium (Vector Laboratories). Immunocytochemical staining was then 
assessed microscopically using an upright Leica Imaging system and Inverted Leica 
Confocal Imaging system (Leica). 
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Table 2.6. Antibodies for Immunofluorescence staining  
Monoclonal FVIII primary antibody used for human FVIII detection (Ab41188, the light chain of 
FVIII). Calnexin is an ER chaperone protein, which binds early stages of protein processing and 
rabbit calnexin purchased from cell signalling. Golgin 97 is a broad Golgi marker, which was 
purchased from Abcam (Cambridge, UK). DAPI (4’,6’-diamidino-2-phenylindole) and used for 
nucleus counterstaining. 
 
2.15.3. Confocal Imaging 
Double stained Stable cell lines were viewed using an inverted microscope equipped 
with a 60x oil objective and a confocal system.  Fluorophores were excited at 406nm, 
488nm, 543nm He/Ne green, and 647nm. Each image was volume rendered from 10 Z-
stacks of 0.85μm thickness using LCS Lite software (Leica). The timed series was 
acquired at a rate of one minute per frame, and each frame represents a volume-
rendered image. 
 
2.16. Statistical analyses  
Statistical analyses were performed using Analysis of Variance (ANOVA) and t-test. 
Groupwise comparisons were performed by using one way ANOVA (Bonferroni 
simultaneous test) and two way ANOVA. The Mann–Whitney U test and two-tailed paired 
tests were used for the independent two groupwise test (GraphPad Prism 5 and 6; 
Graph-Pad Software Inc). 
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Chapter 3 
Engineering B-domain of human FVIII to 
generate stably expressing cell lines 
producing FVIII proteins using Lentiviral 
vectors 
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3.1. Introduction 
Haemophilia A is bleeding disorder that is caused by very low or absent FVIII expression. 
Even normal FVIII expression is lower than any other coagulation factor due to poor 
mRNA expression, inefficient protein folding with subsequent misguided extracellular 
transport by ER and Golgi systems, resulting in approximately two to three-fold decrease 
of FVIII expression level compared with similar sized secretory proteins (Kaufman et al., 
1989; Lynch et al., 1993). Studies of FVIII structure and function have led to opportunities 
to bioengineer forms of improved recombinant FVIII that share an identical domain 
structure (A1-A2-B-A3-C1-C2) (Vehar et al., 1984; Sandberg et al., 2001; Zheng et al., 
2013).  
It has been shown that entire B-domain of FVIII is dispensable for the blood pro-
coagulation process (Toole et al., 1986) and that deletion of the B-domain improved 
mRNA levels as well as FVIII activity. Therefore the B-domain has been a favoured 
strategic target for human FVIII bioengineering to improve FVIII properties of 
biosynthesis, secretion efficiency, functional activity and long half-life in plasma (Pittman 
et al., 1993; Miao et al., 2004).  
However, the production of recombinant FVIII has proved to be costly due to the expense 
of production, purification, and formulation. The manufacturing technology used has 
required specialised production and distribution, limiting access to developed first world 
countries but leaving less developed countries without such treatment. For this reason, 
recombinant FVIII production from stable cell lines is becoming important for the clinical 
field (Wurm, 2004). However there are hurdles to overcome for the stable cell line 
techniques: i) Labour-intensive process due to heterologous DNA integration into the 
genome by current transfection methods, ii) Time-consuming for the selection step to 
pick up efficiently expressing FVIII from the large scale of cell lines, which should be 
monitored for gene silencing overtime of passaging of the lines,  
Chapter3  
 
 131 
iii) The post translational modification of FVIII from the host cells line should be identical 
to human FVIII.  Therefore, alternative gene delivery with highly effective lentivirus will 
facilitate the stable cell line establishment and selection steps (Trono, 2000) because 
lentivirus delivers the target gene efficiently into the host genome by viral integrase with 
a high-frequency manner to active chromatin (Bushman et al., 2005).  Lentivirus-based 
gene transfer used to establish stable cell line has been reported for Chinese hamster 
ovary (CHO) cells, and the result shows that efficient, stable cell lines are established 
compared to non-viral DNA delivery methods (Oberbek et al., 2011).  Non-human 
material contamination in the FVIII protein is an important issue for the production 
methods because antigenicity may cause an immune response in patients to the 
contaminated FVIII products. In this respect, optimisation of the serum-free culture 
condition for established stable cell lines is required as an important step for FVIII 
production. 
The aim of this chapter is to address the overall hypotheses that the length of B- domain 
and N-linked glycosylation of FVIII may have important roles in FVIII production.  In 
testing these hypotheses, human FVIII variants (wild type SQ, N6 versus V1co, V3co, 
V5co and N6co) and their B-domain modification will be described.  Finally, 
characterisation of FVIII producing stable cell lines will be performed for efficient 
production of FVIII.   
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3.2. Results 
3.2.1. Construction of B-domain modified FVIII 
To enhance translation efficiency of FVIII, DNA sequences derived from the B-domain 
were engineered according to preferred codon usage based on human albumin, to 
create codon optimised version of FVIII SQco and FVIII N6co (McIntosh et al., 2013)  
(Fig. 3.1).  
The “SQ” linker consists of 14 amino acids: SFSQNPPVLKRHQR, which contains the 
proteolytic furin cleavage recognition motif RXXR (RHQR) at the C-terminal end of B- 
domain and before the a3 region. The B-domain deleted SQ-linker FVIII molecule is a 
heterodimer of a unique 90kDa heavy chain and an 80kDa of the light chain, which has 
a great advantage regarding expression efficiency compared to full-length FVIII products 
which have variable heavy chain fragments ranging in size from 90~200kDa (Pittman et 
al., 1993).  
The N6 linker 226 amino acid (aa) sequence was developed by Miao et al. It is a 
truncated partial 226aa B-domain consisting of the N-terminal portion of the B-domain. 
Miao et al., concluded that glycosylation was important for high expression of N6/226aa 
due to the presence of six of Asn-X-Thr/Ser (N-X-T/S) motifs, sites of high mannose 
attachment, which support ER to Golgi transport of FVIII. However removal of five of the 
six N-linked glycosylation sites still leads to increased expression compared with B-
domain deleted FVIII  (Miao et al., 2004).  
The V3 linker fragment is composed of 31 amino acids that consist of the six N-linked 
glycosylation motifs from N6 placed adjacent to each other and juxtaposed in front of the 
native PPVLKRHQR sequence of FVIII. Thereby the linker sequence becomes SFSQ-
NATNVSNNSNDSNTSNVS-PPVLKRHQR.  
Preston et al., demonstrated that glycosylation plays a role in both stability and activity 
of FVIII (Preston et al., 2013). To further understand the role of glycosylation in the B- 
domain, we developed several further constructs by varying length, sequence and 
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glycosylation potential. The first of these contains six N-linked glycosylation sites with an 
increased spacer between glycosylation motifs, leading to a 44 amino acid linker 
(designated V1co). Subsequently, to test whether glycosylation has a critical role for 
V3co, we modified the six Asparagine (N) to Alanine (A) in the V3co linker (designated 
V5co) (Fig. 3.1).  
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Figure 3.1. Schematic illustration of domain structures for engineered FVIII V1co, V3co and V5co 
The newly generated five FVIII variants linker peptide sequences are illustrated. Truncated B-domain constructs of SQco and N6co are shown on top. Newly 
synthesised peptide linker sequences substituted into SQco, leading to V1co, V3co, and V5co. N-linked glycosylation sites are indicated as N (red) except 
SQco and V5co. The number of substituted B-domain linker amino acid (aa) are SQco, 14aa; V5co, 31aa; V3co, 31aa; V1co, 44aa and N6co, 226aa. Furin 
cleavage site RHQR naturally exists in SQco, V1co, V3co and V5co. However, the furin cleavage site of N6 was removed, due to the absence of B-domain 
proximal to the a3 region. Abbrevation: co; codon-optimised. 
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3.2.2. Generation of pRRL hPGK mWPRE shuttle vector 
Although AAV expressing the FVIII variants can efficiently transduce cell lines, the transgenes 
are episomally maintained, and integration into the host genome is a rare event; therefore 
AAV is not a suitable viral choice for creating stable cell lines as the transgene will be gradually 
lost with the host cell division. Therefore, lentiviral vectors, which efficiently integrate into the 
target cell genome were used to establish stable cell lines. Lentivirus shuttle vector plasmid 
pRRL PGK perforin mWPRE (originally provided by Professor Adrian Thrasher [UCL.UK]) was 
prepared by removing the transgene using PsPXI and AgeI restriction enzymes and then re-
ligating the rest of the backbone DNA to create minimum shuttle plasmids. Thereby a 6668bp 
empty shuttle plasmid (pRRL.PGK.mWPRE) was generated for further cloning of FVIII 
transgenes (Fig.3.2.A.B). 
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Figure 3.2. Vector maps of lentivirus shuttle vectors used in this study and details of restriction digestion 
A) The original lentivirus shuttle plasmid (kindly provided by Professor Adrian Thrasher, UCL) harbour human PGK promoter, perforin gene and woodchuck 
post-transcriptional response element (WPRE). Restriction digestion with PsPXI and AgeI generate 6668bp and 1681bp band showed on 1% agarose gel.  
B) The DNA (6668bp) fragment re-ligated and two positive colonies were selected either by AgeI/ SphI or NotI/ BamHI, finally chose the clone number one for 
main backbone plasmid. 
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3.2.3. Cloning of lentiviral vectors 
The FVIII variants are in two groups; Group one consisting of wildtype SQ and N6; Group 
two including the other groups are codon optimised (co) SQco, N6co, V1co, V3co and 
V5co. All transgenes were cloned into third generation self-inactivated pRRL vector 
driven by PGK promoter (Fig.3.3). 
 
 
 
Figure 3.3. Schematic representations of human FVIII variants, cloned into third 
generation lentiviral backbone 
The SIN (Self-inactivate) HIV-pseudo typed lentiviral vector includes, Ψ: packaging signal, 
phosphoglycerate kinase (PGK) promoter to drive transgene expression, and woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE), which enhances expression of 
transgenes. Lollipop indicates potential N-linked glycosylation inner linker of FVIII transgenes. 
Chapter 3  
 
 138 
Initially, the WT SQ and WT N6 (kindly provided by Professor Steven Pipe), human FVIII 
variants, containing the wild-type DNA sequences were cloned into the 3rd generation 
pRRL transfer vector driven by PGK promoter. pRRL PGK WPRE backbone was 
digested with BamHI, and then the sticky end was filled with Klenow reaction to create a 
blunt end. pAV2.HLP.WTN6 (4.3kb) and pAV2.HLP.WTSQ (4.2kb) was digested with 
NotI and ScaI to excise the insert. The blunt ends were filled with the Klenow reaction 
(Fig.3.4.A). The digested inserts and backbone DNAs were ligated, and positive colonies 
were selected by BglI or SpeI digestion (Fig.3.4.B).  
 
 
Figure 3.4. Cloning for WT SQ and WT N6 
A) Agarose gel electrophoresis of restriction enzyme (NotI and ScaI) digested WT SQ and WT 
N6. Among the three digested bands, 4.3kb DNA was extracted for the insert. 
pRRL.PGK.mWPRE was linearized by BamHI digestion, and then each end was blunt ended by 
Klenow. The backbone DNA was ligated with 4.3kb inserts. B) Positive clones were selected 
using SpeI or BglI digestion. Predicted SpeI digestion of WT N6 plasmid is 6.2kb, 4.4kb and 0.8 
kb. The colony 1 and 2 showed correct band size upon SpeI digestion. Whereas the WT SQ 
predicted digested band illustrated as 6.2kb, 3.9kb and 0.8kb. Agarose gel separation shows 
correct bands for both clones 3 and 4. BglI digestion is used for full plasmid check, which 
corresponds to 7.8kb, 2.2kb, and 1.2kb bands respectively.   
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One of the goals of this project is to enhance the efficacy of expression of currently used 
FVIII-SQ and FVIII-N6. Therefore, codon optimised N6, SQ, and V3 DNAs, which were 
initially cloned into AAV shuttle plasmids (pAV2. HLP FVIII pA), were digested with NruI 
(blunt end) and BamHI (sticky end) to excise inserts. To create lentiviral backbone 
compatible ends, pRRL.PGK.mWPRE was digested with AgeI and BamHI. The digestion 
was performed in two steps. The first step was AgeI digestion, followed by Klenow fill-in, 
which created a blunt 5’ end to create a compatible end to NruI.  Then a second digestion 
was performed with BamHI, which creates compatible sticky 3’ end to BamHI (Fig.3.5.A). 
Insert, and backbone DNAs were ligated using T4 ligase overnight then transformed into 
Stbl3 E.coli competent cells. Following overnight culture, colonies were selected, grown 
for 16 hours and then DNA was extracted. In total 12 colonies were tested and these 
were digested with SbfI and BamHI. Positively cloned plasmid DNA digestion bands are 
approximately 4.4kb and 7.3kb. Figure 3.5.B showed that colonies 1, 3, 8, 10 and 12 
were positive for the SbfI/BamHI digestion. Clone number one was selected for final 
V3co lentivirus plasmid for maxi-prep. The same cloning strategy was applied to 
generate SQco and N6co lentiviral constructs (Fig.3.5.C, D). Although SQco and V3co 
cloning were successful, N6co cloning with this method was unable to achieve the 
correct positive colony. Figure 3.5 D showed that the SbfI/BamHI digestion exhibits an 
unwanted DNA band at 1.8kb instead of 4.4kb DNA band. To resolve this issue, we used 
the newly generated pRRL PGK V3co WPRE vector (Fig.3.5.B) as backbone plasmid. 
N6co and lentiviral backbone plasmid were digested with KpnI (Fig.3.6.A), and positive 
colonies were selected by KpnI digestion (Fig.3.6.B). The correct direction of the insert 
was checked by SbfI digestion, which shows 2.2kb and 9kb DNA bands (Fig. 3.6.C).   
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Figure 3.5. Cloning for codon optimised FVIII variants into lentivirus shuttle 
plasmid 
A) Agarose gel electrophoresis of NruI/BamHI digestion for N6co (4.9kb/ 3.3kb), V3co (4.5kb/ 
3.3kb), and SQco (4.5kb/ 3.3kb). Each inserts indicated by arrow (4.9kb for N6co, 4.5kb for V3co 
and SQco). pRRL.PGK.WPRE digested with AgeI/BamHI as used for backbone plasmid. B), C), 
D) Positive colonies were selected according to correct digestion pattern with SbfI/BamHI.  
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Figure 3.6. Cloning for codon optimised FVIII N6 into lentivirus shuttle plasmid 
A) The Agarose gel image shows 6.3kb and 2.1kb bands for pAV2 HLP N6co synPA and 9.7kb 
and 1.3kb bands for pRRL PGK V3co WPRE respectively. B) Positive colony selection with KpnI 
digestion. The arrow shows 2.1kb positive DNA band. Colonies 6~12 was selected as a positive 
colony. C) Direction checked by SbfI, which digest positive plasmid DNA to 2.2kb and 9.6kb 
respectively (Arrow).  
.  
Chapter 3  
 
 142 
3.2.4. Cell line selection for stable FVIII expression 
To select the most efficient cell line, which is suitable for this study, the lentiviral vector 
plasmid DNAs were transfected into either HEK-293T or Huh 7 cell lines. Two different 
cell lines were evaluated for FVIII production. The HEK-293T cell lines originated from 
the human embryonic kidney. It is widely used in industry for recombinant protein 
production because of its well-characterised genome and relatively ease of handling for 
scale up. In contrast, Huh 7 cell is a human hepatocyte-derived cellular carcinoma line, 
which allows systematic studies in-vitro of FVIII expression in cells that are similar to 
those of the target organ liver cells (Nakabayashi et al., 1982). For plasmid transfection 
into these two cell lines, two variants were selected: FVIII B-domain modified plasmids 
SQco and V3co. FVIII antigen (%) ELISA assay showed that V3co (28% ± 6.2) and SQco 
(18% ± 4.8) were highly expressed in HEK-293T cells. In contrast, Huh 7 cells showed 
poor expression of V3co (7% ± 1.4) and SQco (2% ± 1.2). Statistics show between the 
two cell lines produced FVIII expressions yielded significant difference between HEK-
293T cells and Huh 7 cells (**P<0.005, Two-tailed paired t-test). The results suggest that 
HEK-293T cells are a more appropriate choice for stable expression of FVIII (Fig. 3.7).   
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Figure 3.7. Expression of FVIII V3co and SQco variants from PGK driven FVIII 
transgene in different cell lines 
Cells were transiently transfected with two variant expressing plasmids, and fresh medium was 
changed after 48 hours. FVIII containing medium was harvested after a further 24 hours of 
incubation and analysed for FVIII expression by ELISA. The graph shows secreted FVIII protein 
expression from HEK-293T and Huh 7 cells under a serum-free condition. Results are reported 
as mean ±SEM, (n=2). Two-tailed paired t-test (**P<0.005). Prism 6.0 (Graph Pad). 
 
  
Chapter 3  
 
 144 
3.2.5. Lentiviral vector production 
Lentiviral vectors were produced using 3rd generation pRRL packaging system with PEI 
transfection, and viral titers were determined by Q-PCR (details in materials and 
methods). Here we achieved high viral titres using small scaled viral preps and include 
Green fluorescence protein (GFP) viral controls; all variants produced more than 1x108 
viral genomes. In the context of viral titre, there was no difference between wild-type and 
codon optimised B-domain deleted FVIII, as illustrated in Table 3.1.  
 
sin pRRL PGK WPRE, FVIII viruses 
 
 
Titer by Q-PCR 
 
pRRL PGK GFP WPRE 
 
 
5.78x108 Viral genome/mL 
 
pRRL PGK WTSQ WPRE 
 
 
1.0x108 Viral genome/mL 
 
pRRL PGK WTN6 WPRE 
 
 
1.0x108 Viral genome/mL 
 
pRRL PGK SQco WPRE 
 
 
1.01x108 Viral genome/mL 
 
pRRL PGK V1co WPRE 
 
 
1.0x108 Viral genome/mL 
 
pRRL PGK V3co WPRE 
 
 
1.24x108 Viral genome/mL 
 
pRRL PGK V5co WPRE 
 
 
1x108 Viral genome/mL 
 
pRRL PGK N6co WPRE 
 
 
1x108 Viral genome/mL 
 
Table 3.1. Quantification of vector titres for VSVG pseudo-typed lentivirus  
The RNA based lentiviruses are unstable at room temperature, due to that fact all processing was 
performed at 4°C, except cell culture and production in incubators. Twice harvested viral 
supernatant was merged then concentrated 150 times using ultra-centrifugation. Viral pellet was 
re-suspended with cold DMEM and aliquots kept at -80°C. Viral titres were determined by qPCR-
based assay. pRRL PGK GFP WPRE virus produced for viral control. Each Q-PCR titre is a mean 
of the values. 
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3.2.6. Optimisation of FVIII lentiviral vectors transduction   
To identify, optimal FVIII expression condition, Human embryonic kidney derived HEK-
293T cells were transduced serially with lentiviral vectors encoding FVIII variants. A 
previous report showed codon optimised FVIII cDNA produced 7~30 fold higher levels 
of FVIII expression level compared to the wild-type sequence (Ward et al., 2011; 
Shestopal et al., 2017). Therefore, the codon optimised lentiviral constructs harbouring 
SQco, V3co and N6co were used to transduce HEK-293T cells at various multiplicities 
of infection (MOI). The FVIII levels were assessed by FVIII antigen ELISA (Affinity 
Biologicals). At day four post-transduction, the maximum expression levels were 
detected at MOI of 10 (FVIII-N6co: 80%, FVIII-V3co: 28% and FVIII-SQco: 18%). N6co 
variant, which contains 226 amino acid out of 908 amino acid partial B-domain linker, 
expressed 3 to 4-fold higher expressions at the MOI of 10. Although results are not 
corrected for proviral copy number a positive correlation between FVIII antigen 
(Polyclonal FVIII antigen, Affinity Biologicals) and MOIs is clearly demonstrated (Fig. 
3.8).  
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Figure 3.8. Optimisation of the multiplicity of infection (MOI) of Lenti-FVIIIs for the 
production of hFVIII expression levels in HEK-293T cells   
Serial transduction of HEK-293T cells using lentiviral vectors were performed at a multiplicity of 
infection (MOI) of 1, 2, 5, and 10 for single transduction. Secreted FVIII was assessed using a 
polyclonal FVIII antigen assay after 72 hours following each transduction. Columns represent 
FVIII antigen expression levels for different MOIs. Cell viability and growth rates were also 
determined and found to be similar among all conditions. GFP lentiviral vector used as positive 
control for viral transduction. GFP-transduced at MOI 10 produced more than 95% GFP positive 
cells (Data not shown). 
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3.2.7. Protein expression by the B-domain modified FVIII cell lines 
All FVIII lentiviral vectors (SQco, V3co, and N6co) produced FVIII Antigen. Our next 
interest was to test how the FVIII protein cleavage pattern is affected by the modified B-
domain.  
To characterise protein expression pattern, the total cell lysate of the B-domain modified 
FVIII (SQco, V3co, and N6co) were separated on the SDS-PAGE gel followed by 
western blot and detected with a polyclonal antibody directed against the full-length FVIII 
to determine the cleavage pattern of the modified FVIIIs. 
The B-domain of FVIII-SQ is composed of 14 amino acids that are truncated from the 
original FVIII B-domain sequence. ReFacto® (Pfizer) is the commercial product of FVIII 
SQ, which we used as a control for the cleavage pattern.  Figure 3.9 showed that 
ReFacto® appeared as a 170kDa (SC: Single chain), 90kDa (HC: Heavy chain) and 
80kDa (LC: Light chain). It should be noted that the ReFacto® is purified and 
concentrated, therefore; the intensity of the cleaved product is too strong to compare 
with our cell lysate.  Next, the codon optimised version of SQ, SQco (lane five) showed 
170kDa, 90kDa and 80kDa of FVIII chains identical in mobility to those present in 
commercial ReFacto®.  
In contrast, N6co with its 266 amino acid of B-domain is predicted to generate bands at 
240kDa (single chain), 90kDa (heavy chain) and 150kDa, 80kDa (light chain). The 
150kDa (226aa+80kDa light chain) is generated by cleavage of the heavy chain (A1, A2) 
from a single chain with B- domain (226 Amino Acid) still attached to 80kDa light chain. 
The actual result showed that 240kDa single chain is not detected while 150kDa was the 
strongest band among the cleaved N6co bands. The result suggests that 240kDa single 
chain might be efficiently processed to a small fragment of the cleavage products such 
as 150kDa chain and 90kDa heavy chain. However, the 80kDa light chain is weaker than 
90kDa implying intermediate 150kDa is not efficiently processed to 80kDa of light chain. 
Chapter 3  
 
 148 
Although a weak band representing the light chain appeared from analysis of N6co, it 
does not necessarily mean a reduced activity.  In fact, thrombin generation assay 
showed no difference with ReFacto®, as will be discussed in chapter 4.  
The B-domain of V3co contains an additional 17 amino acid with six N-linked 
glycosylation motifs (31aa linker) between the B-domain of SQ. Therefore the predicted 
size of cleavage products are 190kDa (single chain), 110kDa (heavy chain + 31aa linker), 
90kDa (Heavy chain) and 80kDa (light chain). Similar to N6co, the single chain of V3co 
is not detected and as we predicted the 110kDa is generated from cleavage of the light 
chain from single chain due to the furin cleavage site and as a result B-domain linker 
(31aa) is still attached to 90kDa heavy chain (Fig.3.9, lane 4).  It is interesting to note 
that the light chain is the most efficiently cleaved amongst these constructs.  
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Figure 3.9.  FVIII protein expression from B-domain modified constructs 
HEK-293T cells were transfected with V3co, N6co, and SQco then the cell lysates were used for 
western blot analysis. Polyclonal antibody (Sheep, Affinity Biologicals, UK) used for the FVIII 
detection. Lane 1: Marker, Lane2: ReFacto® 14aa B-DD, Lane3: 226aa/N6 B-domain, Lane4: 
31aa linker contained V3co, Lane5: 14aa SQco.  
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3.2.8. Single cell clone selection  
To establish a FVIII expressing stable cell line, lentivirus with different FVIII variants were 
used to transduce HEK-293T cells at MOI of 10. From the population of cells that 
underwent ten rounds of transduction, clonal isolates were obtained by limiting dilution 
in 96-well plates. After two weeks, ten clones were selected for each variant and 
assessed for FVIII antigen levels using ELISA (%FVIII/1x106cells/ 24hours expression). 
This ELISA assay using a polyclonal antibody against FVIII antigen shows variable 
expression levels in individual groups of variants (Fig. 3.10). Therefore, the four highest 
FVIII expressing clones were expanded for further analysis. 
 
 
Figure 3.10. Initial selection of single cell lines, according to which are the best 
performing FVIII antigen expressing clones 
Individual clones were assayed for FVIII antigens by Affinity biologicals kit (ELISA), a total of 10 
clones per variants were analysed. Horizontal bars represent the mean of each set of clones and 
± SEM, (n=10). Prism 6.0 (Graph Pad). 
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3.2.9. Secondary screen and selection 
To select the best performing single cell clone, I chose four out of the ten initially selected 
clones according to FVIII antigen level and activities from the medium.  The four clones 
of WTN6 selected are illustrated in Figure 3.11.A. Clone WTN6-8 showed the best 
antigen expression (23%), and activity (2.3 IU/dL). Although the protein levels are 
highest from the colony, we chose the clones according to the level of activity because 
the highly secreted FVIII protein may not be properly processed in the cells.  The same 
selection method was applied to all constructs. The WTSQ clone 1 and clone 2 had same 
activity level. Clone 2 was selected for future work due to high antigen level (Fig. 3.11.B).  
In this study, it is important to note that we can separate into two groups according to 
codon optimisation. The WTN6 and WTSQ have non-codon optimised FVIII, and the rest 
(SQco, N6co, V3co, V1co and V5co) are all codon optimised FVIII. The FVIII antigen 
level of the non-codon optimised group was between 10~25 (%) for antigen level and 
1~8 IU/dL for activity level (Fig.3.10. A and B). However, the codon-optimised variants 
showed higher FVIII antigen (40~80 %) and activity (20~80 IU/dL) (Fig.3.11. C-F). These 
results suggest that the codon-optimisation increases not only the antigen level up to 4-
fold but also FVIII activity by 10-fold respectively.  However, the fold differences between 
FVIII antigen level and activy may be due to discrepancy of the assay. As we mentioned 
in chapter 2, we applied 1 IU/mL to 100% FVIII antigen value for FVIII antigen standards 
that the units are not appropriate for percentage of FVIII antigen. 
The N6co-7 clone was selected according to the highest activity level amongst the N6co 
group at 75 IU/dL of FVIII. Unlike N6co, the levels of FVIII activity of SQ derivatives 
(V3co, V1co and V5co) are either similar to antigen level or much higher as illustrated 
by the selected colony SQco-8. The results suggest that codon optimised SQ transcripts 
may provide optimal conditions for cellular processing of FVIII (Fig.3.11.D-G). V3co 
group showed a consistent FVIII antigen level, the clone (V3co-2), selected expressed 
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FVIII at activity levels of 170 IU/dL (Fig. 3.11.E). V1co clones (44 amino acid B-domain 
linker) showed high FVIII activity consistently in all four-selected colonies. Therefore I 
chose a clone V1co-4, according to its highest activity (139 IU/dL). In FVIII-V5co, the N 
(Asn) amino acids are substituted to A (Ala). Amongst V5co clones, V5co-10 showed the 
highest FVIII activity (222 IU/dL). All subsequent experiments were conducted with the 
clones selected. 
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Figure 3.11. Second selection of single cell line from pre-selected lines  
Further clone selections were performed. Four clones were selected from previouse ten selected 
clones. The FVIII antigen (%) and activity (IU/dL) were tested from second stage-selected clones 
from the group of wild-type (WT) and codon-optimised groups. A) WTN6, B) WTSQ, C) N6co, D) 
SQco, E) V3co, F) V1co, G) V5co. Abbrevation: co; codon-optimised. 
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3.2.10. Determination of proviral copy number in stable cell lines after 
lentiviral transduction  
To investigate if variation in transgene expression was caused by variation in the number 
of vector genomes integrated into the host gene, viral copy number was determined for 
all our transduction HEK-293T clones, since it is possible that variation in relative gene 
transfer efficiency for each of the lentiviral preparation may result in disparate levels of 
FVIII expression. Therefore the copy number was characterised from genomic DNA, 
which was extracted from stable cell lines so that transgene copy number could be 
determined using Q-PCR for each stable cell line (Fig.3.12). The average integration rate 
of the selected stable line for each variant was 0.5 to 1.2 copies per cell, with the 
exception of the WTSQ line, which had 3-fold greater copy number than the other cell 
lines. This raises a possibility that the WTSQ line may have been highly transduced with 
lentiviral vectors by chance. Therefore, three more WTSQ cell lines, which expressed 
lower FVIII antigen levels were tested for genome copy number. According to the Q-PCR 
(3.5, 3.7 and 4.1 copies per cell), we observed that there was consistently higher 
integration rate found among another three WTSQ lines implying that the respective 
lentivirus preparation had higher potency when compared to other vector preparation for 
the other FVIII variants. Therefore to allow for variation in gene transfer efficiency at the 
genomic levels we used genome copy values to normalise FVIII antigen and activity 
levels and expressed the results as FVIII antigen or activity levels per copy of the FVIII 
transgene in the target cells. 
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Figure 3.12. Quantification of viral copy number from lentiviral transduction 
To quantify viral genome copy numbers from stable cell lines, genomic DNA was extracted from 
stable cell lines and q-PCR carried out for each sample for both human house-keeping GAPDH 
gene and viral WPRE sequence to determine integrated proviral copy number per cell. 
Mean (± SEM), proviral copy number in FVIII stable cell lines, (n=3). Prism 6.0 (Graph Pad). 
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3.2.11. Determination of mRNA expression 
Total RNA was extracted from the stable cells, and the relative level of FVIII mRNA was 
assessed using Q-PCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used for normalisation of the loading mRNA. Figure 3.13 shows that FVIII mRNA level 
of two wild-type variants; SQ (WTSQ) and N6 (WTN6) were very similar. Codon 
optimised variants had 5 to 20-fold higher FVIII mRNA levels when compared with wild- 
type variants. Statistical analysis between both wild-type variants and codon-optimised 
variants (N6co, V3co and V5co) were significant (***p<0.0001, One-way ANOVA, 
Bonferroni simultaneous test). The V3co variant showed a 20-fold increase in mRNA 
expression compared with the WTSQ and 4-fold higher than codon-optimised SQ. The 
difference in mRNA levels between WTN6 and codon-optimised N6co was 16-fold. 
However, we did see a difference in FVIII mRNA levels between the V3co and N6co 
clones (*p<0.05). The FVIII mRNA levels for the SQco and V1co clones were similar 
(ns). In contrast, we observed a 2-fold higher level of FVIII mRNA level in the V3co clones 
compared to the V5co (**p<0.005).  
It has been shown that deletion of the entire B-domain leads to a 17- fold increase in 
mRNA and primary translation product compared with full-length FVIII; however, only a 
30% increase in the levels of secreted protein (Pittman et al., 1994; Kaufman et al., 1997; 
Miao et al., 2004).  Our results are consistent with other published reports that indicate 
that codon optimisation results in improvement gene expression through enhancement 
of translation and mRNA stability (Foster et al., 2008; Presnyak et al., 2015).  
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Figure 3.13.  Evaluation of relative mRNA expression of FVIII variant stable cell 
lines 
The relative expression of FVIII variants mRNA expression determined as ∆∆Ct value by real-time 
RT-PCR. WTSQ value used as a control, Total cellular RNA was prepared and FVIII transgene 
expression quantiﬁed by RT real-time quantitative PCR analysis of the WPRE element which 
lentiviral shuttle present in all transcripts. Data presented as mean ±SEM, (n=3). One-way 
ANOVA (Bonferroni simultaneous test), Prism 6.0 (Graph Pad). 
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3.2.13. Assessment FVIII Activity in stable cell lines 
The cofactor activity of stable cell lines culture media samples was assessed using the 
FVIII: Activity (Biophen, Quadratech Diagnostics) according to the manufacturer’s 
instructions. 
Using the chromogenic assay, the WTSQ showed activity (0.08±0.01 IU/mL), which is 
similar with WTN6 activity (0.1±0.07 IU/mL), whereas the codon optimised variants SQco 
(0.83±0.23 IU/mL), N6co (2.19±0.24 IU/mL), V1co (0.87 ± 0.12 IU/mL), V3co (2.05±0.12 
IU/mL) and V5co (1.64±0.03 IU/mL) were significantly increased compared to wild-type 
variants (Fig.3.14). Statistical analysis between wild type variant and the codon-
optimised variant was significant (***p<0.0001, One-way ANOVA, Bonferroni 
simultaneous test). These results suggest that codon optimisation significantly enhanced 
expression of FVIII activity in these cell lines. 
It is important to mention that in terms of FVIII activity, the B-domain is dispensable and 
that smaller B-domain deleted variants have significantly increased stability and activity 
(Pittman et al., 1994). Moreover, N-linked glycosylation has been suggested to be an 
important modification for FVIII activity. Therefore, it is interesting to compare from our 
FVIII activity assay which codon optimised B-domain truncated (N6co, V3co, V5co) FVIII 
variants are significantly more expressed compared with SQco. As a result of statistical 
analysis (One-way ANOVA, Bonferroni simultaneous test), the SQco vs V3co, V5co, and 
N6co was significant (**p<0.005) whereas SQco vs V1co were not significantly different 
from each other (ns). These results suggest that the six N-linked glycosylation sites are 
not affecting FVIII activity due to the fact that FVIII activity from mutated N-linked 
glycosylation construct V5co was not significantly changed. Moreover, the six N-linked 
glycosylation site containing V1co was significantly less active compared with V3co and 
N6co (**p< 0.005).  
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Figure 3.14. FVIII activity comparison between the FVIII variant stable cell lines 
FVIII activity was determined by chromogenic assay, the data was obtained from the conditioned 
medium, and FVIII expressions were normalised by vector copy number. Data presented as mean 
±SEM, (n=3). One-way ANOVA (Bonferroni simultaneous test), Prism 6.0 (Graph Pad).  
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3.2.14. FVIII antigen assay in stable cell lines 
Following the activity assay, we sought to determine the protein expression level of FVIII 
using FVIII antigen assay (ELISA) in the same batch of samples. The FVIII antigen 
expression was evaluated using the Stago kit (Asserachrom). The kits contain prepared 
plates coated with a monoclonal, which has a FVIII A2 domain epitope antibody. It is 
more sensitive than polyclonal antibody for detecting low levels of protein in culture 
media because monoclonal antibodies are much more specific and with less background 
noise than polyclonal antibodies, however very sensitive to small changes in the antigen. 
Figure 3.15 shows a similar pattern of FVIII protein expression as FVIII activity assay. 
The FVIII expression levels were WTSQ (10.6%±1.66), WTN6 (4%±0.01) whereas the 
codon optimised variants expression levels were SQco (123%±3.45), N6co (163% ±32), 
V1co (100%±4.0), V3co (296%±18.5) and V5co (182%±5.8). Statistical analysis (One-
way ANOVA, Bonferroni simultaneous test), between wild type variant and codon-
optimised variants, were significant (***p<0.0001). These results suggest that codon 
optimisation significantly enhanced FVIII protein expression corresponding to elevated 
mRNA levels. 
We hypothesised that N-linked glycosylation may affect FVIII protein trafficking. V3co 
which encodes the shortest linker peptide with six N-linked glycosylation sites among the 
variants had the most significantly increased FVIII expression level. The V5co with its N-
linked glycosylation sites mutated to Alanine shows significantly difference (*p<0.05)  
levels of FVIII expression compared with V3co, however  six N-linked glycosylation sites  
encode N6co, and V1co shows significantly decreased FVIII expression level compared 
with V3co (*p<0.05). These observations suggest that N-linked glycosylation is not the 
only factor influencing FVIII expression. Therefore we used immunocytochemistry to 
investigate the FVIII cellular trafficking from ER to Golgi in established single FVIII variant 
cell lines.  
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Figure 3.15.  Quantification of human FVIII expression of variant stable cell lines 
Quantiifcation of human FVIII antigen expression levels were determined by a commercial ELISA 
(Stago kit). The data was obtained from the conditioned medium and FVIII expressions were 
normalised by vector copy number. Data presented as mean ±SEM, (n=3). One-way ANOVA 
(Bonferroni simultaneous test), Prism 6.0 (Graph Pad). 
  
Chapter 3  
 
 162 
3.2.15. Membrane-bound FVIII in serum-free condition 
Previous studies showed that 90% of recombinant FVIII is attached to the cell membrane 
of the producing cell when the B-domain has been reduced to around 21amino-acids. 
Increasing the length of the B-domain reduces the membrane attached fraction by 50% 
of the total FVIII expressed (Kolind et al., 2010). Further studies showed that the N-linked 
glycosylations within the B-domain did not influence either total FVIII expressed or the 
membrane-bound fraction. The addition of O-phospho-L-serin (OPLS) and Annexin V 
was shown to reduce binding of FVIII to the producer cell membrane (Kolind et al., 2011). 
These observations encouraged us to investigate if we could increase the yield of our 
novel B-domain modified FVIII molecules by washing the producer cells with 0.5M NaCl. 
The FVIII activity profile of both supernatant and membrane bound fraction are shown in 
Figure 3.16. As described before, low FVIII activity was detected from SQco (0.55 IU/mL) 
and V1co (0.6 IU/mL) HEK-293T producer cells, while the N6co (2.3 IU/mL), V3co (2.02 
IU/mL) and V5co (1.53 IU/mL) producer cells  showed two to 3-fold higher FVIII 
expression than SQco and V1co (Fig. 3.16.A).  
Membrane-bound FVIII activity from the stably transduced HEK-293T producer cells 
showed a different patten with amount bound being similar for SQco (0.23 IU/mL), N6co 
(0.18 IU/mL), V1co (0.16 IU/mL), and V3co (0.17 IU/mL) producer cells (average = 0.2 
IU/mL) but surprisingly 2.4-fold higher (0.48 IU/mL) for V5co, which suggesting that this 
variant binds more to the producer cells (Fig. 3.16.B).  
Overall, these data suggest that N6co and V3co will be ideal candidates for large-scale 
production of recombinant protein.  
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Figure 3.16. Profile of membrane-bound FVIII activity from the B-domain 
engineered FVIII   
Established stable cell lines were plated as 1x106 cells per well in 6-well plates. 24 hours later 
mediums replaced with serum free DMEM. Further 24 hours later, cultivated medium harvested 
(supernatant) and cells were wash with PBS then add 1mL of 0.5M NaCl contained DMED for 
incubated in 37°C incubator (membrane bound fraction) both samples performed the 
chromogenic assay. A) FVIII activity in the supernatant. B) Cell membrane bound FVIII activity. 
C) Total FVIII activity, which combined with cell culture medium and cell membrane bound 
fraction. D) Semi-quantative (%) graph for supernatant and membrane-bound FVIII activity. Data 
presented as mean ±SEM, (n=3). Prism 6.0 (Graph Pad). 
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3.2.16. Immunocytochemistry 
The use of bioengineering of the FVIII molecule has resulted in an improvement of FVIII 
mRNA expression and FVIII secretion. There are two important issues for the FVIII so 
produced, one is protein secretion, and the other is the biological activity of the released 
protein in the cultivated medium. B-domain modified constructs have N-linked 
glycosylation, which is important for protein secretion. This raised a question whether 
the N-linked glycosylation is important for the FVIII secretion to the cell culture medium. 
FVIII-V5co, in which all asparagine (N) of B-domain (FVIII-V3co) have been converted 
to alanine (A) to disable the N-linked glycosylation, may have decreased protein 
secretion to the medium. Therefore, we decided to investigate the cellular trafficking of 
FVIII variant proteins using immunocytochemistry. FVIII (SQco) is stained as small 
speckle in the cytoplasm, which is distributed to ER and Golgi apparatus (Fig.3.17.A). 
The majority of immunochemically detectable FVIII proteins were found in the place 
where Golgi and ER are over-laid (see in figure 3.17 of intensity histogram). To assess 
the protein localisation, image analysis was performed using software (LSF-AF, Leica), 
which allows drawing a specific region of interest (ROI) in the vicinity of FVIII 
accumulated region. It confirms that the FVIII granules were located in the overlapped 
region of ER and Golgi (Fig.3.17.A).  
We hypothesised that blocking there trafficking system may lead to specific FVIII 
accumulation either in ER or Golgi. To test this hypothesis, FVIII stable cell lines (SQco) 
were incubated with BFA (Brefeldin A, Abcam), which prevents constitutive vesicular 
transport from the trans-Golgi network. Treatment with BFA increased FVIII 
accumulation in ER and Golgi compartment. Image analysis confirms that the intensity 
histogram of FVIII overlapped with the ER and Golgi (Fig.3.17.B). These findings suggest 
that the majority of FVIII (SQco) protein is released through ER and Golgi network. 
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Next, the most highly expressing FVIII cell line (V3co) was tested for the cellular 
localisation using immunocytochemistry. Figure 3.17.C shows a similar pattern of FVIII 
distribution as SQco cell line. FVIII is stained as large granules in the cytoplasm where 
ER and Golgi are located. The image analysis reveals that the histogram plot of FVIII is 
overlapped with ER and Golgi. In addition, we found an intensity difference between 
SQco and V3co, which may due to the different protein expression level illustrated in 
figure 3.9.C. The BFA inhibition increased the intensity of FVIII (V3co) in Golgi and ER 
compartment (Fig.3.17.D). This suggests that there was no functional difference in terms 
of trafficking between SQco and V3co. We next tested the FVIII V5co cell line, which 
contains disabled N-linked glycosylation sites. Figure 3.17.E shows that again the 
majority of FVIII is localised in ER and Golgi. The BFA inhibition increased the 
accumulation in ER and Golgi (Fig.3.17.F), which behaved in a similar manner to other 
FVIII lines (SQco and V3co). Brown and colleagues reported that human FVIII was 
notably absent in the Golgi apparatus and most FVIII was located in the ER. The study 
suggested that human FVIII is not efficiently trafficked from the ER to the Golgi (Brown 
et al., 2011). In contrast, we observed codon-optimised human FVIII was co-localised to 
both ER and Golgi. Overall, my immunocytochemistry study demonstrates that FVIII 
proteins are predominately accumulating in the site where ER and Golgi compartments 
are overlapped. It suggests that ER and Golgi are both equally essential places for FVIII 
trafficking. It is important to note that ER and Golgi compartment are the places where 
the FVIII post-translational modification is occurring. The movement of proteins from the 
ER to Golgi apparatus has been identified as the rate-limiting step in intracellular 
transport (Lodish et al., 1983), although immunochemistry has failed to detect any 
difference between FVIII variants tested, notably, V3co, which contains six additional N-
linked glycosylation sites compared with SQco and V5co. It should be emphasised that 
the six N-linked glycosylation sites are putative and characterisation of post-translational 
modifications needs to be performed before a firm conclusion can be drawn. Therefore, 
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it is necessary to establish methods for production of purified FVIII protein to enable 
Mass Spectrometry analysis.   
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Figure 3.17. Immunocytochemistry revealing the FVIII variant protein localisation 
between ER and Golgi  
Three FVIII variants cell lines, SQco, V3co and V5co were cultured on glass coverslip then fixed 
with 4% PFA for 15 minutes then immune-stained with antibodies (Green; FVIII, Red; Golgi, 
Purple; ER and Blue; Nucleus). Brefeldin A (BFA) was added to stable cells for an hour then cells 
were fixed with 4% PFA.  A) SQco, B) BFA+ SQco, C) V3co, D) BFA+V3co, E) V5co and F) BFA 
+ V5co.  
Co-localisation of FVIII and ER or Golgi is represented by the colour (Green; FVIII, Red; Golgi, 
Purple; ER, and Blue; Nucleus). The merged images were analysed for intensity histogram using 
LSA-AF Leica imaging software (on the right panel). 100nM BFA- treated in 37°C for an hour then 
cells fixed for staining. Scale bar: 10 μm. 
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3.3. Discussion 
Currently, various forms of B-domain modified recombinant human FVIIIs (rhFVIII) are 
in clinical use for haemophilia A as replacement therapy (High and Anguela, 2015). 
ReFacto® was the first B-domain deleted FVIII commercial product, which is purified 
from the media of the Chinese Hamster Ovary cell line (CHO) that exogenously release 
engineered FVIII (Sandberg et al., 2001; Booth et al., 2007; Pipe, 2009). However, the 
current production procedure of the rhFVIII protein is very expensive, and consequently, 
the cost of FVIII regular infusion therapy (prophylaxis treatment) is too high for patients 
not living in economically developed countries. Alternatively, unlike protein replacement, 
gene therapy would allow endogenous expression of FVIII, which could eliminate the 
ongoing cost of haemophilia A treatment by replacement therapy.  
Most gene therapy is based on delivering therapeutic genes to the patient using viral 
vectors. However, the engineered FVIII so produced must be characterised and 
optimised before human trial.  Therefore, the first goal of this study was to characterise 
B-domain engineered FVIII isoforms. One of the most important hurdles was the short 
half-life of FVIII, which means that achieving a high concentration of the FVIII is 
challenging (High et al., 2014).   
To address these issues, three strategies were applied for enhancing FVIII expression 
in the cell.  Firstly, to engineer the FVIII genomic sequence by codon optimisation, which 
increases transcription efficiency, either by stabilising the RNA transcripts with reduced 
cryptic splice sites and /or by enhancing protein translation.  Secondly, modifying protein 
sequence of B-domain of FVIII to improve protein secretion. Finally, we isolated producer 
cells with maximal FVIII expression following lentivirus-mediated gene transfer of the 
FVIII variants. 
In the context of establishing such a stable cell line, delivering high copy number of the 
gene may be essential, where copies can then be integrated into the genome. Although 
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transient transfection of DNA is able to establish a stable cell line by antibiotics selection 
process, it was not efficient enough to increase the FVIII expression due to low copy 
number insertion into the genome. In contrast, lentiviral vectors are ideal for long-term 
transgene expression either in dividing or non‐dividing cells, which is suitable for 
establishing high copy number containing stable cell lines. Prior to transducing cell lines 
with lentiviral vectors, we identified that HEK-293T was better than Huh 7 cells. 
According to the comparison, HEK-293T cells showed approximately 4.5-fold higher 
FVIII expression than Huh 7 cells. The result indicates that the HEK-293T cells are more 
suitable for stable cell line production. Our observation recapitulates the Kalkhoran’s 
findings that HEK-293T is more efficiently  produced recombinant protein than Huh 7 
cells (Kalkhoran et al., 2013). In addition, Meex et al. reported that HepG2 cells produced 
more transgene protein than Huh 7 cells (Meex et al., 2011). Finally, the transfection 
efficiency between two cell lines might vary. Considering that the observed difference in 
transfection efficiencies of Huh 7 and HEK-293T cells is likely due to inherent differences 
between the two cell lines. Because the DNA uptake and dividing times of HEK-293T 
cells (~24 hours) are two times quicker than Huh 7 cells (≥48hours), implying HEK-293T 
cells are more active in the metabolic process (Nakabayashi et al., 1982).  
In the context of lentiviral vectors production, all the FVIII variants were efficiently 
produced with a titration range that was relatively high giving titres between 1x108 and 
5x108/mL. After the transduction of the FVIII variants carrying lentivirus to HEK-293T 
cells, the best performing single cell clone were selected according to the result of FVIII 
antigen level and activities from the medium. In this study, we can confirm that two group 
can be separated according to the codon optimisation of FVIII gene. Our results showed 
that FVIII activity of codon optimised group (SQco, N6co, V3co, and V1co) was 4-fold 
higher than that observed with FVIII variants that contained wild-type FVIII sequence 
(Fig. 3.11). The codon optimisation increases FVIII mRNA expression level. Therefore it 
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is necessary to confirm the level of FVIII transcripts from stable cell lines. The figure 3.13 
shows that FVIII mRNA level of two wild typed SQ (WTSQ) and N6 (WTN6) are very 
similar, whereas the codon optimised variants were sharply increased from 5 to 20-fold 
when compared with wild-type variants suggesting indeed the FVIII mRNA increased 
level. We can argue that the high copy number of WTSQ is not corresponding to the 
mRNA transcription level, which suggests that the integrated FVIII of WTSQ is silenced 
or poorly transcribed. Zieiske et al., showed that position effects, i.e. the regulatory 
environment of genomic integration sites could influence levels of expression. Others 
have shown that the presence of multiple copies of a transgene in a target cell can result 
in an epigenetic silencing and a variegated pattern of expression that the increased copy 
number of the lentiviral vectors into the host genome may disable the transgene 
transcription due to the integrated location such that becomes transcriptionally inactive 
heterochromatin (Garrick et al., 1998; Zieiske et al., 2004). Regarding protein 
expression, we measured FVIII by using FVIII antigen assay (ELISA) demonstrating by 
statistical analysis a significant difference between wild type variant and codon-optimised 
variant (***p<0.0001) demonstrating that codon optimisation enhanced FVIII protein 
expression and that it corresponds to increased mRNA expression. Finally, FVIII activity 
confirms that codon optimised FVIII constructs are all significantly increased as opposed 
to non-codon optimised, suggesting the stability and activity of FVIII have been improved 
by codon optimisation 
FVIII potency confirmed that a certain level of size or sequences of the B-domain linker 
peptide is important rather than N-linked glycosylation sites for activity and also it 
suggests that outside of the B-domain the other six N-linked glycosylation of FVIII are 
important, most likely  for protein-protein interaction with LMAN1 (Miao et al., 2004; 
Zhang, 2005). 
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With regard to FVIII secretion, Kolind et al. reported that majority of recombinant FVIII 
binds to cell membrane when the natural B-domain is replaced with short linker sequence 
(21 amino acid), while N-linked glycosylation of the B-domain did not affect  FVIII 
secretion (Kolind et al., 2010). Here, we showed that de-glycosylated B-domain carrying 
FVIII-V5co (31 amino acid) exhibited 2.4-fold increased membrane bound FVIII as 
opposed to V3co (31 amino acid), suggesting that lack of N-linked glycosylation on B-
domain linker leads to accumulation of FVIII on the membrane surface of the HEK-293T 
cells (Fig.3.16). Our observation implies that N-linked glycosylation on B-domain linker 
might have an important role for FVIII secretion through an effect on membrane binding 
which is reduced in some glycosylated variants.  
Taken together the results of this study using stable cell lines established by lentiviral 
integration of B-domain engineered FVIII variants, demonstrated that the codon 
optimised variants were significantly improved mRNA transcription and FVIII protein 
expression.  
In conclusion, six N-linked glycosylation motifs juxtaposed the short linker version; FVIII-
V3co has the best expression of FVIII protein. The superiority of this variant is due to the 
higher mRNA transcription and lower membrane binding together with enhanced protein 
translation.  
The role of glycosylation in membrane binding and protein secretion requires further 
elucidation and dissection.  
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Recombinant FVIII protein purification and 
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4.1. Introduction 
The main aim of the studies outlined in this chapter was to define an optimised 
chromatography step that is highly selective for FVIII to enable isolation of a large 
quantity of FVIII protein without losing activity for the further biochemical characterisation 
of the FVIII variants including functional studies and N-linked glycosylation pattern by 
mass spectrometry. Achieving high purity FVIII is challenging by current purification 
methods because FVIII in the inactive state is a heterodimer in which the heavy and light 
chain are linked by a relatively unstable non-covalent metal ion bridge that makes FVIII 
compounds highly prone to degradation under acidic conditions. Consequently, the 
chromatographic purification of FVIII compounds must be performed under mild 
conditions to prevent product degradation.  
Commercial large-scale recombinant protein products are purified by several steps 
including chromatography. Novo Nordisk’s new rFVIII (Novo Eight) is purified in a five 
steps process, including the Capto MMC affinity column, which captured rFVIII from 
culture media and highest yields of proteins were achieved by combining high 
concentrations of both NaCl and ethylene glycol in the elution buffer. An anti-rFVIII 
immune-affinity chromatography using monoclonal antibody (F25), anion exchange step 
and size exclusion chromatography steps were added to attain a high degree of purity 
(Ahmadian et al., 2016). The first human cell line derived rFVIII Nuwiq® (Octapharma) 
production process included nine steps from harvest cultivated medium to final 
formulation and polishing steps of size exclusion chromatography (Winge et al., 2015). 
Recombinant FVIII Fc fusion protein (rFVIII Fc, Biogen Idec) production process also 
uses chromatography purification with steps including FVIIISelect affinity column (GE 
Healthcare), Anion exchange chromatography and Hydrophobic interaction 
chromatography methods (McCue et al., 2015). 
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We therefore collected a large number of media from FVIII stable lines described in the 
previous section as illustrated in Figure 4.1. We then  
1. Performed small-scale studies with a two-step chromatographic purifications 
processes to enable purification of FVIII at high yields without compromising 
function. 
2. Used the optimised purification method to generate sufficient quantities of 
purified FVIII to enable biochemical characterisation including mass 
spectrometry.    
While we need a relatively high concentration of pure FVIII, we don’t need to the FVIII to 
be purified at levels required for infusion into patients.  
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4.2. Results  
4.2.1. FVIII purification step 
Recombinant human FVIII protein isolated from our stable producer cell lines (V3co, 
N6co, V1co, SQco and V5co) was initially purified by two-step chromatography as 
described by Tang et al. (Tang et al., 2013). Step 1 entailed the capture step for which 
we used FVIIISelect a specifically designed affinity adsorbent molecule designed for 
purification of B-domain deleted FVIII. The second polishing step entailed concentration 
of eluant from step 1 by positively charged resin DEAE anion exchange column (GE 
Healthcare) as described in Figure 4.1.  The buffer used for both column purifications 
methods are described in Table 2.2.  FVIIIselect matrix consists of a 13kDa recombinant 
Camelid single domain antibody fragment that is attached to the porous base matrix via 
a hydrophilic spacer arm made available commercially by GE Healthcare (McCue et al., 
2009). We modified the standard protocol to include an additional harvest of the cell 
surface membrane bound FVIII using a buffer containing 0.5M NaCl.  
 All except cell culture step were processed at 4°C due to the instability of FVIII. Minimum 
exposure of FVIII to room temperature was necessary to prevent protein degradation. 
The final products were stored at - 80°C pending further analysis. 
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Figure 4.1. Harvesting and purification steps of human FVIII from cell lines. 
In the first stage, cellular membrane bound FVIII was collected by using 0.5M NaCl followed by 
the first harvest of the medium. Cultivated mediums and membrane-bound fractions were spin 
down and filtered prior to applying on the second stage. In the second stage, the actual purification 
starts with two purification steps of FVIII, collected from the stable cell lines (V3co, N6co, V1co, 
SQco and V5co). In this simple two-step purification, the medium was applied to FVIIIselect 
affinity column then to the DEAE anion exchange for polishing and concentration. 
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4.2.2. Step 1: Affinity purification with FVIIISelect column 
To test whether this FVIIISelect column enables us to achieve efficient yield of high purity 
FVIII, initially, a small-scale column was packed for a pilot purification run (1mL column 
resin used).  The FVIIISelect column was equilibrated with the equilibration buffer (20mM 
Immidazol/ 10mM CaCl2/ 400mM NaCl/ 100ppm Tween 80, pH 7.0) at a flow rate of 
60mL/minute using an ÄKTA explore FPLC instrument. Then, the media obtained from 
V3 stable cell lines grown on 5-layer cell culture flask (T-1000, Millipore, total surface 
area: 1000cm2) was loaded onto the column at the rate of 1mL/minute.  Full ÄKTA 
explore profiles in shown in Appendix 1.   
Figure 4.2 shows absorbance A280 of FVIIISelect eluants (blue) and gradient salt 
concentration for elution step (green). To collect eluents, automated square fraction 
collector (FRAC-950, 15x15) was used (red: tube number).  Automated gradient mixture 
of buffer A (30%) and buffer B (70%) resulted in Elution of two peaks, one at low salt 
concentration and the other at a higher salt (fractions E3 to F11) concentration, the latter 
we speculated FVIII contained peak (Fig. 4.2).  
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Figure 4.2. FVIIISelect column profiles 
Chromatogram (UV absorbance and fractions) of the FVIIISelect purification process performed 
at small scale. The blue line indicates at A280 in protein absorbance units (mAU). A pilot running 
for FVIII V3 stable cell lines cultivated media, two step gradient (depend on salt concentration) 
shows elution pattern in the green box. The bottom lane shows individual collection tube number 
in fraction collector (red). The first peak collection C2 to C7 tubes and second peak collect E3 to 
F11. 
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4.2.3. FVIII activity assay 
To identify the eluted fractions that contained rFVIII, a chromogenic FVIII activity assay 
was used. The elution buffer was included as a negative control. The FVIII activity of 
pooled first peak (fractions C2~C7) showed the the FVIII activity of ~0.43 IU/mL (5.15 
Unit in 12mL), while the FVIII activity in the second peak was 5.65 IU/mL. The FVIII 
activity in the individual fractions (E7~E12) varied between 4~6 IU/mL.  These results 
suggest: 
1.  The elution buffer does not inhibit or interfere with FVIII chromogenic activity 
assay.  
2. The first A280 absorbance peak probably represents elution of cellular proteins 
bound non-specifically to the affinity matrix as illustrated by the fact that these 
proteins came off at relatively low salt concentrations.  
3. The second peak is contained biologically active FVIII as illustrated by the FVIII 
Chromogenic assay. 
In order to calculate the total recovery of FVIII from FVIIISelect, the FVIII activity of 
starting cell culture media was measured (2.73 IU/mL), which revealed total FVIII in the 
starting material was approximately 409 Units (Fig.4.3). The calculated total FVIII activity 
for the second peaks was 101.7 Units, which is a recovery of only 25%.  This implies that 
the 75% of FVIII is unaccounted. The amount of FVIII in the flow-through (FT) was 
measured.  However, the activity of this material was only 0.07 IU/mL, so only 2.5% of 
FVIII was detected in total FT.  Therefore, it appears that about 70% of FVIII is degraded 
during the purification process. Alternatively, the chromogenic assay may have 
underestimated the activity of FVIII in the second peak, perhaps because of the high 
concentration of FVIII, which may have saturated the assay.  
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Figure 4.3. FVIII chromogenic assays for individually collected factions  
To validate FVIII expression in individual samples; the elution buffer FVIII activity was negative 
control, Full media: Benzamidine treated harvest media, FT (collect flow through line): validation 
of unbound protein, First peak: C2~C7, Second peak: E3~F11, highest fractions in the second 
peak, E7 to E12 individual fractions.  FVIII activity determined by chromogenic assay. 
  
El
ut
io
n 
bu
ffe
r
FV
III
 m
ed
ia
1s
t p
ea
k:
C2
-C
7
2n
d 
pe
ak
:E
3+
F1
1 E7 E8 E9 E1
0
E1
1
E1
2 FT
0
2
4
6
8
FV
II
I A
ct
iv
it
y 
(I
U
/m
L)
Chapter 4 
 
 181 
4.2.4. Identification of purified FVIII proteins from silver staining 
To test FVIII protein levels in the key elution fraction, 10μL of eluents were separated on 
SDS-PAGE followed by silver staining (Fig.4.4). Silver staining was chosen because of 
higher sensitivity with the ability to detect protein in the nanogram (ng) range.  
Figure 4.4 shows that full-length-FVIII (Kogenate®, Bayer) exhibits the typical FVIII 
components consisting of a single full-length peptide, heavy, and light chain variants as 
indicated by the arrows. Silver staining of the un-purified, un-concentrated medium 
(Total, lane 2) and FT (lane 3) demonstrated multiple bands of varying sizes. The 1st 
peak in lane 4 shows predominantly light chain of FVIII which has been described before 
(McCue et al., 2009). The 2nd peak fractions (lane 5~11) exhibit that non-specific protein 
bands are reduced and heavy and light chains are more prominent in lane 8 and 9, which 
correspond to the peak amongst the fractions collected. These results suggest that 
FVIIISelect column is efficiently able to isolated FVIII from culture media and helps to 
remove non-FVIII proteins.  
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Figure 4.4. Silver staining for FVIII V3co, post-FVIIISelect column 
FVIIISelect column purified rFVIII fractions performed SDS-PAGE and silver staining. Lane1: Full 
length FVIII, Kogenate® (Bayer), Lane2: Cultivated medium, Lane3: Flow through (FT), Lane4: 
1st peak, Lane5: E7, Lane6: E8, Lane7: E9, Lane8: E10, Lane9: E11, Lane10: E12, Lane11: 
E3+E12 (pooled 2nd peak). 
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4.2.5. FVIII Western blot analysis 
Specificity of FVIIISelect to isolate the FVIII protein was tested by Western blot analysis 
using FVIII specific antibody. Figure 4.5 shows that the fragments of Kogenate® (Bayer) 
that were detected comprised of a single chain, heterologous heavy chains and light 
chain. The starting cell culture medium shows only a small portion of V3 in the single 
chain format probably because of the presence of the furin cleavage site.  The remainder 
of FVIII V3 consisted of heavy chain plus the 31 amino acid V3 B-domain linker, cleaved 
heavy chain and light chain (as discussed in chapter 3). However, the Flow through (FT) 
shows that FVIII V3 protein is predominately the heavy chain with 31 amino acid linker 
attached form (lane 3). This result suggests that the heavy chain with linker form of FVIII 
may not bind to the FVIIISelect resin efficiently. Based on FVIII activity, which was 
uniform across the fractions we choose to pool the fractions of the second peak. 
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Figure 4.5. FVIIISelect column V3co SDS-PAGE analysis in reducing condition 
FVIIISelect Purified FVIII V3 protein performed Western blot, polyclonal antibody (sheep 
polyclonal antibody: affinity biologicals) detects in full media (Harvest stable cell culture media): 
190kDa single chain, 110kDa linker contained heavy chain, 90kDa of A1 and A2 heavy chain, 
80kDa of Light chain. The commercial FL-FVIII (Kogenate®, Bayer) lane1, shows 200~90kDa 
heterologous heavy chains and 80kDa light chain. Flow through (FT) shows dominant heavy 
chain band, but the 1st peak shows dominant light chain band. All of the individual second peak 
fractions show two heavy chains (110kDa, 90kDa) and light chain (80kDa). 
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4.2.6. Double harvested medium from stable cell line improve the FVIII 
recovery 
In order to improve the yield of FVIII, we tested whether it was possible to collect a 
second harvest from the stable cell line and increase the amount of FVIII protein purified. 
First, stable cell lines were seeded at 3X108 cells in 200mL of 10% FBS containing 
DMEM in T-1000 flask. Following overnight incubation, cells were washed twice with 
Dulbecco’s phosphate-buffered saline (D-PBS) then the 150mL of serum free DMEM 
added for further 24 hours. The 1st harvest of media was performed 24 hours later and 
150mL fresh serum-free DMEM added for a second harvest. The first harvest was 
processed as described above with the FVIIISelect method and the chromatogram was 
similar to that previously observed (Fig. 4.5 and 4.6). 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. FVIIISelect chromatogram from first harvested FVIII V3co media  
The FVIIISelect chromatogram shows that two dominant peaks. Absorbance A280 of FVIIISelect 
eluents represents protein concentration (blue), and the green colour line represents salt gradient 
for elution step. Second peak fractions were collected and kept at freeze for next purification step. 
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Since the first peak did not have any biologically active FVIII activity, we only collected 
and pooled the fractions from the second (E4 to E15, ~12mLs in total). The FVIII activity 
of starting unprocessed medium was 600 IU in total and the yield of FVIII in the entire 
second peak was 236 IU/mL, representing a  recovery of 39%, and improvement of 
>50% on the initial experiment (Fig. 4.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Assessment of FVIII activity from the first FVIII SELECT column  
Elution buffer alone used for negative control and Kogenate (FL-FVIII, Bayer) used as positive 
control. FVIII activity determined by using chromogenic assay from starting material (Full media), 
Flow through (FT), 1st peak fraction (C2~C6), 2nd peak (E4~E15), which diluted to 1: 5 and 1:10 
for the sensitivity of the assay. 
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Following the first harvest, the medium was collected the next day (second harvest, 
Fig.4.8) and purified using the FVIIISelect column even though the condition of the cells 
had deteriorated as many cells were observed floating in the medium; likely due to the 
prolonged culture in serum-free conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. FVIIISelect chromatogram from second harvested FVIII V3co media  
The purification pattern shows similar as the first harvest, Absorbance signal shows A280, 
Fraction number means individual tube in an automated fraction collector. The second peak, E4 
to E15 tubes collect and merged for further purification. 
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The purification pattern was similar to that of the first harvest. We collected eluates from 
first peak (C2~C6) and the second peak (E4~E15) (Fig.4.8) as before. According to the 
FVIII activity assay, total activity of FVIII in the starting unpurified material was 600 IU in 
total, the activity in the first peak was 1.2 IU/mL and that in the second peak was 25 
IU/mL, giving a total FVIII yield of 300 IU in Total. This result shows about 42% recovery 
was achieved from the second harvest for purification using FVIIISelect column (Fig. 
4.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Assessment of FVIII activity from the second FVIII SELECT column  
Elution buffer alone used for negative control and Kogenate (FL-FVIII, Bayer) used as positive 
control. FVIII activity determined by using chromogenic assay from starting material (Full media), 
Flow through (FT), 1st peak fraction (C2~C6), 2nd peak (E4~E15), which diluted to 1: 5 and 1:10 
for the sensitivity of the assay.  
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4.2.7. Membrane-bound FVIII protein 
Our previous study in chapter three shows that 10 to 40% of total FVIII was found on the 
cell surface membrane, which suggests that we can increase FVIII recovery if we include 
one more collection steps for membrane bound FVIII proteins. To determine the 
proportion of FVIII bound to cell membrane our established FVIII expressing cell lines, 
were incubated with 50mL of 0.5M NaCl for five minutes to dissociate membrane bound 
FVIII proteins followed by the second harvest of the medium. Then 100mL of fresh cold 
DMEM was added to dilute the high salt (NaCl) then and subsequently loaded onto the 
FVIIISelect column. The chromatogram for the membrane-bound FVIII was similar to 
that of the 1st and 2nd harvest (Fig. 4.10).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. FVIIISelect chromatogram from membrane-bound FVIII V3co  
Two T-1000 flask cells harvest, add 0.5M NaCl to dissociate recombinant protein from cell surface 
membrane. Membrane-bound media was five times diluted with DMEM (110.3mM NaCl) to 
reduce salt concentration before loading on the FVIIISelect column; Chromatogram shows 
membrane bound V3co profile, Absorbance signal shows A280, Fraction number means 
individual tube in an automated fraction collector. 
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 The FVIII activity of starting materials was 300 Units (2 IU/mL, 150mL) and 154 Units 
was recovered (11.8 IU/mL, 13mL) in the second peak, which shows about 51% recovery 
(Fig. 4.11).  
The overall membrane bound fraction was 25% which was higher than that observed in 
our previous small-scale experiment using 6-well plates, in which membrane-bound 
fraction was 10%.  The differences between the two experiments are the 6-well plates 
seeded 1x106 cells per well (4.67cm2) after only 24 hours both cultivated and membrane-
bound rFVIII was harvested, On the other hand T-1000 flask were seeded with 3x108 
cells, which is maximised seeding on plates and also membrane-bound fractions were 
harvested after a 48 hours time gap. The possible reasons are three times more densely 
seeded cells and increased harvesting time. A confounding factor may be that serum-
free condition, may increase the amount of FVIII bound to the cell membrane as reported 
before (Swiech et al., 2011). 
 These results taken together suggest that the total yield of FVIII can be improved by 
combining two harvests of the cell culture media and collection of the FVIII membrane 
bound protein.  This strategy was adopted for large-scale production of the FVIII variants.  
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Figure 4.11. Assessment of FVIII activity from membrane-bound FVIII  
Elution buffer alone used for negative control and Kogenate (FL-FVIII, Bayer) used as positive 
control. FVIII activity determined by using chromogenic assay from starting material (Full media), 
Flow through (FT), 1st peak fraction (C2~C7), 2nd peak (E3~F15), which were diluted to 1: 5 and 
1:10 for assay.  
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4.2.8. Modified FVIII purification procedure 
Although we have established the FVIII expressing stable cell lines, it is difficult to purify 
the pure FVIII proteins in the medium due to the inherent instability of FVIII, and the use 
of serum-free conditions (without any additional supplements) which lead to cell death, 
which prevents multiple harvests of the medium. Finally, maintaining the activity of FVIII 
during purification is difficult due to the high salt buffer (1.5M NaCl) used for elution step 
from the FVIIISelect column during purification. For this reason, we developed the 
protocol described in Figure 4.12 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Schematic diagram of optimised FVIIISelect Purification 
The chart illustrates that the purification procedure for FVIII stable cell lines which will be 
collected in three different conditions.    
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4.2.9. FVIII select column purification for remaining variants  
The chromatograms showed very similar patterns for each FVIII variant (Fig.4.13). 
Therefore the same fractions were collected for each variant from the elution trace of the 
FVIIISelect column. Individual purified fractions were kept at -80°C (Individual peak data 
not shown).   
 
 
 
 
 
 
 
 
 
Figure 4.13. FVIIISelect column chromatograms for FVIII variants  
Further purification carried out with the same protocol as FVIII-V3 purification. The SQco, V5co, 
V1co and N6co show similar profiles in FVIIISelect column. The second peak fractions were 
collected and stored at -80°C freezer for later DEAE column purification. 
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4.2.10. Optimisation of FVIII concentration using DEAE column 
The FVIIISelect chromatography step enriched for FVIII, although there were other 
proteins eluted alongside as detected in the silver stained protein gel (Fig.4.4). Therefore 
to increase the purity and concentration, which is essential for further characterisation, 
an additional chromatography step was included.  DEAE is a weak anion-exchange resin 
and was reported by Tang et al. as part of their FVIII purification process (Tang et al., 
2013).  The DEAE step will also increase the concentration of FVIII, which is necessary 
for the further biochemical analysis.  
The FVIII proteins (FVIII activity, 20~35 IU/mL) containing fraction (~12mLs) from the 
FVIIISelect column were diluted to ~800mLs lower the concentration of ethylene glycol 
and NaCl and then loaded at the speed of 1mL/minute. After washing the column with a 
mixture of 80% Buffer C (20mM MOPS, 10mM CaCl2, 100ppm Tween 80, pH7.0) and 
20% of Buffer D (20mM MOPS, 10mM CaCl2. 1M NaCl, 100ppm Tween 80, pH 7.0) the 
bound FVIII was eluted with a mixture 60% Buffer C (20mM MOPS, 10mM CaCl2, 
100ppm Tween 80, pH7.0) and 40% of Buffer D (20mM MOPS, 10mM CaCl2. 1M NaCl, 
100ppm Tween 80, pH 7.0), which washed off residual unbound protein and cellular 
debris. Absorbance at A280 showed three peaks (Fig.4.14); the first peak was contained 
in fractions A14 to B14 in a total of 4mL, the second peak B2 to C3 in 5mL and the third 
peak was collected in fractions C13 to D13 in total 6mL.  
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Figure 4.14. Chromatogram of DEAE Sepharose FF, Anion exchange column 
purification 
 DEAE anion exchange column used for this purification following manufacturers 
recommendation. The chromatogram shows three peaks, which relies on three steps gradient 
elution stage, according to the salt concentration (Green). Absorbance 280 (Blue), Conductivity 
(Brown), Fraction collect tube number (Red). The elution stage, A280 and Conductivity show 
similar profiles. 
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The collected fractions from the peaks were subjected to a FVIII chromogenic assay 
(Fig.4.15) to identify the peaks containing the active FVIII fractions. The chromogenic 
assay shows that the 800mL starting material contained 1.69 IU/mL of FVIII (1,352Units 
in total). The first peak had FVIII activity of 0.07 IU/mL (0.28Unit in total), the second 
peak 143.4 IU/mL (717Units in totals) and the third peak 3.89 IU/mL (23.34Units in 6mL). 
These results suggest that the majority of active FVIII is eluted in the second peak of the 
DEAE step. As a result, the first and third, non-FVIII proteins fractions were discarded 
and only the second peak that contains the majority of the FVIII was collected in further 
studies. In addition, the DEAE column increased the concentration by 85-fold, the 
starting material contained 1.67 IU/mL and the final pool of the second peak was 143.4 
IU/mL, the final recovery rate was 52.6% in total. 
  
Chapter 4 
 
 197 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Assessment of FVIII activity for fractions corresponding to the DEAE 
column chromatogram 
Three peaks harvested and validated; Full Media-Basic material load on the column, FT-Flow 
through collect, A14 to B14-1st peak, B2 to C3-2nd peak, C13 to D13- 3rd peak on elution profile 
following the figure 4.6.1.The second Peak shows dramatically increased FVIII activity, on the 
other hand, the first and third peaks show very little FVIII activity.  
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To assess the purity of the purified FVIII in the second peak, 10μL of eluents were 
separated on a SDS-PAGE gel and silver stained. The V3co purified fractions showed 
190kDa single chain, 110kDa/90kDa heavy chain bands and 87~73kDa of doublet light 
chains in all B2 to C3 fractions. We believe that the two light chain bands are the 87kDa 
a3-A3-C1-C2 domains and the 73kDa A3-C1-C2 domains. The acidic a3 domain in the 
latter is cleaved at Arg 1689 (Kaufman et al., 1988). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Silver staining for fractions corresponding to the DEAE 
chromatogram 
Lane1: Marker, Lane2: Recombinant FL-FVIII (Kogenate, Bayer) Lane3: Full material, Lane4: F3 
(Flow through), Lane5: B2, Lane6: B1, Lane7: C1, Lane8: C2, Lane9: C3, Lane10: B2-C3, 
Lane11: 1st peak A11- B14, Lane12: 3rd peak C13~D13. SC (Single chain, 190kDa), HC (Heavy 
chains, 110kDa-A1+A2+31aa Linker, 90kDa-A1+A2), LC (A3+C1+C2). The visualised silver 
stained gel showed that FL-FVIII showed several heterologous bands. Full media and Flow throw 
exhibit weak protein bands due to FVIII concentration from starting materials were very low in 
both samples.   
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To confirm that the protein bands seen on the silver stain were FVIII, a western blot was 
carried out with a polyclonal antibody that detects both the heavy and light chain of FVIII 
(Fig.4.17). The result shows typical protein bands (FL-FVIII; 210kDa~90kDa of broad 
heavy chains, 87~73kDa light chain bands. FVIII V3; 190kDa of a single chain, 
110~90kDa heavy chain and ~80kDa light chains (doublet) shows purified fractions in 
B2 to C3). These results imply that our approach of dual column purification is an efficient 
method for further FVIII protein structural and biochemical studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Western blot analysis of fractions corresponding to the DEAE 
chromatogram 
Purified proteins show strong FVIII expression, full media and flow through expressions were 
showed very poor FVIII expression. Lane1: Marker, Lane2: Recombinant FL-FVIII (Kogenate, 
Bayer) Lane3: Full material, Lane4: FT (Flow through), Lane5: B2, Lane6: B1, Lane7: C1, Lane8: 
C2, Lane9: C3, Lane10: B2~C3, Lane11: 1st peak A11~B14, Lane12: 3rd peak C13~D13.  The 
lane 2, which is FL-FVIII (kogenate, Bayer) observed as a mixture of heterodimers of a variable-
length heavy chain of 210~90kDa, due to fully or partially cleaved B-domain by limited proteolysis.  
Light chain appeared at a constant length of ~80kDa. 
Chapter 4 
 
 200 
4.2.11. DEAE purification for SQco, V5co, V1co and N6co 
FVIII affinity column purified rFVIII was processed by DEAE column purification and 
elution patterns were similar as V3co (Fig.4.18).  The whole process was carried out as 
previously described for V3co purification. Therefore the same fractions were collected 
for each variant from the elution trace of the DEAE column (Individual peaks assessment 
not shown).  
 
 
 
 
 
Figure 4.18. DEAE anion exchange column chromatogram for FVIII variants 
SQco, V1co, V5co and N6co purified with DEAE anion exchange column, Chromatograms 
showed each variants were similar profiles. 
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4.2.12. Dialysis  
The next step entailed reformulation of the eluate from the DEAE column, which 
contained metal ions, and salts, and may disrupt the functional analysis of FVIII. To 
remove these unwanted components, a dialysis step was included with Ambic Buffer 
(Ammonium Bicarbonate, pH7.2). A schematic of the final FVIII purification process is 
shown in Figure 4.19.  
 
 
 
Figure 4. 19.  Complete procedure of FVIII purification process  
DEAE FF column and Dialysis steps are added following the FVIII select column, which 
concentrates proteins and removes unnecessary salts and chemicals.   
 
 
Chapter 4 
 
 202 
4.2.13. Characterisation of purified variants FVIII materials. 
Thrombin is necessary for the activation of FVIII, which cleaves the FVIII molecule after 
Arg372, Arg740 and Arg1689 (Barrow et al., 1994; Pittman et al., 1994). In the First step 
Arg1648 is cleaved, so full-length FVIII is initially divided into the A1- A2- B-domain, of 
210kDa designated the heavy chain and a3-A3-C1-C2 domain of 87kDa of the light 
chain. Then cleavage between Arg1689 and Arg740 produces the 93kDa heavy chain 
(A1 and A2) and the 73kDa light chain (40 amino acid a3 region cleaved from 87kDa). 
The remnants of the large B-domain are degraded by proteolysis. Finally, Arg372 is 
cleaved in the middle of A1 and A2, and thus the heavy chain is separated into a 50kDa 
A1 domain and a 43kDa A2 domain. Finally, thrombin-activated FVIII so produced 
consists of the 50kDa A1 domain, the 43kDa A2 domain, and the 73kDa light chain 
(Fig.4.20.A). The thrombin cleavage products of FVIII activation are illustrated 
schematically in figure 4.20.B. 
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A 
 
B 
 
Figure 4.20. Schematic representation of FL-FVIII and FVIII V3 domain cleavage 
by thrombin activation  
A) The diagram shows the FL-FVIII expected size fragments produced by thrombin cleavage at 
Arg372, Arg740, and Arg1689. The cleavages at Arg740 in the heavy chain (A1-A2-B) to release 
the B-domain, at Arg372 in the heavy chain to form the A1 and A2 subunits, and at Arg1689 in 
the light chain to produce the A3-C1-C2 subunit. Cleavage at Arg372 is required for the 
development of intrinsic FXase cofactor activity. Cleavage at Arg1689 releases an acidic 14kDa 
fragment that leads to dissociation of vWF allowing the association of FVIIIa to phospholipid 
membranes such as activated platelets.  
B) The diagram shows the 31aa novel linker contained FVIII V3 expected size fragments. The 
potential sites of thrombin cleavages are located at Arg372, Arg740, and Arg1689 (in front of a3). 
The final fragments predicted as 50kDa for A1 domain, 43kDa for A2 domain and 73kDa for the 
light chain. 
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4.2.14. Thrombin digestion of BDD-FVIII and FVIII-V3 
Thrombin proteolysis in FVIII is important because proteolytic activation of FVIII is 
necessary for the development of the FXa complex (Barrow et al., 1994). 
The purified 31 amino acid linker FVIII V3co and commercial B-domain deleted 14 amino 
acid linker ReFacto® (Pfizer) were activated by thrombin to compare the composition of 
the thrombin activated products. On a Silver stained gel inactivated BDD-FVIII consisted 
of a 190kDa single chain, 110kDa heavy chain, and 87kDa light chain. After thrombin 
activation, the light chain has been cleaved to 73kDa, and heavy chain has been cleaved 
to the A1 and A2 subunits, 50kDa and 43kDa respectively (Fig.4.21). This was confirmed 
by western blotting using two antibodies, a polyclonal antibody and a monoclonal 
antibody to the A2 domain of the heavy chain. The polyclonal antibody western blot 
showed 73kDa (light chain), 50kDa, and 43kDa (A1 and A2 units of the heavy chain) 
bands for V3co as well as ReFacto®. When the Western was repeated with a monoclonal 
antibody which recognises the A2 epitope we were only able to detect 43kDa band for 
both V3co and ReFacto® (Fig.4.22).  Therefore the 31 amino acid linker peptide in FVIII-
V3co is fully cleaved on activation by thrombin, and this peptide does not appear to 
hinder thrombin cleavage at other sites. In the silver stained gel and SDS-PAGE western 
blot, a 37kDa fragment was seen. We believe that this corresponds, to the human α-
thrombin.  Hence, once activated FVIII V3co has the same profile as ReFacto®. 
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Figure 4.21. Silver staining for thrombin digestion of purified FVIII-V3  
Approximately 1unit of FVIII-V3 protein with or without thrombin was separated on a 4-12% Bis-
Tris gel in reducing condition. Protein bands were visualised by silver staining. Molecular weights 
were given in kDa for the standard NuPAGE marker on the left. The naïve rFVIII V3 shows 
190kDa single chain (SC), 110kDa/90kDa of heavy chains and doublet 80kDa of light chains. 
Thrombin digested rFVIII V3 shows 73kDa of A3+C1+C2 light chain, 50kDa of A1 and 43kDa of 
A2 band visualised in the silver stained gel. 
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Figure 4.22. Western blotting for thrombin digestion of purified FVIII-V3co 
Novel 31 amino acid linker V3 and commercial B-domain deleted recombinant FVIII product 
(ReFacto®, Pfizer) were activated by thrombin. A) 73kDa, 50kDa and 43kDa polypeptide 
fragments generated by thrombin digestion, polyclonal hFVIII antibody: 73kDa-A3+C1+C2, 
50kDa:A1, 43kDa:A2 
B) 43kDa A2 domain detected by the A2 epitope monoclonal antibody, both A and B gels exhibited 
thrombin band at 37kDa, which nonspecifically binds polyclonal and monoclonal antibody. 
 
 
 
 
 
 
A B 
Chapter 4 
 
 207 
4.2.15. FVIII biological activity using the thrombin generation Assay and 
Thrombogram 
Thrombin generation is a key measurement of FVIII function and is a sensitive and 
reliable method for determining the haemostatic status. Thrombin generation was 
measured with the Calibrated Automated Thrombogram System (CAT, Stago diagnostic) 
based on Fluoroskan Ascent Analyser (390nm excitation 460nm emission wavelength: 
Thrombinoscope, Stago diagnostic). All FVIII variants were measured at a concentration 
of ~1 unit/mL of a recombinant protein which was determined by the chromogenic assay. 
FVIII variants were added to FVIII deficient plasma (HemosIL, Werfen). Thrombin 
generation was initiated with 1pico mole (pM) of tissue factor (TF) and 4μM phospholipid 
(PPPlow reagent, Thrombinocope, Stago diagnostic). For the negative control FVIII 
deficient plasma was used (HemosIL, Werfen) and Nuwiq® a recently approved rhFVIII 
produced in a human cell line (kindly gifted by Octapharma) was used as a positive 
control to be consistent with the fact that all our FVIII variants were made in HEK-293T 
cells. 
The profiles for all our FVIII variants and Nuwiq® were similar (Fig.4.23). In addition to 
the thrombin generation profile four other parameters were measured; lag time, time to 
peak, peak height and the endogenous thrombin potential (area under the curve).  
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Figure 4.23. Activity of FVIII measured by thrombin generation upon activation of 
coagulation  
FVIII deficient plasma used as a negative control. Purified variants of FVIII did not show any 
difference compared to each other. 
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The individual parameters (Fig.4.24) show that the lagtime of all variants and positive 
control (Nuwiq®) ranged in between 7.7 to 8 per minutes and endogenous thrombin 
potentials (ETP) were in between 1387 to 1463 fluoresce per units (FU). Peaks appeared 
at 95 to 114 and the time to peak (ttP) started between 14 to 14.67 minutes. The 
thrombogram indicate that the efficiency of clot formation for all the variants did not show 
significant differences (Fig. 4.24).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24. Quantitative parameters of the thrombograms for FVIII variants 
The lagtime, ETP: endogenous thrombin potential, ttP: Time to peak and Peak height were 
assessed by CAT machine. Normal plasma deficient (without corn trypsin inhibitor-CTI) and 
Normal plasma with CTI used as a normal control. Thrombin generation assay was performed at 
the Royal Free Hospital, London.  
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4.2.16. Coagulation assay 
The coenzyme FVIII cannot be measured directly. Therefore FVIII activity is measured 
indirectly through the target enzyme FIX, which converts FX to active FXa (Potgieter et 
al., 2015). There are three methods for measuring FVIII activity, one stage, two stage 
and chromogenic assay (which is a development of the two-stage assay). Most 
diagnostic laboratories use the one-stage and chromogenic assays for measuring FVIII 
activity. However, discrepancies have been noted between the two assays and were first 
reported in 1976.  It is now known that some mutations (located in the A2 domain) giving 
rise to mild haemophilia can give a discrepant result between the two methods (Pipe et 
al., 1999). Since then many cases of different assay results not aligned with patient 
severity and depending on mutations have been reported, and those assays have 
discrepancies observed in FVIII proteins (Pipe, 2001; Hakeos et al., 2002). It is advised 
that haemophilia treatment centre coagulation laboratories should use both one-stage 
and chromogenic FVIII activity assays, particularly when screening for possible 
haemophilia A (Potgieter et al., 2015). There are also assay discrepancies when 
measuring FVIII concentrates, however; improvements in the design of the methods 
have reduced these discrepancies (Barrowcliffe et al., 1998;  Barrowcliffe et al., 2002).  
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4.2.17. Factor VIII activity measured by Chromogenic Assay and One 
stage clotting assay 
Purified proteins were diluted in the R4 buffer, contained in the chromogenic kit and for 
the one stage assay FVIII deficient plasma (Biophen, UK). Due to the limited amount of 
purified FVIII, quantification was carried out on the chromogenic assay with a manual 
microtiter plate method. 
All FVIII variants had a similar level of FVIII activity when measured by the Chromogenic 
assay.  However, when measured by one-stage assay (ReFacto AF as standard) for the 
same samples N6co, V1co, V3co and V5co had much greater activity values. In 
particular, V1co and V5co showed 4-fold and 3-fold increased activity with the one-stage 
assay (Fig. 4.25). 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
 212 
 
 
 rFVIII Chromogenic Assay (IU/mL) One stage Assay: ReFacto STD (IU/mL) 
Nuwiq 0.77 0.60 
V5co 0.71 2.12 
V3co 0.82 1.29 
V1co 0.87 3.86 
N6co 0.79 0.96 
 
Figure 4.25. Comparison of FVIII activity measured by chromogenic assay and one 
stage clotting assay  
Purified rFVIII variants performed clotting assay. A human cell line derived commercial B-domain 
engineered FVIII (Nuwiq®, Octapharma) used assay control. Although most of the proteins show 
some discrepancy, variants V5co and V1co show highly significant difference between the two 
assays. One stage clotting assay uses ReFacto AF standard, and chromogenic assay used 
Biophen plasma STD. Statistically not significant between two coagulation assays, column factor 
(p=0.16), row factor (p=0.467), (t-test, two tailed). Prism 6.0 (Graph Pad). 
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To determine if the choice of standard in the one-stage assay had influenced assay 
discrepancies, activity measurements were repeated with two different FVIII 
preparations for the one-stage assay, ReFacto® as in the previous experiment and the 
same plasma calibrator as used in the chromogenic assay (Fig.4.26). However, the 
previously observed discrepancy between the one-stage and chromogenic assay 
remained irrespective of the type of FVIII used or the standard (Fig. 4.26).  
Assay discrepancies have previously been reported for B-domain deleted FVIII 
concentrates, where chromogenic assay values were up to 50% higher than the one-
stage assay clotting assay (Barrowcliffe et al., 2002; Pahl et al., 2012). In the 
experiments presented here, ReFacto® shows the same profile as previous reports as 
does the N6 construct (Fig. 4.26).  However, the other FVIII variants have a different 
profile with increased activity on the one-stage assay when compared to the 
chromogenic. Therefore, a standardised protocol for the measurement of patient 
samples and recombinant concentrates is critical.  
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rFVIII Chromogenic Assay One stage Assay: Plasma STD One stage Assay: ReFacto STD 
Nuwiq 1.14  0.67 0.91 
V5co 1.52 2.32 3.10 
V3co 1.17 1.57 1.80 
V1co 1.38 3.30 4.20 
N6co 1.29 0.90 1.01 
 
Figure 4.26. Comparison of FVIII activity measured by chromogenic assay and one 
stage clotting assay using plasma STD and ReFacto AF 
Same batch proteins, but the different concentration of proteins (IU/mL) applied to coagulation 
assay. FVIII activity from one stage clotting assay shows an increment of V5co and V1co as 
opposed to chromogenic assay. Biophen plasma calibrater was used for chromogenic assay 
standard. Biophen plasma and ReFacto AF standards were used for one stage clotting assay on 
an ACL TOP coagulometer (IL, MA, USA). 
Statistically significant among the coagulation assays, row factor, P=0.028, column factor, 
P=0.175 (Two-way ANOVA). Prism 6.0 (Graph Pad).  
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 4.2.18. FVIII and vWF affinity assay 
The half-life and stability of FVIII are an association with the vWF protein, which is the 
most identified determinant of FVIII survival in blood, as it provides protection from 
premature clearance or activation of FVIII (Lenting et al., 2007).   
My hypothesis was that the B-domain modification of FVIII would not change the vWF 
binding affinity because vWF binding region on FVIII is not modified.  
To test this hypothesis, the purified recombinant FVIII variants proteins (V3co, V5co and 
V1co) were sent to Dr Mckinnon (Imperial College London) who kindly analysed the 
binding affinity of vWF to FVIII (rFVIII).  ELISA binding assay of vWF-FVIII interaction 
were undertaken (Fig.4.27). Analysis of binding assays showed that FVIII-Helixate® 
binds to vWF with a dissociation constant (KD) of 0.82nM, which is similar to the binding 
affinity of the B-domain deleted FVIII Nuwiq to vWF (0.63nM). Using the same 
experimental conditions, we also determined the binding affinity of FVIII variants to vWF 
which were V1co (0.89nM), V3co (0.65nM) and V5co (0.75nM) respectively; all of which 
are similar to the wild-type control. This result confirms our hypothesis that the B-domain 
modification has nothing to do with affinity to vWF.  
Overall, the binding assay results suggest that modification of the B-domain region in 
these variants does not interefer with their biologically important binding function.  
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Figure 4.27. Binding analysis of FVIII variants functionality.  
Commercial full-length FVIII (Helixate) and Human cell line derived B-domain deleted FVIII 
(Nuwiq) were assayed as a control. Three purified recombinant FVIII variants were analysed vWF 
binding affinity by ELISA. Prism 6.0 (Graph Pad). 
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4.3. Discussion 
In this chapter, we have described the expression, purification and characterisation of 
new recombinant FVIII variants. First of all, we have established a two column 
chromatographic purification procedure (Fig.4.1). The first step entails the capture of 
FVIII using FVIIIselect, which is composed of 13kDa recombinant single-domain 
antibody fragment that is attached to a porous base matrix via a hydrophilic spacer arm 
(McCue et al., 2009). The total recovery of FVIII from FVIIISelect was 39%, suggesting 
61% of the FVIII activity has been lost most probably due to sample degradation during 
the purification procedure (Fig.4.3).    
To increase the overall yield of purified FVIII, we decided to harvest media twice over a 
48 hour period. Also, we decided to introduce a 0.5M NaCl wash step to elute FVIII bound 
to the cell membrane. As a result of these measures, our overall yield of FVIII increased 
to 1500 Units in 3x108 cells (First harvest; 600Unit, Second harvest; 600Unit, and 
Membrane-bound; 300Units).   
A DEAE column step was introduced to enable a ~85-fold concentration of the material 
isolated from the FVIIISelect column (Fig.4.15). The “concentrated” FVIII showed the 
expected pattern and bands on a silver staining of SDS-PAGE gel and western blotting, 
which demonstrate the presence of the single chain FVIII peptides as well as the heavy 
and light chain FVIII fragments.   
The purified and concentrated FVIII was assessed in biological activity/activation assays. 
A calibrated automated thrombogram system showed (Fig.4.23) that the endogenous 
thrombin potential was similar and equivalent to commercially available FVIII, implying 
that the B-domain modification we made (FVIII-V1, FVIII-V3 and FVIII-V5) did not affect 
thrombin activation.  
Discrepancies were seen between the one stage clotting assay and the chromogenic 
assay as described previously for BDD-FVIII variants (Potgieter et al., 2015). Most of our 
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B-domain variants showed relatively higher activity as compared to Nuwiq® (control, 
Octapharma) as shown in Figure 4.25 and 4.26. This discrepancy may be procedural 
with one stage clotting assay requiring relatively longer times for the assay when 
compared with the chromogenic assay, during which differences in susceptibility to 
activation of FVIII by contact phase generated proteases can be manifested. The one 
stage/two stage clotting assay discrepancy between plasma standard compared 
recombinant protein reference standard has previously been observed and explored 
(Potgieter et al., 2015). It is also possible that this discrepancy may be because of 
differences in post-translational modification of the B-domain in the engineered FVIII 
variants, which is the subject of study in the next chapter. The European 
Pharmacopoeia and the ISTH (International Society on Thrombosis and Haemostasis) 
FVIII and FIX Subcommittee recommended the chromogenic assay for reference 
method. Based on our results we concluded that the chromogenic assay might provide 
a better indication of FVIII activity after gene transfer than a one stage assay. 
Moreover, the vWF and FVIII affinity assay shows a similar affinity for variants with a 
range in length or sequence of the linker domain substituted for the B-domain, some with 
and some without N-linked glycosylation. Hence affinity to vWF cannot explain the 
variation in expression of different variants (Fig.4.27).  
In summary, we have established a two-step chromatography method for purification of 
FVIII variants expressed by producer cell line. We showed that the yield of purified FVIII 
protein was at a level that enabled further biochemical characterisation. Our preliminary 
studies suggest that FVIII activity and its ability to generate thrombin when added to FVIII 
deficient plasma was equivalent to that seen with commercial FVIII protein concentrates 
as was the profile of the FVIII molecule when running in its native form or following 
thrombin digest when assessed by a silver staining and Western blot analysis. Moreover, 
the variation in expression cannot relate to vWF binding. This is consistent with the 
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inference from biochemical studies that the vWF binding domains are in the a3, A3, C1 
and C2 regions of FVIII, so do not involve the B-domain.  
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5.1. Introduction 
FVIII is synthesised in the liver, which has been supported by the fact that liver 
transplantation can cure haemophilia A. Recent data indicates that the liver sinusoidal 
endothelial cells are responsible for the secretion of FVIII into the circulation (Stel et al.,  
1983, Nichols and Ginsburg, 1999). However, most of the data on the features of FVIII 
biosyntheses have been obtained using heterologous expression systems as attempts 
to immortalise liver sinusoidal endothelial cells have been largely unsuccessful. Before 
secretion, this single-chain FVIII polypeptide undergoes complex post-translational 
modification, including significant glycosylation.  
The native full-length human FVIII protein has 25 potential N-linked glycosylation sites, 
including 19 sites in the B-domain and three each in heavy (two in A1, one in A2) and 
light (one in a3, one in A3 and one in C1) chains (Lenting et al., 1998). Of these, 25 sites 
(19 are located in the B-domain) carry oligosaccharides (Fig.5.1). The B-domain, if 
human FVIII is therefore extensively glycosylated. Although the amino acid sequence 
encoding the FVIII B-domain has widely distributed among the human, porcine, and 
murine genes. The large number of N-linked glycosylation sites has remained strikingly 
conserved between species, suggesting an evolutionary importance (Strasser, 2016).  
Within the lumen of the ER, significant folding and modification of newly synthesised 
FVIII proteins occur. This process is regulated by enzymes and molecular chaperones, 
including BiP, calnexin and calreticulin (Pipe, 1998). The BiP–FVIII polypeptide complex 
exhibits ATPase activity; and therefore the isolation of FVIII from BiP and secretion 
require exceptionally high ATP expenditures, which appears to slow its secretion 
(Nichols & Ginsburg 1999; Becker et al., 2004). Only correctly folded proteins are allowed 
to exit the ER. Misfolded protein either is retained within the ER or subject to degradation 
by the ER-associated protein degradation pathway. These interactions are mediated 
through N-linked glycan structures expressed within the FVIII B-domain. 
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On successful folding and packaging, newly synthesised FVIII proteins are transported 
from the ER to the Golgi for additional posttranslational modifications before secretion.  
This is achieved by formation of COPII vesicles, which bud from the ER lumen and 
migrate to the Golgi apparatus via the ERGIC. The FV and FVIII have a shared 
prerequisite for specialised ER-to-Golgi transport machinery. In particular, LMAN1 and 
MCFD2 are cargo transporters for ER-to-Golgi traffic of FV and FVIII (Nichols et al., 
1999; Zhang et al., 2005; Khoriaty et al., 2012). The specific FVIII motif that binds the 
cargo proteins has not been identified, but N-linked oligosaccharides are key to FV/FVIII 
interactions with the LMAN1/MCFD2 complex. LMAN1 association with FV/FVIII is 
enhanced by the presence of full glucose trimmed high mannose (9) structures on B-
domain located carbohydrates, as demonstrated using a LMAN1 mutant with defective 
mannose binding ability and, consequently, severely diminished FVIII-LMAN1 
interaction. Mutations resulting in the loss of LMAN1 function or disturbing the interaction 
between LMAN1 and the component of the transport complex MCFD2 cause inherited 
coagulopathy, a combined deficiency of FV and FVIII (Nichols et al., 1998; Neerman-
Arbez et al., 1999, Zhang et al., 2003). Cumulatively, these data serve to emphasise the 
critical importance of N-linked glycan structures in regulating the intracellular trafficking 
of secretory glycoproteins. 
Within the Golgi apparatus, FVIII undergoes further processing, including modification of 
the N-linked oligosaccharides to complex-type structures, O-linked glycosylation, and 
sulphation. Limited proteolysis of the single-chain precursor at residues R1313 and 
R1648 give rise to a light and a heavy chain, which  is occuring in the final stage of FVIII 
processing in the trans-Golgi prior to secretion. The sites of proteolytic processing 
correspond to the Arg-X-X-Arg motif can be cleaved by protease furin/PACE (paired 
basic amino acid cleavage enzyme. However, it remains unclear which signalling 
protease of the PACE family is responsible for FVIII processing. 
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In addition to modulating intracellular processing, the glycan can also modulate FVIII 
susceptibility to proteolysis. The N-linked FVIII glycans are commonly capped by 
terminal negatively charged sialic acid moieties. The removal of capping sialic acid 
residues leading to exposure of Gal and GalNAc moieties typically results in markedly 
enhanced glycoprotein clearance mediated primarily via the hepatic lectin 
asialoglycoprotein receptor (ASGPR). This interaction is mediated through the N-linked 
carbohydrate structures clustered within the B-domain of FVIII. Treatment of ASGPR 
antagonist significantly inhibited FVIII clearance in mice (Bovenschen et al., 2005a), 
implying that the ASGPR may contribute to normal physiological clearance of FVIII from 
plasma. 
The natural FVIII circulating in the bloodstream contains multiple forms of the truncated 
B-domain, which are formed by proteolysis of a full-length two-chain molecule. The 
procoagulant properties of these FVIII variants shows no differences. Amongst these is 
the BDD SQ variant (ReFacto®) in which FVIII amino acid residues 746~1639 have been 
deleted; effectiveness and safety of which has been demonstrated over the past 16 years 
with its extensive use in patients with severe haemophilia A. Other variants similar to the 
BDD SQ FVIII e.g. Novo Eight® (deletion of residues 751~1637; NovoNordisk) and 
Nuwiq® (substitution of the 747~1648 region by the “non-natural” peptide QAYRYRRQ; 
Octapharma) have been created and tested in humans with good comparable efficacy 
and safety (Ezban et al., 2014; Sandberg et al., 2012).  A FVIII variant carrying the first 
226 amino acids of the B-domain and six N-linked glycosylation sites (variant 226aa/N6) 
was found to be secreted 5-fold more efficiently as compared with FVIII with the deletion 
of the full-length  B-domain (Miao et al., 2004). This was thought to be due to the 
improved transport of the precursor protein from the ER to the Golgi apparatus (as 
compared with the full-length form) and a decrease in adsorption of the secreted FVIII 
onto the membrane surface of producer cells (as compared with BDD-FVIII). 
Additionally, FVIII-N6 has a reduced tendency to give rise an unfolded protein response 
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when compared to the full length and BDD-hFVIII variant, thus making it a useful variant 
for further evaluation of gene transfer.  
We, therefore, developed a novel FVIII-V3co variant in which the N6/226 amino acids B-
domain linker was replaced with a 31 amino acid peptide that contains the six N-linked 
glycosylation signals that were thought to be required for efficient and safe expression 
of FVIII. FVIII-V1co is identical to FVIII-V3co except that the N-linked glycosylation 
triplets are flanked by additional amino acids that are normally adjacent to these moieties 
in the native FVIII B-domain, thus extending the size of the B-domain peptide from 31 to 
44 amino acids. Finally, FVIII-V5co is identical to FVIII-V3co except that the asparagine 
in the six N-linked glycosylation triplets with the V3co peptide was replaced with alanine 
(Fig.3.1 & Fig.5.1).  
In the studies, we determined the N-glycan structures of these different forms of 
recombinant human FVIII as carbohydrate structures on human FVIII plays important 
roles in determining stability, circulatory half-life, and biological activity. It is accepted 
that recombinant FVIII protein will likely have different N-glycan structures compared to 
the endogenously synthesised FVIII protein. Moreover, glycosylation variation has also 
been described between different commercial recombinant FVIII products that have 
been synthesised in different mammalian cell lines (including CHO and BHK). For 
example, rFVIII from Chinese hamster ovary cells express the NeuGc epitope, which 
accounts for 0.5% of total sialic acid. In contrast, Gal-α(1,3)Gal structures have been 
detected approximately 3% of BHK expressed rFVIII. Moreover, high levels of antibodies 
against NeuGc and Gal-α(1,3)Gal naturally generated in the most humans, and  specific 
glycan chains on FVIII could influence dendritic cell uptake mediated by the macrophage 
mannose receptor (CD206) (Preston et al., 2013; Dasgupta et al., 2007). 
In this chapter, we, therefore, attempted to determine how N-glycan structures of the 
FVIII variants using a combination of high performance liquid chromatography (HPLC), 
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and mass spectrometry, to further develop an understanding of the difference in the 
glycosylation pattern and how this may influence biological activity.  
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Figure 5.1. Schematic representations of N-linked glycosylation sites on FVIII 
variant domains   
Numbers on the left indicate the peptide sequence length of each variant. Total peptide length 
number/number of linker sequence length. The annotated and potential N-linked glycosylation 
sites of each protein are also displayed on the domain. The red lollipops represent annotated N-
linked glycosylation sites, and blue lollipops represent non-natural N-linked glycosylation sites.  
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5.2. RESULTS 
5.2.1. PNGase F digestion 
We compared the N-linked glycosylation in our FVIII variants with commercial BDD FVIII 
SQ (ReFacto®; Pfizer). As an initial evaluation purified, FVIII variants were treated with 
PNGase F, which cleaves between the innermost GlcNAc and complex oligosaccharides 
from N-linked glycoproteins. Subsequently, unglycosylated protein migrates faster than 
glycosylated protein in SDS-polyacrylamide gel. PNGase F catalyses the cleavage of an 
internal glycoside bond in an oligosaccharide. It cleaves all asparagine-linked complex, 
hybrid, or high mannose oligosaccharides unless the core GlcNAc contains an alpha 1,3- 
fucose. The asparagine residue, from which the glycan is removed, is deaminated to 
aspartic acid. PNGase F requires a minimum of two GlcNAc oligosaccharide residues 
attached to the asparagine in order for catalysis to occur. This enzyme utilises a catalytic 
triad of cysteine-histidine-aspartate in its active site, which is a common motif for 
amidases. It is used extensively for characterising N-linked glycan structures and for 
identifying N-linked glycosylation sites in proteomic studies. 
As the actual status of the potential N-linked glycosylation sites in the V3 linker peptides 
in FVIII-V3co is unknown. We compared PNGase F digest of this molecule with 
ReFacto® which is produced in CHO cell and our BDD-FVIII SQ made in the same HEK-
293T cells as FVIII-V3co (Fig.5.2). The FVIII variant preparations used for this study 
were purified by double column method described in the previous chapter.  We did not 
observe differences in the de-glycosylated products derived from PNGase F treatment 
of ReFacto® and BDD-FVIII-SQ. This suggests that that for BDD-FVIII manufacture in 
different cells lines does not significantly influence glycosylation. A marked shift in 
110kDa heavy chain of FVIII-V3co occurred with PNGase F digest compared to un-
digest cognate suggesting that the linker peptides being heavily glycosylated. 
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A modest shift in the de-glycosylated products of N6 was observed which has six 
potential N-linked glycosylation sites contained within the 226 amino acid partial B- 
domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. PNGAse F Digestion of FVIII variants 
The purified FVIII variants were subjected to 4~12% Bis-Tris gradient gel electrophoresis under 
reducing conditions and visualised by SYPro Ruby staining. The samples were treated with 
PNGase F endoglycosidase for 60 minutes before analysis to demonstrate the presence of N-
linked glycan modifications. Recombinant human FVIII purified, N6co, V3co, SQco: Digestion with 
PNGAse F. Commercial B-domain deleted ReFacto® was included for comparison. N6co variant 
gave dominant high molecular weight single chain because of the absence of the furin cleavage 
sequence in its linker peptide.  
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5.2.2. Mass spectrometry 
The recombinant FVIII proteins (V3co, N6co, V5co, SQco, and V1co) purified by the new 
protocols were concentrated and up to 100ug was sent to Dr Haslam (Imperial College 
London) who kindly analysed the glycome profile using MALDI-TOF/TOF MS/MS 
technology (Appendix 2. 3). Mass spectrometry (MS) has gained widespread use in 
protein glycosylation analysis and has become an indispensable, powerful analytical 
technique in this research area. A great advantage of MALDI-TOF MS is that the process 
of soft ionisation give rise little or no fragmentation of analytes, allowing the molecular 
ions of analytes to be identified. Moreover, mass mapping of a protein can be achieved 
by breaking it into specific peptide fragments using amino acid specific proteolytic 
enzymes. Mass spectrometric analysis of the enzymatic digest generates a profile, which 
is unique to the analysed protein allowing unambiguous identification by the matching 
with the database searches.  
Hence, glycosylation profiling of our FVIII variants was based on the combination of two 
basic analyses, which are monosaccharide composition and fragmentation analysis of 
over 15 glycans per sample. Monosaccharide composition analysis helps to confirm the 
glycan composition of monosaccharide content as an orthogonal technique. In terms of 
profiling changes in total glycan composition, monosaccharide analysis can also be used 
as a technique for identifying various monosaccharide modifications, phosphorylation 
and sulphation.  A refractive index detector is used for monosaccharide composition 
analysis. In contrast, fluorescence detection is used for saccharide composition analysis 
of antibody drugs as it provides higher sensitivity. The sugars are not fluorescent; they 
undergo derivatisation by an appropriate method to make them fluorescent before 
analysis by high-performance liquid chromatograph with a fluorescence detector.  
In contrast, fragmentation analysis is based on mass spectrometry (MALDI) MS. The key 
aspect of MALDI-MS is to isolate macromolecules in a suitable matrix of highly laser light 
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absorbing small organic molecules, such as an a-cyano-4-hydroxycinnamic acid 
(CHCA), sinapinic acid (SA) and 2,5-dihydroxybenzoic acid (DHB). Then it to dry on a 
MALDI-target into a crystalline deposit throughout which the molecules of the analytes 
are dispersed. Following excitation of the matrix by a high-intensity laser pulse of short 
duration, the absorbed energy causes vaporisation and ionisation of the analytes in a 
very dense MALDI crest. The ions are generated by a point source in space and time 
then enter a vacuum where they are accelerated by a strong electric field in a tube. They 
are then separated in time and finally reach to the detector. The time-of-flight (TOF) taken 
for particular ions. The flight time of an ion relates to its mass-to-charge ratio (m/z). Thus, 
mass spectra can be generated from simple time measurements. 
MS spectra of all five variants are illustrated in figure 5.3 with most abundant glycan 
structures annotated in association with their m/z values (the full N-glycome of the five 
variants is displayed in Appendix 3).  
A wide range of N-glycan structures was detected in all samples, specifically, a 
significant proportion in all five spectra involved high-mannose structures (m/z 1579.8, 
1783.9, 1987.9, 2192.0, 2396.2 peaks). In contrast, hybrid structures (i.e., m/z 1824.9) 
were detected in lower abundance. Prominent bi-antennary (i.e., m/z 2040.0), tri-
antennary (i.e., m/z 3415.6) and tetra- antennary (i.e., m/z 4110.1) glycans were also 
present in the spectra. Their antennae structures consisted primarily of HexNAc-Hex 
moieties (i.e., m/z 2489.3), with a significant proportion containing N- acetylneuraminic 
acid (sialic acid) (i.e., m/z 3602.7, 3748.8 and 3241.6). Finally, tandem MS analysis 
confirmed an abundance of core-fucosylated moieties (i.e., m/z 2850.4, 2966.5) in the 
variant FVIII molecules.  In general, the N-glycomes were more frequently found in FVIII-
N6co, V1co and V3co spectra when compared to V5co and SQco glycomes, in which 
mainly the intermediate saccharides were found.  
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Figure 5.3. MALDI-TOF mass spectra of permethylated N-glycans in five FVIII 
variants 
Glycoprotein variants of all spectra display [M + Na]+ molecular ions. Panel intensities 
were normalised to 100% unless otherwise stated. Only ions with the highest relative 
abundance are presented here. Structural assignments are based on monosaccharide 
compositions, knowledge of glycan biosynthesis and fragmentation analyses. In m/z 
values with more than one structure: M: Major (more abundant) structure; m: minor (less 
abundant) structure. Data provided by Dr Haslam, imperial college, London. 
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5.2.3 N-glycome analysis separates FVIII variants to two groups 
To identify the differences of glycosylation profile of five FVIII protein variants, N-glycans 
were counted, including the difference in the types of structures.   The result shows that 
the total range of N-glycan compositions was 37 to 66 in all five variants. Interestingly, 
20~30 more glycan structures were found in FVIII-V3co, V1co and N6co as opposed to 
SQco and V5co (Fig.5.4.A). We speculate that this is likely a reflection of the different 
constitution of the B–domain peptide in the individual molecules. FVIII- V3co, V1co and 
N6co, which have six N-linked glycosylation sites in the B-domain linker peptides. In 
contrast in FVIII-V5co substitution of Asparagine with Alanine reduced overall 
glycosylation of FVIII.  
Sialic acid residues protect N-glycan moieties from interaction with ASGPR and increase 
the circulation half-life of FVIII. The sialylation representing approximately one-third of 
the FVIII glycome levels and differed modestly between the FVIII variants with FVIII-
SQco and V1co were showing a slight increase in the number of sialylated glycans (Fig. 
5.4.B).  
We observed core-fucosylated glycan levels in FVIII-V3co, V1co and N6co when 
compared to FVIII-V5co and SQco (Fig.5.4.C). Several studies have reported an 
increase in fucosylated N-glycans in recombinant proteins derived from human cell lines 
(Diaz et al., 2009; Zhang et al., 2010;  Böhm et al., 2015).  A fucose residue is attached 
to the first N-acetylglucosamine of these complex-type N-glycans. The unusual m/z 
3963.9 ion in FVIII-SQco profile suggests possible contamination derived from FBS 
(Foetal Bovine Serum), subsequently affecting the ability for further interpreting of this 
preparation (Appendix 3, SQco) (Monk et al., 2006).  
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Figure 5.4. Overview of FVIII variants N-linked glycosylation  
A) Bar chart depicts total number of N-glycomes. The quantity of view separate in two groups, 
SQco, V5co and V3co, V1co, N6co.  B) Bar chart illustration of % sialylated observed in N-
glycomes. C) Bar chart illustration of % core-fucosylated observed in N-glycomes. 
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5.2.4. Distribution of sugar chain and antennary structure profiles of FVIII 
variants 
A similar quantity of high mannose structures in all variants, which corresponds with 
Kaufman’s finding that high mannose structures are common in the light chains of FVIII. 
Moreover, the hybrid and complex types are more common in the heavy chain, which is 
more easily degraded than the light chain in serum-free condition (Kaufman et al., 1988). 
In addition to the qualitative analysis of the glycan structures, detected m/z ion peaks 
were relatively quantified in each spectrum. Their semi-quantitative distribution shows 
that more than 80% of N-glycans are complex types in each of the five variants (Fig. 
5.5.B). The quantity of high mannose-type structure was similar in FVIII- SQco and V5co, 
which have no Asn-X-Thr/Ser peptides sequences in their B-domain linkers. In contrast, 
FVIII-V3co, V1co and N6co variants, which contain six potential N-linked glycosylation 
sites in their linker peptides, displayed a prominent enrichment in high-mannose type 
(Man5 to Man8), hybrid, bi-antennary, tri-antennary and tetra-antennary structures in a 
quantitative manner (Fig. 5.5.A).  
  These molecules had a dominance of tetra-antennary antennae structures while FVIII-
SQco and V5co displayed tri-antennary structures. This may reflect the difference in the 
Asn-X-Thr/Ser sites in the B-domain peptide in these variants when compared to FVIII-
SQco and V5co. However, further glycoproteomic mapping of the N-glycan repertoire of 
each Asn (N) site is necessary to prove this unequivocally.  
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Figure 5.5. Qualitative and semi-quantitative analysis of N-glycan structures 
A) Condensed bar depicts the qualitative distribution of five N-glycan structure groups in variants. 
B) Semi-Quantitative distribution of five N-glycan structure groups in variants. Complex type bi-
tri-tetra-antennary structures were shown to constitute approximately 90% of the glycans 
identified, accompanied by a minority of high mannose type and hybrid. The majority of N-glycan 
structures were of complex-type in all five variants. 
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5.2.5. Biologically significant common epitopes 
Figure 5.6 shows the commonly detected epitopes and glycan features in each FVIII 
variant. Specifically, the presence of blood group antigen Lewisx/a (Hex1Fuc1HexNAc1) 
and LacdiNAc with fucosylated LacdiNAc (Fuc1GalNAc1 GlcNAc1) epitopes were 
observed all variants. The Lewis x/a epitope is present all five FVIII variants including 
commercial recombinant Nuwiq® (Octapharma), which may be due to the products being 
produced in cell lines of embryonic origin (HEK-293 cells). However, the Lewis y/b 
(Fuc2Hex1HexNAc1) antigens were detected only in FVIII-V3co and N6co.The 
fucosylated LacdiNAc (Fuc-LacdiNac) epitope reported from human HEK293F produced 
recombinant Nuwiq® (Octapharma), in which the epitope is not present in plasma-
derived FVIII but kidney cell line produced Nuwiq® and five variants appeared (Kannicht 
et al., 2013).  
Most importantly, the antigenic Gal-α1,3-Gal and N-glycolylneuraminic acid (Neu5Gc) 
glycoforms detected in recombinant human FVIII variants expressed in BHK and CHO 
cells, respectively (Valentino et al., 2014), however, human cell line produced Nuwiq and 
any of the five variants N-glycans were not present. The human anti-α-Gal is one of the 
most abundant natural antibodies, representing approximately the 1% of the human 
circulating immunoglobulin. It has also been shown that anti-α Gal prevents porcine 
xenograft organs transplantation in humans, as it binds to α-Gal epitopes expressed in 
porcine cells, mediating rejection (Galili, 2005). Similar studies revealed that the majority 
of the remaining anti-α-Gal antibodies in healthy human serum are specific against the 
Neu5Gc epitope. The so-called Hanganutziu-Deicher (HD) antigen, Neu5Gc, exists in 
almost all other animals except humans and has been associated with hyperacute 
rejection during xenotransplantations (Zhu and Hurst, 2002). As was previously 
described, expression of FVIII in human cell lines for pharmaceutical purposes avoids 
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the potential for incorporation of such non-human epitopes, leading to a higher safety 
level. 
 
  
 
Figure 5.6. Common epitopes of N-glycans on FVIII variant glycoproteins 
A Synoptic view of epitopes with biological significance, presented in samples N-glycomes. 
Structures of the present (+) or absent (-) glycan features in each profile are indicated next to 
their respective names. pdFVIII: plasma-derived FVIII, Table adopted from Kannicht et al., 2013 
(Kannicht et al., 2013). 
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5.3. Discussion 
Glycosylation is one of the most common posttranslational modifications of proteins. It 
has important roles in protein structure, stability and function. Differences in protein 
glycosylation occur in recombinant proteins expressed in mammalian, yeast and insect 
cells as well as between different mammalian cell lines (Diaz et al., 2009; Croset et al., 
2012). Recombinant proteins derived from HEK-293 cells are found to have lower 
degrees of terminal sialic acids on the N-glycans and higher levels of fucosylation 
compared with other cell lines and naturally occurring forms of glycans (Böhm et al., 
2015).  
PNGase assay performed on the FVIII proteins (N6co, V3co, and SQco) demonstrated 
a shift banding pattern as shown in figure 5.2 suggesting that FVIII is heavily 
glycosylated.  
The glycan repertoire of five FVIII variants was identified based on the compositional 
analysis (MALDI-TOF), fragmentation analyses (MALDI-TOF/TOF) and knowledge of 
glycan biosynthesis. All FVIII variants displayed a complex profile, comprising of different 
oligosaccharide structures: high mannose, hybrid and complex (bi-, tri- and tetra-
antennary) structures. Sialylated glycan levels were relatively similar among the FVIII 
variants, representing approximately one-third of their profiles (Fig.5.4). Prominent 
epitopes Lewis x/a, LacdiNAc, and Fuc-LacdiNAc antigen were detected in various N-
glycans in all five variants, including commercially approved recombinant human FVIII 
(Nuwiq®, Octapharma). We believe that this is possibly attributable to the fact that these 
proteins were expressed HEK-293T cells, which is derived from embryonic tissues. Most 
importantly, the antigenic Gal-α1,3-Gal and Neu5Gc glycan structures, which have been 
demonstrated to trigger immune responses in humans, were absent from all profiles. In 
addition, all FVIII variants exhibited an increased population of N-glycan structures 
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including enrichment of high-mannose structures when compared to a recent report of 
the glycan pattern in the B-domain deleted recombinant human FVIII protein (Kannicht 
et al., 2013).  This could reflect differences in the method for generating the FVIII variants, 
the sensitivity of the method of analysis and possibly by differences in the B-domain 
linker sequence and cell culture conditions.   
Differences were however noted between FVIII- SQco and -V5co and FVIII- V3co, -V1co 
and -N6co (Fig.5.3) as summarised below: 
 Higher average number of glycan moieties in FVIII- V3co, -V1co and -N6co.  
 Relatively higher levels of core-fucosylated glycans in FVIII- V3co, -V1co and -
N6co  
 Lewis y/b epitope present exclusively in the in FVIII- V3co and -N6co (Fig. 5.6) 
These difference could be explained by the presence of six potential N-linked 
glycosylation sites in the FVIII-V3co, -V1co and -N6co B-domain linker regions. However, 
further glycoproteomic studies are required to prove this hypothesis.  
Our knowledge of the biological significance of these complete glycans on FVIII function 
is still not clear. Additional studies (i.e. B-domain peptide analysis) could be performed 
to identify the exact type of the epitopes. Substitutions of Asn residues from the N-linked 
consensus sequences Asn-X-Ser/Thr in the FVIII-V3co with alanine resulted in a 
substantial change in the glycosylation pattern. However, the activity of FVIII-V5co 
appeared to be higher in in-vitro studies (previous chapter) than FVIII-SQco even though 
their glycosylation pattern was similar. In ReFacto® (BDD-FVIII) ∼80% of the N-linked 
glycosylation sites were deleted when compared to full-length wild-type FVIII but without 
loss of specific activity and stability. These data suggest that the glycans present in B-
domain may not be critical for the clotting activity and possibly stability of the 
protein. However, the B-domain has been shown to be important for intracellular 
trafficking and binding to asialoglycoprotein receptor. Therefore, glycans in the heavy 
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chain (A1 and A2 domains) and the light chain (A3 and C1 domains) may be responsible 
for the activity. This is contrary to study by Kosloski et al, where they showed that 
deglycosylation of the full-length protein led to ∼32% loss of protein activity (Kosloski et 
al., 2009).  
In this chapter, I have explored the difference in the glycosylation of FVIII variants 
containing different B-domain linkers using deglycosylation enzymes and MALDI-
TOF/TOF tandem mass spectrometry methods. While FVIII is heavily glycosylated we 
observed the distinct difference in the glycosylation pattern observed with FVIII variants 
V1co, V3co and N6co compared with FVIII-V5co and SQco suggesting that the 
configuration of the B-domain peptide configuration influences the overall glycosylation 
pattern.   
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6.1. Introduction 
Haemophilia A caused by a deficiency of FVIII is well suited for a gene replacement 
approach because a modest increase in the level of FVIII (>1% of normal) could be 
able to improve the severe bleeding phenotype (Ljung, 1999).  Among the gene 
transfer approaches for haemophilia, AAV vectors are showing exceptional promise 
due to an excellent safety profile and ability to direct long-term transgene expression 
from post-mitotic cells, making them useful for genetic modification and analysis of 
wide range of tissues (Nathwani et al., 2007). Indeed, a single vein administration of a 
FIX AAV vector to haemophilia B patients increased FIX expression from <1% to 1~6% 
of normal levels, this enabled four of the seven patients to stop their prophylactic 
infusions, and the other three patients were able to extend the interval between 
infusion (Nathwani et al., 2014).  
However, the use of AAV vectors for haemophilia A gene therapy is challenging, due 
to the large size of the F8 gene and a low level of FVIII expression. FVIII is highly 
inefficient compared to other coagulation factors such as FV (Kaufman et al., 1989; 
Nichols and Ginsburg, 1999). AAV packaging capacity is limited to 4.7 kb, although it 
has been demonstated that large transgenes can be packaged with sufficient 
expression levels (Allocca et al., 2008). However, this finding has not been 
recapitulated by others (Lu et al., 2008; Wu et al., 2010).  Therefore, the ~7.0 kb size 
of the F8 gene is not suitable for AAV.  However, the deletion of FVIII B-domain, which 
is not required for haemostatic function resolves the size constraint problem, reducing 
the total size of the F8 gene and increasing secretion of FVIII by the 30% (Pittman et 
al., 1993; Kaufman et al., 1997; Miao et al., 2004). Moreover, it has been demonstrated 
that improved secretion of FVIII is mediated through N-linked glycosylation with the 
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mechanism facilitated by binding with LMAN1 and MCFD2 (Kaufman et al., 1988; 
Zhang et al., 2003; Graw et al., 2005). 
Our innovative approaches in Chapter 3 demonstrated that the six N-linked 
glycosylation triplets, juxtaposed in the V3 linker peptide sequences, promote the best 
expression of FVIII among the variants studied. Therefore, FVIII-V3, composed of a 
short B-domain linker sequence, allows the use of the AAV gene transfer system, as 
the total cassette size is 5.13 kb, only marginally over AAV’s packaging capacity. 
Secondly, we showed with the mutant V5, where N-linked glycosylation sites are 
removed expression was not altered compared to V3 (Fig.3.14), suggesting the 
configuration or confirmation of linker amino acids may have a role in FVIII expression 
other than N-linked glycosylation.  
In this chapter, we tested whether we can recapitulate the FVIII expression of the V5, 
V2 and V1 variants in-vivo, by single peripheral vein administration of AAV vector to 
C57BL/6 mice.  We demonstrate with the V5 construct the N-linked glycosylation is not 
required for efficient expression of FVIII. We further characterise alternative deletions 
around the V3 linker.  
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6.2. Results 
6.2.1 Construction of FVIII variant expressing AAV  
We demonstrated in chapter five that the purified FVIII V3 variants were heavily 
glycosylated. We showed modified linker V5, where putative N-linked glycosylation 
sites were removed, and overall N-linked glycosylation decreased, did not exhibit lower 
FVIII  activity. This suggested that perhaps linker configuration or conformation may 
have more influence on FVIII expression than the number of N-linked glycosylation 
sites.  To this end, we showed with variant V1 adding amino acids between the 
glycosylation triplets (N-X-T/X), does not influence the level of glycosylation yet a 
decrease in FVIII acivity compared to V3 was observed (Fig.3.15 and Fig.5.4). This 
result further supports the concept that conformation of the linker sequences is more 
important than the number of N-linked glycosylations in the linker. Therefore, we set 
out to test whether the in-vitro findings are recapitulated in- vivo. 
For in-vivo testing, the FVIII variants were incorporated into AAV vectors. Details of 
AAV expressing the FVIII variants is illustrated in a schematic diagram (Fig.6.1.A). The 
AAV expression cassettes were designed to compare the effect of linker V5, V2 and 
V1 with V3 in  liver cells for FVIII production, the liver-specific capsid serotype eight 
(AAV8) was used for packaging (Sands, 2014). In addition, a hybrid liver  specific 
promoter (HLP) was used to drive tissue-specific transgene expression. 
Coomassie blue staining was used to assess virion assembly and detection of capsid 
proteins. Allall variants show clear separation of the capsid protein VP1, VP2 and VP3 
corresponding to upper middle and lower band, respectively (Fig.6.1.B). The alkaline 
gel showed full packaging and fragmented or partial packaging viral DNAs (Fig.6.1.C). 
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Figure 6.1. Characterization of AAV particles harbouring FVIII variants (V1, V2, 
V3, and V5) 
A) Schematic diagram of four AAV vector genomes encoding FVIII variants under the control 
of HLP promoter and synthetic polyadenylation sites. The V3 linker (31aa) composed of six N-
linked glycosylation triplets (17aa) juxtaposed between the remainder sequence of original part 
of B-domain (14aa). The V5 linker  (31aa)  of 17aa substitute Asn(N) to Ala(A) to destroy 
glycosylation triplets sequences. The V2 linker (31aa) is a scrambled sequence of  V3. The V1 
linker (44aa) has six N-linked glycosylation motifs each separated by additional amino acids. 
B) Coomassie staining of purified AAV particles  (V3:1x1013 vg/mL, V5:1.5x1013vg/mL, V2: 
2x1012 vg/mL, and V1: 8x1012 vg/mL). Three capsid viral proteins (VP)s  were separated on 10% 
SDS-PAGE gel. VP1; 87kDa, VP2; 72kDa; VP3; 62kDa respectively and molecular weight 
marker representing 70kDA and 55kDa.  
C) Alkaline gel analysis shows full packaging approximately between 5.3kb to 5.1kb top band 
(square box), which was followed by partial or fragmented DNAs band, 
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6.2.2. Comparison of AAV FVIII variants in-vivo 
Intravenous injections of FVIII expressing AAV into C57BL/6 mice were performed to 
test the efficacy of newly designed FVIII variants, according to the procedure approved 
by the UK Home Office and institutional guidelines at University College London.  
Maximum of 200μL of viral vectors were administered into each animal, containing 
approximately 2.5 × 1011 viral genome copies per body weight (vg/kg).  
Mice were sacrificed four weeks after the injection, liver tissues and blood samples 
were collected.  
Human FVIII expression was determined by FVIII: Antigen assay in murine plasma at 
4 weeks using human FVIII monoclonal antibodies based ELISA (Stago). Results 
showed that the percentage expression of FVIII: Antigen (%) in mouse plasma 
samples,  were V3 (237±27), V5 (123±54), V2 (60±18) and V1 (48±19) respectively 
(Fig. 6.2.A).   
The rAAV-hFVIII gene transfer efficiency was assessed based on viral copy number in 
the liver determined at four weeks after administration of AAV. 
Genomic DNA was isolated from liver tissue, and quantitative PCR (Q-PCR) was 
performed to determine the copy number of the viral genome in transduced liver 
tissues. Primers, which were designed to amplify the FVIII A2 domain (Heavy chain), 
were used for all rAAV-HLP FVIII variants injected mice. The proviral copies per cell of 
all variants showed relatively similar copy number from V3 (1.86±0.69), V5 (0.98±0.4), 
V2 (2.51±0.26) and V1 (1.63±0.6) respectively, suggesting equivalent dosing of 
vectors (Fig.6.2.B).  
Due to the logical inference that transgene expression varies depending on proviral 
copy number, i normalised FVIII expression between vectors according to proviral copy 
numbers. After normalisation, FVIII  antigen(%) expression/transgene copy was V3 
(140±52), V5 (121±23), V2 (24±9) and V1 (30±13), respectively (Fig. 6.2.C).   
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The correction for proviral copy number shows that the expression of V3 was similar 
to V5 (ns). These results are in agreement with the in-vitro study, which implies that 
the N-linked glycosylation modification on the linker sequence is not responsible for 
the enhanced FVIII expression. Importantly, extending the size of the B-domain 
peptide from V3 (31aa) to 44 amino acids V1 decreased the FVIII expression in-vivo 
(**p<0.005), further supporting our hypothesis that the number of N-linked 
glycosylation is not a major factor for improving FVIII expression.  
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Figure 6.2. Evaluation of AAV FVIII variants in-vivo  
A) Analysis of FVIII antigen expressions at four weeks after gene transfer, hFVIII expression 
determined by ELISA specific for hFVIII:Ag. B) Quantitative PCR was used to determine the 
number of viral genomes in transduced livers. A standard was prepared to consist of pAV2 HLP 
FVIII V3 plasmid linearized with single cutter restriction enzyme digestion and serial dilutions 
made between 1x10 8 to 1x103 for FVIII DNA standard curve. Mouse liver tissues genomic DNA 
was extracted and serial dilutions made from 500ng to 3.9ng for the standard curve for GAPDH 
housekeeping gene. Primers directed against the FVIII A2 domain were used to determine the 
number of viral genome copies of this domain per cell for all mice receiving rAAV-HLP FVIII 
variants. Mouse GAPDH primer designed and used to determine mouse liver GAPDH 
expression. C) Proviral copy number correction normalised antigen levels. Data presented as 
mean ±SEM, n≥3. One-way ANOVA (Bonferroni simultaneous test), Prism 6.0 (Graph Pad). 
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6.2.3 Modification of V3 linker sequences according to size 
Having demonstrated that either interruption (V1) or complete rearrangement (V2) of 
the linker sequence decreases FVIII levels in the mouse plasma, it may be infered that 
the configuration of the amino acid sequence in the linker  influences FVIII expression.   
To further understand how confirmation of linker influences FVIII expression, we 
constructed additional variants, N0-N5. We took the original variant the V3 linker 
sequence which was built by adjoining six N-X-T/S sites and then juxtaposed to the 
remainder of the B-domain deleted amino acid sequences (SFSQ-PPVLKRHQR). 
Systematic deletion according to the number of N-linked glycosylation motif was used 
to evaluate the influence of linker length and composition. These new linkers are 
shown in figure 6.3.A. 
These new variants were packaged into AAV, pseudotyped with AAV8 capsid, purified 
and characterised (Fig.6.3.B.C). To determine the efficacy of these new variants, we 
injected a dose of 2.5 × 1011 vg/kg into the tail vein of male C57BL/6 mice with V3 
linker deleted version of FVIII variants. 
The human FVIII expression was determined by FVIII: Antigen assay, using human 
FVIII specific monoclonal antibodies was used for ELISA (Stago, UK). The level of 
FVIII expression from each of the variants was determined by ELISA and compared to 
V3. The assay results showed that the highest levels of FVIII:Ag (%) among the new 
variants were with construct N2 (174±68) followed by N1 (126±66), N3 (101±47), N0 
(82±36), N4 (67±61) and N5 (42±22) respectively (Fig. 6.4.A).   
The results demonstrate that the serial deletion of linker sequence (N series) showed 
relatively lower FVIII antigen (%) expression compared to V3co (237±27). Interestingly, 
N5, in which NVS amino acid in the V3 linker sequence is deleted, showed the lowest 
FVIII expression (42±22) suggesting the NVS motif has an important role for FVIII 
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expression. In contrast, further deletion between N4 to N2 showed recovery of FVIII 
expression. The result of N2 suggests that linker sequence conformation change 
between N2~N4 alters the FVIII expressions. Furthermore, N1 and N0 showed that the 
further deletion of amino acids from N2 decrease FVIII expression.  
The proviral copies per liver cell of all variants showed relatively similar copy number 
from N0 (1.91±0.3), N1 (1.86±1.29), N2 (1.19±0.22), and N5 (1.65±1.48) respectively 
(Fig.6.3.B). In contrast, N3 (3.35±2.74) and N4 (5.82±5.6) showed relatively high copy 
number due to the one or two mice with high copy number of viral genomes transduced 
in the liver (Fig. 6.4.B). 
We normalised FVIII expression between vectors according to proviral copy numbers. 
The normalised FVIII  antigen(%) expression /transgene copy was N0 (43±20), N1 
(90±65), N2 (142±38), N3 (49±37), N4 (14±9), N5 (47±35), V3 (140±52) respectively 
(Fig. 6.4.C). The result showed that N4 is the lowest expressing construct after copy 
correction due to high proviral copies for this insert (**P<0.005, significant compared 
to V3 and N2) (Fig.6.4.C). However, the trend of FVIII expression was not changed 
between N4~N2. Importantly, the FVIII expression level of N2 is similar with V3 
suggesting that a shorter linker sequence derived from V3 can be achieved without 
comprising FVIII expression.  
While this study is only preliminary, we show that the triplet deletion exhibited unique 
FVIII expression patterns. It is important to note that the natural c-terminal end of B-
domain peptide “PPVLKRHQR” is preceded by a glycosylation triplet (NXT/S) motif. 
Here, we found that FVIII expression was dramatically altered when amino acid valine-
serine (VS) motif is deleted from in front of PPVLKRHQR, as in variants N0, N1, N4 
and N5. Therefore, we can propose that N2 shows similar activity with V3, despite four 
more deletions of glycosylation motifs, due to a structural conformation between VS 
(Valine-Serine) and PPVLKRHQR. This result may support the hypothesis that V5 
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exhibits similar activity with V3 through PPVLKRHQR although its N-linked 
glycosylation motifs are all disabled.  
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Figure 6.3. Characterisation of AAV particles harbouring FVIII V3 linker deletion 
variants  
A) Schematic diagram of six AAV vector genomes encoding FVIII variants under the control of 
HLP promoter and synthetic polyadenylation sites. FVIII-N0; B-domain deleted 13aa linker, 
Gln744 fused Pro1641, None for N-linked glycosylation, FVIII-N1; 16aa linker but 3aa 
substitute, one N-linked glycosylation, FVIII-N2; 19aa linker 6aa substitute, two N-linked 
glycosylation, FVIII-N3: 21aa linker, 9aa substitute, potential three N-linked glycosylation, FVIII-
N4: 24aa linker, 12aa substitute, potential four N-linked glycosylation, FVIII-N5: 27aa linker and 
original 31aa FVIII-V3.  
B) Coomassie staining of purified AAV particles (N0:1x1012 vg/mL, N1:5x1012vg/mL, N2: 4x1012 
vg/mL, N3:5x1012vg/mL, N4:5x1012vg/mL and N5:4x1012 vg/mL) of three capsid viral proteins 
(VP)s  were separated on 10% SDS-PAGE gel.  
C) Alkaline gel analysis shows heavily fragmented or partial packaing AAV. 
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Figure 6.4. Evaluation of AAV hFVIII V3 linker deletion variants in-vivo 
A) Analysis of FVIII antigen expressions from rAAV vectors produced from FVIII variants in-
vivo. The FVIII antigen expression illustrated as mean of %FVIII levels ± SEM. 
B) Proviral copies/cell in the liver. A Q-PCR assay determined proviral copy number on murine 
liver samples collected four weeks after transduction with 2.5×1011vg/kg of each vector 
depicted. Results are presented as mean proviral copies/cell ±SEM.  
C) Proviral copy number correction normalised antigen. Data presented as mean ±SEM, (n≥3). 
One-way ANOVA (Bonferroni simultaneous test), Prism 6.0 (Graph Pad). 
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6.2.4. Other modified FVIII constructs 
To test the hypothesis that the NVS motif is key to the high level of FVIII expression, 
four additional modified linkers were generated by amino acid substitution.  
The first variant N1 (SFSQNATPPVLKRHQR) of NAT substituted to NVS, which we 
named N1.5 (SFSQNVSPPVLKRHQR), while N2 (SFSQNATNVSPPVLKRHQR) 
changed NVS to NDS and is named N2.5 (SFSQNATNDSPPVLKRHQR).  
As we demonstrated that the V1 expression was poor, although it has the same 
number of N-linked glycosylation motifs as V3. Moreover, the V2, which has scrambled 
linker sequence of V3, showed significantly low expression of FVIII, implying the 
constitution of linker sequence may alter the FVIII expression. Therefore, we replaced 
c-terminal linker VSS (V1) to VVS (V1.5) and ANT (V2) to AVS (V2.5) (Table 6.1). 
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Table 6.1. Additional modified FVIII constructs cloned into single stranded AAV 
backbone  
Variants of V3 linker sequences, N1.5, N2.5, V2.5 and V1.5 were designed and cloned into 
AAV vectors using Q5 site direct mutagenesis kit. 
The table describes their designated names and a description of the structure of each gene.  
To test the efficacy of newly designed FVIII variants in-vivo, AAV vectors were prepared and 
injected into C57BL/6 mice as previously described.   
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The in-vivo plasma FVIII:Ag (%) expressions were N1 (125±65), N1.5 (185±95), N2 
(173±68),  N2.5 (448±336), V2 (60±18), V2.5 (24±1.1), V1 (48±18), and V2.5 (25±3) 
respectively. N2.5 dramatically increased FVIII:Ag expression compared with  other 
versions (Fig. 6.5.A).  These results may suggest that the substitution on N2.5 may 
enhance FVIII expression.  
The proviral copies were determined by quantitative-PCR, which demonstrated that 
similar copy numbers were delivered to treated cohorts; N1 (1.86±1.29), N1.5 
(1.58±0.41), N2 (1.19±0.22), N2.5 (1.45±0.94), V2 (2.5±0.26), V2.5 (0.89±0.38), V1 
(1.63±0.60), and V2.5 (0.56±0.05) respectively (Fig. 6.5. B).  
The normalised FVIII  antigen(%) expression, which shows that N1 (89±64), N1.5 
(109±34), N2 (141±37), N2.5 (297±115), V2 (24±9.5), V2.5 (32±14), V1 (30±12.8), and 
V2.5 (43±4) respectively (Fig.6.5.C). Statistical analysis performed by using Mann 
Whitney showed that N2.5 ( a 2.5-fold increase of FVIII expression), as opposed to N2, 
was not significant (ns). The data from this study does not suggest that VS (Valine-
Serine) peptide sequences in front of PPVLKRHQR are important in the enhanced 
expression with the FVIII constructor. The exact mechanism behind the linker 
improvements remains unclear, and further analysis is required. 
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Figure 6.5. V-S to D-S modification of N2 (N2.5) increased FVIII expression 
A) FVIII:Ag expression in mouse plasma.  B) Proviral copy number in mouse liver cell.  
C) Normalised FVIII:Ag with proviral copies. Data presented as mean ±SEM, (n≥3), Mann 
Whitney test, ns: not significant. Prism 6.0 (Graph Pad). 
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6.3. Discussion 
FVIII consists of a large portion of B-domain which has no functional role in the 
coagulation process. Currently, the well established B-domain modified version of FVIII 
is SQ, containing a 14 amino acid linker between the a2 and a3 domains are 
commercially available as ReFacto® (Pfizer). The B-domain deleted version of “SQ” 
has been tested in-vivo using lentiviral vectors (Ward et al., 2011; Spencer et al., 2015). 
This construct has been also utilised in AAV vectors where capability was tested for a 
long-term therapeutic effect in haemophilia A (McIntosh et al., 2013).  The in-vitro 
expression of B-domain modified versions of  FVIII SQ, V1, V3 and V5 have been 
investigated.  
In this chapter, we investigated the expression of  V1, V2, V3 and V5 constructs  in- 
vivo using AAV gene transfer. Based on FVIII expression in plasma, we did not oberve 
a significant difference  in potency between constructs containing linker V3 and V5 
(ns). However scrambled V3 sequence in the V2 variant, decreased FVIII expression 
approximate 7-fold (**p<0.005). 
To further understand and optimise the linker sequence, we developed ten other 
variants with various deletions and substitutions. The best performers were N2 and 
N2.5. These results are in line with previous report Srour et al. (Srour et al., 2008).  
In this report, three additional consensuses N-linked glycosylation sites in the FVIII-
BDD were created by inserting the 14 amino acid sequence (ADNSSTNLSLSNGS), 
resulting in FVIII-BDD-G3. The Asn(N) mutated to Gln(Q) of FVIII-BDD-G3, leading to 
FVIII-BDD-G0. The FVIII expression levels showed no significant difference between 
the expression of G3 and G0 constructs (Srour et al., 2008). This result supports our 
findings that the glycosylation deleted version V5 was not significantly different 
compared with V3 regarding FVIII expression.  
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In contrast, Miao et al., performed a similar study where the FVIII linker sequence 
version FVIII-N6 (266aa/N6) had Asn(N) mutated to Gln(Q) at the consensus site for 
N-linked glycosylation. This constructs fully devoid of N-linked oligosaccharides within 
the partial B-domain fragments and was named as FVIII-266aa/N1. The FVIII-
266aa/N1 construct showed significantly lower FVIII expression than 266/N6 in COS-
1 cells (Miao et al., 2004). Additional studies have shown the deglycosylation of wild-
type FVIII by endoglycosidases resulted in substantial loss of activity (by about 32%) 
compared to glycosylated FVIII (Kosloski et al., 2009). These result may suggest that 
the glycosylation of total protein may change the total FVIII expression, but  partially 
modified glycosylation on the B-domain or a linker is not influential.  
Here we confirm that  glycosylation of the linker sequence in our original FVIII variant, 
V3 is not a key factor in it’s improved expresssion profile.  
To further understand the linker modifications that affect expression we studied a 
series of linker variants. Our next question for a modifier of the FVIIl-V3 is confirmation 
change by deletion of the linker sequence. The deletion of V3 linker study shows 
glycosylation of the linker sequence is not an important factor, but conformation 
change may be the key for the Improved expresssion profie.  
We showed lowest FVIII expressions from N4 suggesting structural confirmation 
influences efficiency of FVIII expression (Fig. 6.4). Furthermore, the FVIII expression 
from N2 was similar to V3 implying that V3 linker sequence can be shortened without 
affecting FVIII protein expression.  Our data is similar to Kolind et al., where vectors 
containing a serial deletion of wild-type B-domain of FVIII demonstrated the shortest 
B-domain of 21aa, without N-linked glycosylation motif was the most efficiently 
expressed FVIII (Kolind et al., 2010). Our preliminary data with 19aa linker variant N2 
and N2.5 suggest smaller linkers can be used without sacrificing expression level.   
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Overall, I conclude that N-linked glycosylation of V3 linker is not the main determinant 
of FVIII expression, but the conformation change of the linker imposes the key for the 
cryptic effect of B-domain linker sequences of V3 on expression efficiency of FVIII.  
 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 261 
 
 
 
 
 
Chapter 7 
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Discussion and Future Directions 
Haemophilia A therapy has been reliant on plasma derived or recombinant protein 
products, which are widely used for prophylaxis and treatment in clinical practice. One 
of the major complications seen in the past was the transmission of blood born viruses. 
Another serious complication of replacement therapy is inhibitor development. Also, 
the lack of stability of the FVIII protein in the circulation means that frequent infusions 
must be given to prevent or treat bleeding. Since recombinant FVIII replacement 
therapy has been applied to patients, the first of those problems was eliminated from 
the management of haemophilia (Boedeker, 1992).  However, the potential 
immunogenicity of recombinant FVIII proteins, which generate inhibitor antibodies 
against FVIII in blood appears to be increased over the plasma-derived products while 
the stability of recombinant proteins in-vivo is similar to that of plasma-derived 
concentrates (Schwartz et al.,1990; Bray et al., 1994).  Therefore, the further biological 
characterisation and understanding of FVIII products are required. 
The main focus of this thesis was the development of stable cell lines for the 
production, purification and biological characterisation of novel FVIII variants. In 
addition, preliminary studies incorporating these variants in an AAV gene therapy 
vector was undertaken.  
Previous work within our group developed novel FVIII proteins, in which the B-domain 
is substituted with potential N-linked glycosylation motifs in linker sequences (McIntosh 
et al., 2013).  Mcintosh et al. demonstrated that codon optimisation of FVIII containing 
a 266 amino acid B-domain linker under the hybrid liver-specific promoter (HLP) 
exhibited 10-fold higher FVIII expression levels in mice compared with non-codon 
optimised variants (McIntosh et al., 2013).  Further improvement was achieved by 
replacing the 266 amino acid N6 spacer with the 31 amino acid peptide (V3co), in 
which the six-N-linked glycosylation motifs from N6 were re-arranged in immediate 
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proximity to make the shortest possible linker still containing the motifs.  As a result, 
V3co shows not only increased potency up to 2-fold but also achieved more efficiently 
packaged AAV virions. Importantly, FVIII levels were continuously expressed from F8 
knockout mice following administration of V3co vector. This thesis set out to perform 
an in-depth exploration to dissect the improved expression of V3co, using various gene 
delivery or engineering methods.   
To study novel FVIII variants, the generation of FVIII stable cell lines was required. 
Utilising a lentiviral gene transfer system we established stable integration of the FVIII 
variants in HEK-293T cells, initially as polyclonal populations before refinement to the 
generation of single clone homogenous stable cell lines. Our results are in agreement 
with Oberbek et al., who reported the use of lentivirus for the generation of stable cell 
lines in CHO cells.  They reported the stable expression of transgene over three 
months in serum-free conditions (Oberbek et al., 2011). In the current study, we 
performed a preliminary test for FVIII variants expressing lentivirus with different MOIs. 
As a result, we found that an MOI of 10 exhibited the best concentrations for 
transduction into HEK-293T cell lines.  
The initial cell lines were a mixed population of clones, due to the random lentiviral 
integration of FVIII, which resulted in variation in FVIII expression levels. Subsequently, 
using a selection process of serial dilutions in 96-well plates, we achieved single clonal 
cell cultures, which showed uniform growth conditions and protein expression. A 
benefit of having established single clone is the possibility of tighter quality control. 
Unlike Oberbek’s methods, FACS cannot be applied to our approach because our FVIII 
does not contain green fluorescent protein (GFP) therefore the selection process had 
to be performed by serial dilution on 96-well plates, which was time-consuming.   
The McIntosh report found that the codon optimised V3 exhibited greater expression 
among the B-domain modified variants. This suggested that the six N-linked 
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glycosylation motifs may have a critical role for the expression. This conclusion was 
further supported by our finding that elimination of N-linked glycosylation motif by 
mutating amino acid Asparagine (N) to Alanine (A) in the modified version variant V5co 
decreased by approximately 40% FVIII antigen expression as compared to V3co in-
vitro (Fig.3.15).   This result corresponds to a 2-fold change of mRNA expression level 
between V3co and V5co (Fig.3.13). Although the mechanism for this increased 
transcription or different  secretion levels was not further investigated,  it is possible 
that BiP interaction with the B-domain may be involved (Pittman et al., 1994).  
Furthermore, Kaufman et al. showed by immuno-precipitation that most FVIII is bound 
with 78kDa BiP and 80% of FVIII in the rough ER is associated with BiP, which 
prevents FVIII secretions (Kaufman et al., 1988). The glycosylation state and 
association with BiP could be correlated with secretion efficiency, unglycosylated 
protein and BiP association increased stability and retention in the ER, thus blocking 
efficient secretion (Dorner et al., 1987). However, we can argue that the FVIII activity 
(Fig.3.14) was not significantly changed between V3co and V5co, suggesting potential 
N-linked glycosylation does not influence biological activity on the B-domain linker.  
In relation to the N-linked glycosylation of the B-domain, the biology of FVIII secretion 
from the cell system is a core mechanism for FVIII production. N-linked glycosylation 
of V3co may have improved ER to Golgi trafficking through the high mannose 
oligosaccharides which bind within the ER to a cargo protein-LMAN1 (Moussalli et al., 
1999; Cunningham et al., 2003; Miao et al., 2004). Our study in Figure 3.16 
demonstrates that the codon optimised V3 co-localised with ER/Golgi and the ER-
Golgi trafficking inhibitor BFA lead to accumulation of FVIII in the Golgi compartment. 
However, the pattern of accumulation in the ER/Golgi was similar between variants, 
which prevents us from ruling this out as a cause of the discrepancy in expression. 
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Therefore, further experiments are required to understand the exact mechanisms for 
the differences in FVIII expression.  
Since FVIII is a secreted protein, it is a requirement that FVIII containing vesicles are 
fused to the plasma membrane in the course of release from cells (Fig.1.5). Kolind et 
al., reported that 90% of recombinant FVIII is bound to cell membrane when the FVIII 
contained a short B-domain (21 amino acid), suggesting the size of B-domain is 
inversely correlated with FVIII attachment to the membrane (Kolind et al., 2010). They 
also showed that N-linked glycosylation within the B-domain has no influence on either 
total expression level or membrane attached FVIII. In contrast, we showed that the 
FVIII-V5co (31 amino acid) exhibited 2.4-fold increased membrane bound FVIII under 
the serum-free condition as opposed to V3co (31 amino acid), suggesting that lack of 
N-linked glycosylation on the V5co B-domain linker leads to accumulation of FVIII on 
the membrane surface of the HEK-293T cells (Fig.3.16). Although we demonstrate 
contradictory result to Kolind et al., N-linked glycosylation of amino acids juxtaposed 
in V3co may be structurally different from Kolind’s short 21 amino acid B-domain linker. 
Therefore, we conclude that N-linked glycosylation difference between V3co and V5co 
has an effect on membrane binding, at least in our FVIII-V3co system.  
Taken together, B-domain modified short linker version of FVIII, V3co has been 
confirmed as the best expressing FVIII protein among the variants. FVIII V3co was 
expressed at approximately 2.5-fold greater levels in HEK-293T cells compared with 
FVIII SQco, 30% more antigen detected than for FVIII V5co and these observations 
were made using both cell lines and gene transfer methodologies. The increased 
expression resulted from increased levels of FVIII V3co mRNA and increased 
secretion efficiency. 
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To purify a large amount of recombinant FVIII, I have developed an optimised 
purification procedure, which allowed me to concentrate FVIII up to 100ug in total for 
further PTM characterisation.  
Thrombin activation of the protein by proteolytic cleavage was characterised. We 
showed that the thrombin cleavage pattern of FVIII-V3co corresponds exactly with 
wild-type FVIII (Fig.4.21 and Fig. 4.22), implying FVIII-V3co is biologically active.  
Regarding the stability of FVIII, vWF protein is the most identified determinant of FVIII 
survival in blood, as it provides protection from premature clearance or activation of 
FVIII and vWF deficiency leads to a secondary deficiency of FVIII  (Bendetowicz et al., 
1998; Lenting et al., 2007).  Our vWF and FVIII binding affinity assay demonstrated 
that the marked difference in expression between FVIII variant constructs has nothing 
to do with affinity to vWF (Fig.4.27) suggesting the B-domain region modified FVIII 
variants are not interfereing with vWF and their biological function.  
In this study, the biochemical properties of FVIII were characterised by using MS 
(MALDI-TOF) and MS/MS (MALDI-TOF/TOF) technology. For the production of FVIII, 
cell culture and purification conditions were optimised for all variant cell lines to test 
the differences between the five variants (SQco, V5co, V3co, V1co and N6co). Then, 
all five variants were analysed for N-glycans, and the results exhibit unique patterns 
that can separate into two groups depending on N-linked glycosylation motifs in their 
respective linkers.  The result from SQco and V5co variants showed a relatively low 
glycosylation rate as opposed to the V1co, V3co and N6co, where a high number of 
glycan structures were observed. Importantly, the most highly glycosylated FVIII 
variant was V3co, which is in agreement with our initial hypothesis that V3co harbours 
potential N-linked glycosylation sites. In terms of PTM, the enrichment of high-
mannose structures was similarly exhibited in all five variants. V3co, V1co and N6co 
also demonstrated higher levels of core-fucosylated glycans than the SQco and V5co 
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group. In contrast, sialylated glycan levels were observed in one-third of their total 
glycan profiles and were relatively similar among variants.  
In this respect, the sialic acid residues on the N-glycans are important because of 
protection from being recognised by the asialoglycoprotein receptor in the liver, which 
affects the circulation half-life of glycoproteins in the blood (Zhang et al., 2010).  In this 
study all FVIII variants exhibit similar levels of sialylated glycan, implying that slight 
difference between the variants may not influence FVIII half-life significantly. 
The mass spectrometry data showed the terminal structure of recombinant FVIII, 
including complex-, hybrid- and high mannose-type glycosylation, are present at the 
same sites as in native human plasma-derived FVIII (Kannicht et al., 2013).   Our data 
show the prominent epitopes Lewis x/a, LacdiNAc, and Fuc-LacdiNAc antigen were 
detected in various N-glycans in the FVIII variants (Fig.5.6). The presence of Fuc-
LacdiNAc in all five variants, including recombinant human FVIII (Nuwiq®, 
Octapharma), is possibly attributable to the expression cell line HEK-293T cells which 
are derived from a kidney cell line and might affect the biological properties of the 
protein, as this epitope was not found in the native plasma-derived FVIII protein. 
Regarding immunogenicity, antigenic carbohydrate epitopes Neu5Gc and α-Gal are 
detected in FVIII that is produced in non-human cell lines. For example, the Gal α-1.3 
Gal epitopes were detected in FVIII produced in BHK (Kogenate®, Baxter).  However, 
Nuwiq® (Octapharma) derived from human cell line HEK-293T does not contain either 
antigenic carbohydrate epitope (Kannicht et al., 2013).  This is consistent with our FVIII 
variant results in fig. 5.6. Overall we discovered that the N-linked glycosylation profile 
of FVIII-V3 is almost identical to the human cell line derived commercial rFVIIII 
(Nuwiq®) and plasma-derived FVIII. As mentioned above, glycan structures were 
identified based on the compositional analysis (MALDI-TOF), fragmentation analyses 
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(MALDI-TOF/TOF) and knowledge upon glycan biosynthesis. Additional assays, such 
as linkage analysis and galactosyl-transferase assay could be performed to increase 
the depth of the current structural analysis. Moreover, targeted glycoproteomic 
techniques could be used to further explore the distribution of the identified N-glycan 
in each of the N-linked glycosylation sites, possibly elucidating their biological 
significance upon FVIII function.  
X-ray crystal structure analysis of FVIII is necessary to obtain high-resolution structural 
information, which triangulates the linker structure and N-glycosylation pattern of B-
domain. For example, the tertiary structure of B-domain deleted FVIII permits 
unambiguous modelling of the relative orientations of the five domains of rFVIII (Ngo 
et al., 2008; Shen et al., 2008). Overall crystal structures give much information to 
better understand the FVIII tertiary structure and domain organisation.  However, due 
to the time required for producing a large amount of recombinant protein and 
subsequent crystallography methods, this approach was not feasible in the current 
study. 
The final section of this thesis focused on AAV gene transfer of the novel FVIII variants 
in-vivo. While AAV gene therapy is showing exceptional promise for a range of genetic 
disease a major obstacle for its use in haemophilia A is the limited packaging capacity 
of this vector.  The packaging limit of rAAV is about 4.7kb, whereas FVIII cDNA has a 
size of 7kb. To overcome this, several novel AAV vector technologies have been 
developed to increase the genome capacity for AAV or enhance gene expression using 
trans-splicing or hybrid vectors (Yan et al., 2000; Trapani et al., 2014). Although this 
system allows for the incorporation of transgenes, which exceed the packaging 
limitation of AAV, the gene transfer efficiency was lower than conventional AAV vector 
system (Daya and Berns, 2008). The ability to achieve functional gene transfer with 
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large genomes in AAV has been shown, with the mechanism of expression being 
partially packaged sequences complementary to each other to restore a full expression 
cassette (Hirsch et al., 2010). The two potential pathways of large gene reconstruction 
from the partially packaged AAV vectors is recombination at overlapping homologous 
genome sequences and direct annealing of opposite polarity partial large-transgene 
fragments because the ITRs are thought to stimulate intermolecular recombination and 
non-homologous end joining (Wu et al., 2010). However, neither relying on transgene 
recombination or trans-splicing is ideal. Therefore ways to reduce genome size is 
required. Previously, we have demonstrated the reconstitution of partially packaged 
AAV-FVIII-V3co by using southern blot which clearly exhibited the fully assembled 
5.2kb bands (McIntosh et al., 2013), suggesting more efficient large gene delivery is 
available with an AAV system. McIntosh et al., exhibit significant enhancement of FVIII 
gene transfer through successful downsized FVIII V3co, which allows AAV delivery in-
vivo to target liver and administration of AAV-FVIII V3co to F8 knockout mice and non-
human primates, demonstrating constant production of FVIII (McIntosh et al., 2013). 
However, the role of V3 B-domain linker sequence for enhancement of FVIII 
expression was not investigated. 
In this study, we further explored the mechanism by which modification of length or 
conformation change of V3 B-domain linker influences expression in-vivo using AAV 
gene transfer. According to in-vitro FVIII variants study, disabling N-linked 
glycosylation sites (V5) does not inhibit FVIII production suggesting the linker amino 
acids themselves have an effect on FVIII production other than glycosylation. AAV 
administration of V5 to mouse tail vein also showed that the N-linked glycosylation 
profile did not affect FVIII expression. Therefore, the high FVIII expression from AAV-
FVIII-V3  may due to the conformational change of B-domain of FVIII. We showed here 
that this hypothesis is supported by developing a variety of linker deletion mutants.  
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The deletion of  the V3 linker in the N0-N5 series showed that the number of deletions 
fluctuates the FVIII expression levels.  Indeed, AAV-FVIII-N2 (19 amino acids), has a 
shorter linker than AAV-FVIII-V3co (31 amino acid ), but their FVIII expression is 
similar. We conclude that it is a conformation change of B-domain linker polypeptide 
influenced by linker length and composition that dramatically affects the FVIII 
expressions.  
While AAV mediated gene therapy has shown promise for the treatment of haemophilia 
B, clinical trials targeting FVIII deficiency are limited. However, BioMarin 
Pharmaceutical (BMN 270), who licenced the UCL technology described by McIntosh 
et al (McIntosh et al., 2013)  announced preliminary data that no serious adverse 
events were observed when an  AAV vector encoding the UCL codon optimised BDD 
FVIII pseudotyped with AAV5 capsid  was administered into patients with severe 
haemophilia A. Stready state FVIII expressions at therapeutic levels (range 12-150%) 
was observed in the 7 patients recruited to the high dose level (6x1013vg/kg) over a 
period of 34 to 50 weeks (https://www.hemophilia.org/Newsroom/Industry-News/ 
BioMarin-s-Hemophilia-A-Gene-Therapy-Trial-Demonstrates-Increased-FVIII-Levels). 
BDD-FVIII-SQ version was used for this trial although FVIII-V3 expression is at least 
2-fold higher because of the established safety profile of BDD-FVIII protein 
concentrates in the clinic over the past 16 years. In terms of establishing AAV gene 
therapy as a routine treatment option for haemophilia A, there are many hurdles to 
overcome. However, our studies contribute to providing fundamental data for the safety 
of future gene therapy for newly engineered FVIII variants.  
To conclude, I have critically evaluated the role of V3 B-domain linker in the context of 
human FVIII expression in cellular models and AAV gene transfer in-vivo. In all cases, 
the FVIII-V3 variant performed better than the B-domain deleted FVIII (SQ). 
Chapter 7 
 
 271 
The basic mechanism behind V3 B-domain linker was evaluated by analysing hFVIII 
mRNA levels following gene transfer. Our results are indicative of improved 
transduction of liver cells and enhanced transcription levels and/or improved mRNA 
stability. The expression of FVIII-V3 was improved compared to other variants both in-
vitro and in-vivo. The biological activity of the purified recombinant FVIII V3 variant was 
the same as control (full-length FVIII and commercial BDD FVIII), assessed by 
thrombin generation, and vWF/FVIII binding affinity assay. Although mutations within 
the N-linked glycosylation sites in V5 decrease the number of N-glycans,  V5 did not 
significantly change the FVIII expression. These results suggest the enhanced FVIII 
expression by the V3 linker is not due to the N-linked glycosylation motifs. In addition, 
deletion series of the  V3 linker showed that a shorter form FVIII-N2 exhibited similar 
FVIII expression as FVIII-V3. Thus, B-domain linkers enable higher levels of 
expression possibly through a conformational change, but this requires further studies. 
Whilst the precise mechanism remains unclear, future therapy for haemophilia A will 
utilise a variety of new methods to improve efficacy and safety. The mechanistic in-
sights into the role of V3 described in this thesis will help advance the field in this 
regard. In particular, our observation that smaller peptides in FVIII-N2 and -N2.5 may 
also be suitable for effective AAV-mediated gene transfer for haemophilia A.  
Therefore, the results presented here suggest that FVIII V3co and variants may be 
efficacious for replacement therapy and/or gene therapy for haemophilia A. This thesis 
has utilised many of different approaches to understanding the role of FVIII B-domain 
and how this could be used for future bioengineering of FVIII.   
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Appendix. 1, FVIIISelect column Äkta explore profile 
 
 
 
UNICORN 5.20 (Build 500)
Result file: C:\...\default\rFVIII V3co 300ml 6e82t1000 20140219 FVIII SELECT 001
7 (13)
     0.00  Base  SameAsMain 
    0.00  Block  System_Volume_Compensation
       (System_Volume_Compensation)
       0.00  Base  Volume 
       (8.00)#Compensation_Volume  End_Block  
     (5.00)#Reequilibrate_with  End_Block  
 
Documentation
Variables
  Column                  VIIISelect
  Flow_Rate               1.00   {ml/min}
  Column_PressureLimit    0.50   {MPa}
  Wavelength_1            280    {nm}
  Wavelength_2            OFF    {nm}
  Wavelength_3            OFF    {nm}
  Averaging_Time_UV       0.01   {sec}
  BufferValve_A1_Inlet    A11
  Pump_A_Inlet            A1
  Pump_B_Inlet            B1
  Wash_Inlet_A1           OFF
  Wash_Inlet_A2           OFF
  Wash_Inlet_B1           OFF
  Wash_Inlet_B2           OFF
  Column_Position         Position3
  Compensation_Volume     8.00   {ml}
  Equilibrate_with        5      {CV}
  OutletValve_Position    F3
  SampleInlet             A11
  Injection_Flow_rate     1.00   {ml/min}
  Sample_Volume           300.00 {ml}
  Wash_column_with        2      {CV}
  1_PumpAInlet            A1
  1_PumpBInlet            B1
  1_Buffer_Inlet_A        A11
  1_Wash_Inlet_A1         OFF
  1_Wash_Inlet_A2         OFF
  1_Wash_Inlet_B1         OFF
  1_Wash_Inlet_B2         OFF
  1_ConcB_Step            0      {%B}
  1_Tube_Type             12mm
  1_Fraction_Size         2      {ml}
  1_Start_at              FirstTube
  1_Length_of_Step        60     {CV}
  2_PumpAInlet            A2
  2_PumpBInlet            B1
  2_Buffer_Inlet_A        A11
  2_Wash_Inlet_A1         OFF
  2_Wash_Inlet_A2         OFF
  2_Wash_Inlet_B1         OFF
  2_Wash_Inlet_B2         OFF
  2_ConcB_Step            70     {%B}
  2_Tube_Type             12mm
  2_Fraction_Size         2      {ml}
  2_Start_at              NextTube
  2_Length_of_Step        60     {CV}
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UNICORN 5.20 (Build 500)
Result file: C:\...\default\rFVIII V3co 300ml 6e82t1000 20140219 FVIII SELECT 001
8 (13)
  3_PumpAInlet            A2
  3_PumpBInlet            B1
  3_Buffer_Inlet_A        A11
  3_Wash_Inlet_A1         OFF
  3_Wash_Inlet_A2         OFF
  3_Wash_Inlet_B1         OFF
  3_Wash_Inlet_B2         OFF
  3_ConcB_Step            100    {%B}
  3_Tube_Type             12mm
  3_Fraction_Size         1      {ml}
  3_Start_at              NextTube
  3_Length_of_Step        20     {CV}
  Reequilibrate_with      5.00   {CV}
 
Scouting
 No information to print.
 
Questions
 No 1:   Sample Volume and Type
         rFVIII V3co, 300ml, 6e8/2-t1000. 2014-02-19 FVIII SELECT 
 
 No 2:   Column
         
 
 No 3:   Eluent A
         
 
 No 4:   Eluent B
         
 
 No 5:   Remarks
         
 
 
Column(s):
 
 VIIISelect
 
 Height                             3.5 cm
 Diameter                           0.6 cm
 Column volume                      0.99 ml
 Technique                          Affinity
 Vt                                 0.0 ml
 Vo                                 0.0 ml
 Max pressure                       0.5 MPa
 Default flowrate                   1.0 ml/min
 Max flowrate                       
 Typ. peak width at base            
 pH High value, longterm            
 pH Low value, longterm             
 pH High value, shortterm           
 pH Low value, shortterm            
 Average particle diam.             
 Code no                            
 Typical loading range              
 Mol. weight range                  
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UNICORN 5.20 (Build 500)
Result file: C:\...\default\rFVIII V3co 300ml 6e82t1000 20140219 FVIII SELECT 001
9 (13)
 Scan rate                          
 ________________________________________
 
 
Start Notes
 No information to print.
 
Run Notes
 No information to print.
 
Evaluation Notes
 No information to print.
 
Calibration
 P900Press Calibrated 18/12/2013 10:20:24 by default
 
 P950Press Calibrated 08/06/2010 17:54:20 by default
 
 pH Calibrated 18/12/2013 11:04:39 by default
    Reference Value 1 : 9.000000 pH
    Reference Value 2  : 2.700000 pH
 
 P950Flow Calibrated 23/01/2013 12:03:56 by default
    Reference Value 1 : 5.000000 ml
    Reference Value 2  : 5.000000 ml
 
 
Logbook
     0.00 min  Method Run 19/02/2014, 08:31:22 GMT Standard Time, Method : FVIII
 direct load imadiazole, Result : C:\...\default\rFVIII V3co 300ml 6e82t1000
 20140219 FVIII SELECT 001.res
     0.00 min  User default in control of the run
     0.00 min  Batch ID: 39C7A226-282C-48D7-B3AF-2B7F7DBC03B8
     0.00 min  Base CV, 0.99 {ml}, VIIISelect
     0.05 min  Block Flow_Rate
     0.05 min  Base SameAsMain
     0.05 min  Flow     1.00 ml/min
     0.05 min  End Block
     0.05 min  Block Column_Pressure_Limit
     0.05 min  Base SameAsMain
     0.05 min  Alarm_Pressure Enabled ,     0.50 MPa,     0.00 MPa
     0.05 min  End Block
     0.05 min  Block Start_Instructions
     0.05 min  Base SameAsMain
     0.05 min  Wavelength  280 nm, OFF , OFF 
     0.05 min  AveragingTimeUV 0.01 sec
     0.05 min  End Block
     0.05 min  Block BufferValve_A1_Inlet
     0.05 min  Base SameAsMain
     0.05 min  BufferValveA1 A11 
     0.05 min  End Block
     0.05 min  Block Eluent_A_Inlet
     0.05 min  Base SameAsMain
     0.05 min  PumpAInlet A1 
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Result file: C:\...\default\rFVIII V3co 300ml 6e82t1000 20140219 FVIII SELECT 001
10 (13)
     0.05 min  End Block
     0.05 min  Block Eluent_B_Inlet
     0.05 min  Base SameAsMain
     0.05 min  PumpBInlet B1 
     0.05 min  End Block
     0.05 min  Block Start_with_PumpWash_Explorer
     0.05 min  Base SameAsMain
     0.05 min  PumpWashExplorer OFF , OFF, OFF, OFF
     0.12 min  End Block
     0.12 min  Block Start_Conc_B_0_pc_B
     0.12 min  Base SameAsMain
     0.12 min  Gradient     0.00 %B,    0.000 CV
     0.12 min  End Block
     0.12 min  Block Column_Valve
     0.12 min  Base SameAsMain
     0.12 min  ColumnPosition Position3 
     0.12 min  End Block
     0.12 min  Block System_Volume_Compensation
     0.12 min  Base Volume {ml}
     8.19 min  End Block
     8.19 min  Block Column_Equilibration
     8.19 min  Base SameAsMain
    13.14 min  End Block
    13.14 min  Block AutoZero_UV
    13.14 min  Base SameAsMain
    13.14 min  AutoZeroUV 
    13.14 min  End Block
    13.14 min  Block Flowthrough_Collection
    13.14 min  Base SameAsMain
    13.18 min  Pause 19/02/2014, 08:44:30 (Manual)
    13.18 min  OutletValve F3 
    13.18 min  Continue 19/02/2014, 08:45:03 (Manual)
    13.18 min  End Block
    13.18 min  Block Sample_Inlet_BufferValve
    13.18 min  Base SameAsMain
    13.18 min  PumpAInlet A1 
    13.18 min  BufferValveA1 A11 
    13.18 min  End Block
    13.18 min  Block Load_Sample_with_SystemPump
    13.18 min  Base Volume {ml}
    13.18 min  InjectionMark 
    13.18 min  Flow     1.00 ml/min
   310.94 min  Pause 19/02/2014, 13:42:49 (Manual)
   310.94 min  Next Breakpoint (Manual)
   310.94 min  Continue 19/02/2014, 13:43:48 (Manual)
   310.94 min  End Block
   310.94 min  Block BufferValve_A1_Inlet
   310.94 min  Base SameAsMain
   310.94 min  BufferValveA1 A11 
   310.94 min  End Block
   310.94 min  Block Eluent_A_Inlet
   310.94 min  Base SameAsMain
   310.94 min  PumpAInlet A1 
   310.94 min  End Block
   310.94 min  Block Flow_Rate
   310.94 min  Base SameAsMain
   310.94 min  Flow     1.00 ml/min
   310.94 min  End Block
   310.94 min  Block Complete_Sample_Loading
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11 (13)
   310.94 min  Base Volume {ml}
   330.98 min  End Block
   330.98 min  Block Wash_Out_Unbound_Sample
   330.98 min  Base SameAsMain
   332.96 min  End Block
   332.96 min  Block Pump_Inlet_A_Segment_1
   332.96 min  Base SameAsMain
   332.96 min  PumpAInlet A1 
   332.96 min  End Block
   332.96 min  Block Pump_Inlet_B_Segment_1
   332.96 min  Base SameAsMain
   332.96 min  PumpBInlet B1 
   332.96 min  End Block
   332.96 min  Block Buffer_Inlet_A_Segment_1
   332.96 min  Base SameAsMain
   332.96 min  BufferValveA1 A11 
   332.96 min  End Block
   332.96 min  Block Wash_Explorer_1
   332.96 min  Base SameAsMain
   332.96 min  PumpWashExplorer OFF , OFF, OFF, OFF
   333.03 min  Block Delay0p05min
   333.03 min  Base Time {min}
   333.08 min  End Block
   333.08 min  End Block
   333.08 min  Block ConcB_Step_1
   333.08 min  Base SameAsMain
   333.08 min  Gradient     0.00 %B,    0.000 CV
   333.08 min  End Block
   333.08 min  Block Fractionation_Segment_1
   333.08 min  Base SameAsMain
   333.08 min  Fractionation 12mm , 2.000  ml , FirstTube , Volume 
   333.10 min  End Block
   333.10 min  Block Step_Segment_1
   333.10 min  Base SameAsMain
   333.10 min  Block Step_1
   333.10 min  Base SameAsMain
   392.50 min  End Block
   392.50 min  Block Delay0p02min
   392.50 min  Base Time {min}
   392.52 min  End Block
   392.52 min  End Block
   392.52 min  Block Pump_Inlet_A_Segment_2
   392.52 min  Base SameAsMain
   392.52 min  PumpAInlet A2 
   392.52 min  End Block
   392.52 min  Block Pump_Inlet_B_Segment_2
   392.52 min  Base SameAsMain
   392.52 min  PumpBInlet B1 
   392.52 min  End Block
   392.52 min  Block Buffer_Inlet_A_Segment_2
   392.52 min  Base SameAsMain
   392.52 min  BufferValveA1 A11 
   392.52 min  End Block
   392.52 min  Block Wash_Explorer_2
   392.52 min  Base SameAsMain
   392.52 min  PumpWashExplorer OFF , OFF, OFF, OFF
   392.59 min  Block Delay0p05min
   392.59 min  Base Time {min}
   392.64 min  End Block
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   392.64 min  End Block
   392.64 min  Block ConcB_Step_2
   392.64 min  Base SameAsMain
   392.64 min  Gradient    70.00 %B,    0.000 CV
   392.64 min  End Block
   392.64 min  Block Fractionation_Segment_2
   392.64 min  Base SameAsMain
   392.64 min  Fractionation 12mm , 2.000  ml , NextTube , Volume 
   392.66 min  End Block
   392.66 min  Block Step_Segment_2
   392.66 min  Base SameAsMain
   392.66 min  Block Step_2
   392.66 min  Base SameAsMain
   452.06 min  End Block
   452.06 min  Block Delay0p02min
   452.06 min  Base Time {min}
   452.08 min  End Block
   452.08 min  End Block
   452.08 min  Block Pump_Inlet_A_Segment_3
   452.08 min  Base SameAsMain
   452.08 min  PumpAInlet A2 
   452.08 min  End Block
   452.08 min  Block Pump_Inlet_B_Segment_3
   452.08 min  Base SameAsMain
   452.08 min  PumpBInlet B1 
   452.08 min  End Block
   452.08 min  Block Buffer_Inlet_A_Segment_3
   452.08 min  Base SameAsMain
   452.08 min  BufferValveA1 A11 
   452.08 min  End Block
   452.08 min  Block Wash_Explorer_3
   452.08 min  Base SameAsMain
   452.08 min  PumpWashExplorer OFF , OFF, OFF, OFF
   452.15 min  Block Delay0p05min
   452.15 min  Base Time {min}
   452.20 min  End Block
   452.20 min  End Block
   452.20 min  Block ConcB_Step_3
   452.20 min  Base SameAsMain
   452.20 min  Gradient   100.00 %B,    0.000 CV
   452.20 min  End Block
   452.20 min  Block Fractionation_Segment_3
   452.20 min  Base SameAsMain
   452.20 min  Fractionation 12mm , 1.000  ml , NextTube , Volume 
   452.22 min  End Block
   452.22 min  Block Step_Segment_3
   452.22 min  Base SameAsMain
   452.22 min  Block Step_3
   452.22 min  Base SameAsMain
   472.02 min  End Block
   472.02 min  Block Delay0p02min
   472.02 min  Base Time {min}
   472.04 min  End Block
   472.04 min  End Block
   472.04 min  Block Fractionation_Stop
   472.04 min  Base SameAsMain
   472.04 min  FractionationStop 
   472.06 min  Peak_FracStop 
   472.08 min  End Block
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Appendix 2  
 
 
Mass Spectrometry Materials and Methods.    
 
2.1 Samples Description  
 
Samples containing five FVIII variants were kindly provided by Dr. Nathwani’s group (University 
College London) in collaboration with the Royal Free Hospital, London, UK. Glycoproteins were 
expressed in HEK-293T cell lines purified and dispatched to Imperial College London for 
glycomic analysis. The experimental approach followed in the current study is extensively 
described in Canis et al., 2012.  Unless otherwise stated, all chemical reagents were obtained 
from Sigma-Aldrich.    
 
2.2 Dialysis  
Samples were inserted into dialysis cassettes (MWCO3500, Pierce) and incubated in 50mM 
ammonium hydrogen carbonate (AMBIC) buffer (pH 8.5) for 48 hours at 4°C with regular buffer 
replacements. Next, samples were efficiently frozen at -80°C and subsequently freeze-dried.    
 
2.3 Reduction and carboxymethylation   
Samples were reduced with dithiothreitol (DTT) and carboxylated using iodoacetic acid (IAA). 
An initial solution of 0.6M Tris, 4M GuHCl was prepared, its pH was adjusted to 8.5 using HCl 
and it subjected to de-gas under nitrogen for 20 minutes, in order to make 2mg/mL DTT 
solution. Then, DTT solution was inserted to sample and incubated at 50°C for 2 hours. A 
second solution of 0.6M Tris adjusted to pH 8.5 and de-gassed under nitrogen for 20 minutes, 
in order to make 12mg/mL IAA solution. Next, this solution was added to the sample and 
incubated at room temperature for 2 hours in the dark. A subsequent dialysis was performed 
as described above.    
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2.4 Trypsin digestion   
Trypsin digestion of reduced and carboxymethylated samples was performed in 50mM AMBIC 
buffer, adjusted with diluted ammonia in pH 8.4. For every 100μg of sample, 0.2μg of trypsin 
(Bovine pancreas, T-1426, Sigma) were used. Samples were incubated for 14 hours at 37°C. 
The reaction quenched by adding a few drops of Acetic acid. Digested glycopeptides were 
purified using C18 reversed-phase chromatography column (Oasis HLB Plus) with the PrOH/ 
5% Acetic acid method. Then, propanol fractions were combined, their volume was reduced 
using SpeedVac (Savant), they were frozen at -80°C and lyophilised.   
 
2.5 PNGase F digestion    
N-Glycosidase F (PNGase F, Roche) was used to release N-glycans from glycopeptides. 
Lyophilised samples were dissolved in 50mM AMBIC buffer of pH 8.4, adding 3~5 units of 
PNGase F and incubating for 24 hours at 37°C. The second aliquot of PNGase F was added 
at an interim interval during incubation. Samples were frozen at -80°C and lyophilised. Samples 
were re-dissolved in 5% Acetic acid and subjected reversed-phase chromatography with PrOH/ 
5% Acetic acid method. N-glycans were isolated at the 5% Acetic acid fraction, and along with 
the other fractions were reduced in volume with SpeedVac, frozen at -80°C and lyophilised. 
Peptide fragments was collected from the 20% and 40% propanol fractions.  
 
2.6 Reductive elimination  
Reductive elimination was performed to release O-glycans from glycopeptides. 1 M KBH4/ 0.1 
M KOH solution was used to dissolve lyophilised samples, and the solutions were incubated 
for 14-16 hours at 45°C. A few drops of Acetic acid were added to terminate the reaction. Then, 
a column made with Dowex beads (VWR) was constructed to desalt the samples by ion-
exchange. The column conditioning was made with 15 mL of 5% Acetic acid; the sample was 
loaded and eluted (4mL) with 5% Acetic acid in a tube. The eluent was frozen at -80°C and 
lyophilized. Excess borates were removed by co-evapolating with 10% Methanolic Acetic acid 
with nitrogen at room temperature.   
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2.7 Derivatisation of O- and N-glycans  
O- and N-glycans were permethylated with DMSO (3mL), and NaOH (5 pellets) slurry with 
0.5mL methyl iodide under constant shaking for 15 minutes at room temperature. Reaction 
terminated by adding 1mL of ultra-pure water. Chloroform (1~2mL) was added to the solutions, 
and permethylated glycans were extracted with chloroform layer after several washings with 
water. The samples were dried under nitrogen and purified by reversed-phase chromatography 
with MeCN/H2O method (see description below). All fractions collected, reduced in volume with 
SpeedVac, frozen at -80°C and lyophilised.   
  
2.8 MALDI-TOF and MALDI-TOF/TOF analysis  
Samples dissolved in 10μL MeOH, and 1μL was mixed 1:1 with matrix (3,4-diamino-
benzophenone 20mg/mL in 75% acetonitrile and 25% water), spotted onto MS plate and dried 
under vacuum. Both MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight 
Mass spectrometry) and MALDI-TOF/TOF MS/MS analyses were performed on 4700 
Proteomics Analyzer (Applied Biosystems). Reversed-phase column chromatography, unless 
stated otherwise, purifications were carried out with Sep-Pak C18 cartridge (Waters).  
 
2.9 PrOH/5% Acetic acid system  
C18 cartridge conditioning was performed by sequentially adding MeOH (5 mL), 5% Acetic acid 
(5mL), propanol (4mL), and 5% Acetic acid (15mL). After loading the sample, cartridge washed 
with 5% acetic 22  acid (3 x 5mL) and samples eluted with 5% Acetic acid (15mL), 20% PrOH 
(4mL), 40% PrOH (4mL) and 100% PrOH (4mL). MeCN/H2O system C18 cartridge 
conditioning was performed by sequentially adding MeOH (5mL), ultra-pure water (5mL), 
MeCN (5mL), and ultra-pure water (3 x 5mL). After loading the sample, cartridge washed with 
ultra-pure water (5mL) and the fractions 15%, 35%, 50%, and 75% MeCN (3mL each) were 
collected. 
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Appendix 3. Mass spectrometry  
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Full MALDI-TOF mass spectra of samples presenting the total identified N-glycomes. Structural 
assignments are based on monosaccharide compositions, knowledge upon glycan 
biosynthesis and fragmentation analyses. All spectra display [M + Na]+ molecular ions. Panel 
intensities were normalized to 100% unless otherwise stated. In m/z values with more than one 
structures: M: Major (more abundant) structure; m: minor (less abundant) structure, Data 
provide from Dr Stuart Haslam (Imperial college). 
